Compositions and systems for RNA programmable cell editing and methods of making and using same
CellREADR technology uses endogenous ADAR to act on RNA, and uses RNA perception mechanism to achieve efficient monitoring and operation of cell types, solving cumbersome and ethical problems in the existing technology, realizing specific monitoring and operation of cell types, and improving operation. Efficiency and scalability.
Patent Information
- Application Number
- CN202280082204.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-19
- Filing Date
- 2022-10-31
- Publication Date
- 2024-11-08
AI Technical Summary
The existing cell type operation technology is cumbersome, inefficient and serious ethical problems. DNA-based transcriptional regulation methods are difficult to expand and promote, especially in primates and humans.
CellREADR technology is used to access cells through endogenous ADAR adenosine deaminase acting on RNA. Using RNA perception and editing mechanisms, modular RNA molecules are designed to monitor and manipulate cell types, bypass DNA transcription process, and achieve targeting. Specific monitoring and manipulation of cell types.
It realizes efficient, easy to construct, programmable and universal monitoring and operation of cell types across species, avoiding the complexity and ethical problems of DNA transcription regulation, and improving operational efficiency and scalability.
Smart Images

Figure CN118922541A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This PCT application claims the benefit of U.S. Provisional Application No. 63 / 343,669, filed on May 19, 2022, and U.S. Provisional Application No. 63 / 273,343, filed on October 29, 2021, the contents of each of which are incorporated herein by reference in their entirety.
[0003] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0004] This invention was made with government support under Federal Grant Nos. U19MH114821-03 and DP1MH129954 awarded by the National Institutes of Health. The federal government has certain rights in this invention.
[0005] Sequence Listing
[0006] This application contains a sequence listing, which has been submitted through the Patent Center as a WIPO standard ST.26 XML file. The XML file was created on October 31, 2022, is titled "123658-10903.xml" and is 193,913 bytes in size. The sequence listing is incorporated herein by reference.
[0007] background
[0008] The diversity of cell types underlies the diversity of life forms and physiological systems within individual organisms [1]. Cell types, defined by distinct gene expression profiles, morphological and physiological properties, and tissue function, are the intermediaries through which genetic information shapes the phenotype and behavior of an organism. All bodily functions emerge from interactions between cell types, and abnormal cell type physiology and function lead to a myriad of diseases [2]. Recent high-throughput single-cell genomic approaches have the potential to identify all major molecularly defined cell types in humans and many other organisms [3][4]. In addition to molecular profiling, it will be necessary to monitor and manipulate each cell type in order to identify their specific roles in tissue architecture and systemic function across levels of biological organization.
[0009] In the context of cell type acquisition and manipulation in multicellular organisms, most, if not all, genetic approaches to date have attempted to recapitulate cell type-specific mRNA expression by engineering DNA regulatory elements in the genome, either through the germline or somatic cells, or by using transcriptional enhancer-based viral vectors. To date, almost all genetic approaches to cell type targeting rely on DNA-based transcriptional regulatory elements to express tool genes (e.g., markers, sensors, effectors) that mimic certain cell-specific RNA expression, primarily through germline engineering in only a few organisms [5-7]. All germline approaches, including CRISPR [8-10], are inherently cumbersome, slow, difficult to scale and generalize, and raise ethical questions, especially in primates and humans [11, 12]. Recently, transcriptional enhancer-based viral vectors have shown promise in targeting animal cell types [13-19]; however, such enhancers are difficult to identify and validate, and often require large-scale efforts due to their complex relationships with target genes and cell types
[13] . Somatic cell engineering, typically performed through CRISPR / Cas9 technology, is currently inefficient and often includes unintended off-target effects. Enhancer viral vector approaches also have major limitations, rooted in their complex relationship with gene expression and cell type; they require large-scale efforts, special expertise, extensive validation, and are unlikely to be truly scalable, user-friendly, and universal across species. Thus, although transcriptional enhancer-based viral vectors show promise for targeting animal somatic cell types; due to their complex relationship with target genes and cell types, such enhancers are difficult to identify and validate, often requiring large-scale efforts. In essence, all DNA- and transcription-based approaches are inherently indirect in their attempts to mimic and exploit cell-type-specific RNA expression patterns. SUMMARY OF THE INVENTION
[0011] The present disclosure is based in part on the discovery of a new class of cell type technologies that bypass the DNA-based transcription process and directly use RNA that defines the cell type. In some embodiments, this novel technology (called CellREADR: Cellular Access via RNA Sensing by Endogenous ADARs [Adenosine Deaminases Acting on RNA], utilizes RNA sensing and editing machinery ubiquitous in all animal cells to detect the presence of cellular RNA and turn on translation of effector proteins to monitor and manipulate cell types. The compositions and methods provided herein can be deployed as a single RNA molecule that acts through Watson-Crick base pairing, which is targeted to a specific cell type due to the presence of the target RNA. Therefore, CellREADR is inherently specific, easy to build and use, scalable, programmable and universal across species.
[0012] Therefore, the present disclosure provides a modular RNA molecule comprising: (i) a 5' region containing a sensor domain, wherein the sensor domain comprises a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a cellular RNA of a mammalian central nervous system cell, wherein the sensor domain comprises a stop codon editable by ADAR; and (ii) a 3' region containing a protein-encoding domain, wherein the protein-encoding domain is located downstream of the sensor domain and in frame with it, wherein when the modular RNA is introduced into a cell of a mammalian central nervous system comprising an Adar enzyme, the contiguous nucleotide segment of the sensor domain forms an RNA duplex comprising a stop codon with the corresponding nucleotide segment of the cellular RNA, wherein the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing protein translation.
[0013] Also disclosed herein is a modular RNA molecule comprising: (i) a 5' region containing a sensor domain, the sensor domain comprising a continuous nucleotide segment sequence complementary to a corresponding continuous nucleotide segment of a cell RNA of a mammalian peripheral nervous system cell, wherein the sensor domain comprises a stop codon that can be edited by an ADAR; and (ii) a 3' region containing a protein-encoding domain, wherein the protein-encoding domain is located downstream of the sensor domain and in the same frame with it, wherein when the modular RNA is introduced into a cell of a mammalian peripheral nervous system containing an Adar enzyme, the continuous nucleotide segment of the sensor domain forms an RNA duplex containing a stop codon with the corresponding nucleotide segment of the cell RNA, wherein the stop codon contained in the RNA duplex is edited by an ADAR in the cell, thereby allowing protein translation. In the modular RNA molecule, the continuous nucleotide segment of the sensor domain is capable of forming an RNA duplex with at least a portion of the mRNA. In the modular RNA molecule, the protein coding region encodes an effector protein. In one aspect of the modular RNA molecule, it also encodes a self-cleaving 2A peptide located between the sensor domain and the effector RNA region. In one aspect of the modular RNA molecule, the self-cleaving 2A peptide is selected from the group consisting of: one or more of a T2A peptide, a P2A peptide, an E2A peptide, and a F2A peptide. In one aspect of the modular RNA molecule, the protein encoded by the efRNA comprises a protein selected from the group consisting of: a marker and a transcriptional activator or repressor.
[0014] Also disclosed herein is a composition comprising: (i) a first nucleic acid comprising a modular RNA molecule, the modular RNA molecule comprising: (a) a sensor domain comprising a continuous nucleotide segment complementary to a corresponding continuous nucleotide segment of a cell RNA of a mammalian cell of the central nervous system, wherein the sensor domain comprises a stop codon that can be edited by ADAR; and (b) a first protein coding domain encoding an effector protein, wherein the first protein coding region is located downstream of the sensor domain and in frame with it, and (ii) a second nucleic acid comprising a second protein coding domain. Also disclosed herein is a composition comprising (i) a first nucleic acid containing a modular RNA molecule, the modular RNA molecule comprising: (a) a sensor domain comprising a continuous nucleotide segment complementary to a corresponding continuous nucleotide segment of a cell RNA of a mammalian cell of the peripheral nervous system, wherein the sensor domain comprises a stop codon that can be edited by ADAR; and (b) a first protein coding domain encoding an effector protein, wherein the first protein coding region is located downstream of the sensor domain and in frame with it, and (ii) a second nucleic acid comprising a second protein coding domain. In one aspect of the composition, the first and second nucleic acids comprise a single nucleic acid molecule. In one aspect of the composition, wherein the first and second nucleic acids comprise two nucleic acid molecules. In one aspect of the composition, the first and second nucleic acids are covalently linked. In one aspect of the composition, the second protein coding domain is contained in a gene containing a transcription control element (optionally, a promoter). In one aspect of the composition, the effector protein is bound to the gene. In one aspect of the composition, the expression of the second protein coding domain is regulated by the effector protein. In one aspect of the composition, the first protein coding domain encodes a transcription activator or a transcription repressor. In one aspect of the composition, the first protein coding domain encodes a DNA recombinase. In one aspect of the composition, brain cells include mammalian cortical cells. In one aspect of the composition, brain cells include mammalian Schwann cells or mammalian satellite cells of the peripheral nervous system. In one aspect of the composition, the first protein coding region encodes an effector protein comprising a tetracycline-dependent transcription activator tTA2, and wherein the continuous nucleotide segment of the sensor domain is complementary to the continuous nucleotide segment of the selected cell RNA of the cerebral cortical cell encoded by the Fezf2 gene, and wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of the TRE-3G eukaryotic inducible promoter. In one aspect of the composition, the first protein coding region encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, and wherein the contiguous nucleotide segment of the sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of a surrounding CNS cell, and wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of a TRE-3G eukaryotic inducible promoter.In one aspect of the composition, the first protein coding region encodes a cell killing protein selected from the group consisting of thymidine kinase (TK) and cytosine deaminase (CD), a programmed cell death protein selected from the group consisting of CASP3, CASP9, BCL, GSDME, GSDMD, GZMA and GZMB, a neural activation protein selected from the group consisting of ChR2 and DREADD-M3Dq, an immune enhancement protein selected from the group consisting of IFNB, IFNG, TNFA, IL2, IL12, IL15 and CD40L, a physiological editing protein selected from the group consisting of NaChBac and Kir2.1, a protein synthesis inhibitory protein including ricin, a neural inhibitory protein selected from the group consisting of DREADD-hM4D, NpHR and GtACR1, proteins involved in neural cell fate such as NEUROD, and proteins involved in cell regeneration including epidermal growth factor.
[0015] Also disclosed herein is a nucleic acid delivery vehicle comprising a modular RNA molecule as described herein or a composition as described herein or a DNA encoding a modular RNA molecule as described herein. On the one hand, the nucleic acid delivery vehicle can be a nanoparticle, a liposome, a carrier, an exosome, a microvesicle (micro-vesicle), a gene gun, and a selective endogenous cell delivery encapsulation (SEND) system. On the one hand, the nucleic acid delivery vehicle includes a viral vector, wherein the viral vector includes but is not limited to the group consisting of: adeno-associated virus (AAV), adenovirus, retrovirus, slow virus, herpes virus, vesicular stomatitis virus.
[0016] Also disclosed herein is a modular RNA molecule, wherein the modular RNA molecule is encoded by a DNA vector. Also disclosed herein is a composition, wherein the modular RNA molecule is encoded by a DNA vector. Also disclosed herein is a delivery vehicle, wherein the delivery vehicle comprises a modular RNA molecule encoded by a DNA vector. Also disclosed herein is a pharmaceutical composition, which comprises a pharmaceutically acceptable carrier, an excipient and / or a diluent and a modular RNA molecule as described herein, and / or a composition comprising a modular RNA molecule as described herein, and / or a delivery vehicle as described herein. Also disclosed herein is a cell comprising a modular RNA molecule as described herein, and / or a composition comprising a modular RNA molecule as described herein, and / or a delivery vehicle as described herein. In addition, the cell disclosed herein is a mammalian cell. Also disclosed herein is a kit and its packaging comprising a modular RNA molecule as described herein and / or a composition comprising a modular RNA molecule as described herein and / or a delivery vehicle as described herein.
[0017] Also disclosed herein is a method for introducing modular RNA or a nucleic acid composition encoding modular RNA or a delivery vehicle comprising modular RNA or a nucleic acid composition encoding modular RNA into selected cells of a mammal, the method comprising: contacting the mammalian cells with modular RNA molecules, nucleic acid compositions encoding modular RNA or a delivery vehicle comprising modular RNA or a nucleic acid composition encoding modular RNA under conditions that allow the mammalian cells to contain the modular RNA described herein or the delivery vehicle comprising the modular RNA or a nucleic acid composition encoding the modular RNA.
[0018] Also disclosed herein is a method of initiating ADAR editing of a stop codon to allow expression of a protein encoded downstream in frame in a mammalian cell comprising a selected target cellular RNA, the method comprising introducing a modular RNA molecule into a mammalian cell under conditions wherein the modular RNA is contained in the cell, the modular RNA comprising (i) a 5' region comprising a sensor domain, the sensor domain comprising a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a selected cellular RNA, wherein the sensor domain comprises a stop codon editable by ADAR; and (ii) a 3' region comprising a domain encoding an effector protein, wherein the protein coding region is located downstream of and in frame with the sensor domain, wherein upon introduction of the modular RNA molecule into the mammal, an RNA duplex is formed in the cell between the contiguous nucleotide segment of the sensor domain and the corresponding contiguous nucleotide segment of the cellular RNA, wherein the RNA duplex comprises an ADAR-editable stop codon, and wherein ADAR edits the stop codon contained in the RNA duplex, thereby allowing protein translation, and wherein the protein is produced in the mammal.
[0019] Also disclosed herein is a method for treating a disease or condition in a mammal, the method comprising: providing an agent comprising a modular RNA molecule, a composition containing a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein; and administering the agent to a mammal in a therapeutically effective amount to allow the effector protein to be translated in a selected cell of the mammal, thereby producing a protein in the cell, wherein the production of the protein in the cell can be used to treat a disease or condition in the mammal. In aspects of the method, the agent comprises a composition containing an agent comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle as described herein, administering the agent, and the first protein coding region encoding the effector protein contained in the agent encodes a transactivator that activates the expression of the second protein coding region, and wherein expressing the second protein coding region in the selected cell is therapeutically effective in treating the disease or condition.
[0020] Also disclosed herein is a method for stimulating L5b / L6 cortical projection neuron (CFPN) signaling in the forelimb sensory cortex of a mouse (as measured by photometry in response to mechanical stimulation of the forepaw), comprising administering to the mouse the composition, wherein the sensor domain comprises a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a cellular RNA encoding Ctip2, wherein the first protein-coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, and wherein the second nucleic acid comprises a gene encoding the calcium indicator protein GCaMP6s under the transcriptional control of a TRE-3G eukaryotic inducible promoter.
[0021] Also disclosed herein is a method for stimulating forelimb movement in response to light stimulation of the caudal forelimb area (CFA) of a mouse, comprising administering the composition to a mouse, wherein the sensor domain comprises a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a cellular RNA encoding Ctip2, wherein the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, and wherein the second nucleic acid comprises a gene encoding a light-activated ion channel rhodopsin-2 under the transcriptional control of a TRE-3G eukaryotic inducible promoter. In one aspect of the method, the second gene is operably linked to the TRE-3G eukaryotic inducible promoter, and the second gene encodes an enhanced yellow fluorescent protein (eYFP).
[0022] Also described herein is a pharmaceutical composition comprising a medicament containing modular RNA molecules, a composition containing modular RNA molecules and / or a nucleic acid composition and / or a delivery vehicle as described herein and a pharmaceutically acceptable carrier, excipient and / or diluent. Also described herein are cells containing modular RNA molecules, compositions containing modular RNA molecules and / or nucleic acid compositions and / or delivery vehicles, all as described herein. Also described herein are kits containing modular RNA molecules, compositions containing modular RNA molecules and / or nucleic acid compositions and / or delivery vehicles as described herein.
[0023] Also described herein is a method for identifying gamma-aminobutyric acid (GABAergic) neurons in a mammalian cortex in vivo, comprising targeting vesicular gamma-aminobutyric acid transporter (vGAT) mRNA in the mammalian cortex in vivo, the method comprising administering to the S1 barrel cortex and hippocampus of the mammal a composition comprising modular RNA molecules and / or nucleic acid compositions and / or delivery vehicles, all as described herein, wherein the contiguous nucleotide segment of the sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of a cortical cell encoded by a vGAT gene, and wherein the first protein-coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding smV5, and wherein the second nucleic acid comprises a coding region for a green fluorescent protein under the transcriptional control of a TRE-3G eukaryotic inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter, and wherein the modular RNA molecule comprises a gene encoding mCherry located upstream of the sensor domain and under the transcriptional control of the hSyn promoter, wherein upon administration, vGAT in the S1 barrel cortex and hippocampus of the mammal is expressed. The mRNA is co-labeled with a magenta dye and GFP, indicating the identification of GABAergic neurons in the mammalian cortex. In one aspect of the method, the sesRNA targeting vGAT mRNA is complementary to all or part of exon 1 of the vGAT mRNA.
[0024] Also described herein is a method for identifying GABAergic neurons in the cortex of a mammal in vivo, comprising targeting transducin-like enhancer protein 4 (Tle4) mRNA, the method comprising administering a composition and / or a nucleic acid composition and / or a delivery vehicle containing modular RNA molecules, all as described herein, into the S1 barrel cortex of a mammal, wherein a contiguous nucleotide segment of a sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of a cortical cell encoded by the Tle4 gene, and wherein the first protein-coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding smFlag, and wherein the second nucleic acid comprises a coding region for a green fluorescent protein under the transcriptional control of a TRE-3G eukaryotic inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter, and wherein the modular RNA molecule comprises a gene encoding mCherry located upstream of the sensor domain and under the transcriptional control of the hSyn promoter, wherein after administration, the Tle4 mRNA in the S1 barrel cortex of the mammal is co-labeled with a magenta dye and GFP, indicating that Tle4-positive projection neurons are identified in the mammalian cortex. In one aspect of the method, the sesRNA targeted to Tle4 mRNA is complementary to all or part of exon 15 of Tle4 mRNA.
[0025] Also described herein is a method for determining a cortical layer expressing human FOXP2 in an organotypic culture platform, the method comprising administering to the culture a composition and / or a nucleic acid composition and / or a delivery vehicle comprising modular RNA molecules, all as described herein, wherein a contiguous nucleotide segment of a sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of a cortical cell encoded by a forkhead box protein P2 (FOXP2) gene, and wherein the first protein-coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding smV5, and wherein the second nucleic acid comprises a coding region for a green / yellow fluorescent protein (mNeon) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter, and wherein the modular RNA molecule comprises a gene encoding ClipF located upstream of the sensor domain and under the transcriptional control of the hSyn promoter, wherein 5 days after administration, mNeon-labeled cell bodies are observed in the upper and deeper layers of the cortical layer of the organotypic culture platform, indicating that human FOXP2 is expressed in the upper and deeper layers.
[0026] Also described herein is a method for inhibiting neural activity that promotes focal epileptic seizures, comprising targeting pathophysiological neural ensembles (PNE), including cell type targeted modulation of neural activity of PNE involved in seizure activity, the method comprising: (i) providing a modular RNA molecule and / or nucleic acid composition and / or delivery vehicle as described herein, wherein the contiguous nucleotide segment of the sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of a cortical cell encoded by a human SST gene, and wherein the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising an osmFlag encoding gene, and wherein the second nucleic acid comprises a coding region for a green fluorescent protein (GFB) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter; and wherein the modular RNA molecule comprises a gene encoding mCherry located upstream of the sensor domain and under the transcriptional control of the hSyn promoter, further providing a gene encoding a designer receptor (DREADD) that is activated only by a designer drug or a gene encoding a pharmacologically selective actuator module / pharmacologically selective effector molecule (PSAM), and (ii) administering the agent and the designer receptor gene to a mammal in a therapeutically effective amount to allow translation of the effector protein in selected cells of the mammal after administration of an oral dose of olanzapine or clozapine-n-oxide that activates the DREADD or an oral dose of varencline that activates the PSAM, thereby producing the protein in the cell, wherein producing the protein in the cell can be used to treat epilepsy in a mammal.
[0027] Also described herein is a method of inhibiting neural activity that promotes focal epileptic seizures, comprising targeting pathophysiological neuronal clusters (PNEs), including cell type-targeted modulation of neural activity of PNEs involved in seizure activity, the method comprising (i) providing an agent comprising a composition and / or a nucleic acid composition and / or a delivery vehicle comprising modular RNA molecules, all as described herein; and wherein the contiguous nucleotide segment of the sensor domain is complementary to a contiguous nucleotide segment of a selected cellular RNA of cortical cells encoded by the human early intermediate growth cfos gene, and wherein the first protein-coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising an osmFlag encoding gene, and wherein the second nucleic acid comprises an encoding gene for a green fluorescent protein (GFB) under the transcriptional control of a TRE-3G eukaryotic inducible promoter; coding region, wherein the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of the hSyn promoter, and wherein the modular RNA molecule comprises a gene encoding mCherry located upstream of the sensor domain and under the transcriptional control of the hSyn promoter, (ii) further providing a gene encoding a designer receptor (DREADD) that is activated only by a designer drug or a gene encoding a pharmacologically selective actuator module / pharmacologically selective effector molecule (PSAM), and (iii) administering the agent and the designer receptor gene to a mammal in a therapeutically effective amount to allow translation of the effector protein in selected cells of the mammal after administration of an oral dose of olanzapine or clozapine-n-oxide that activates the DREADD or an oral dose of varenicline that activates the PSAM, thereby producing the protein in the cell, wherein the protein produced in the cell can be used to treat a disease or condition in the mammal.
[0028] Also described herein is a method for treating chronic pain in a mammal, comprising (i) providing an agent comprising a composition and / or a nucleic acid composition and / or a delivery vehicle comprising modular RNA molecules as described herein; wherein the first module of the modular RNA comprises a continuous nucleotide segment of a sensor domain that is complementary to a continuous nucleotide segment of a selected cellular RNA encoded by the human TRPV1 gene or the human NaV1.8 gene, and a first protein-coding domain encoding an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, wherein the first module of the modular RNA molecule is under the transcriptional control of the hSyn promoter and further comprises a spacer located upstream of the sensor domain, wherein the modular RNA further comprises a second module, wherein the second module is located upstream of the first module, wherein the second module encodes an shRNA of NaV1.7 or NaV1.8 and is under the transcriptional control of a TRE-3G eukaryotic inducible promoter, and (ii) administering the agent to a mammal in a therapeutically effective amount to allow translation of the effector protein in selected cells of the mammal, thereby producing the protein in the cells, wherein producing the protein in the cells can be used to treat chronic pain in the mammal.
[0029] Also described herein is a method for treating Alzheimer's disease in a mammal, the method comprising (i) providing an agent comprising a composition and / or a nucleic acid composition and / or a delivery vehicle containing modular RNA molecules as described herein; wherein the first module of the modular RNA comprises a contiguous nucleotide segment of a sensor domain, which segment is complementary to a contiguous nucleotide segment of a selected cellular RNA encoded by one of the following groups: acetaldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP), human astrocyte marker genes of excitatory amino acid transporter 1 (EAAT1), and microglia genes: C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119) , ionized calcium binding adaptor molecule 1 (IBA-1), and a first protein coding domain encoding an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, wherein the first module of the modular RNA molecule is under the transcriptional control of an hSyn promoter and further comprises a spacer located upstream of the sensor domain, wherein the modular RNA further comprises a second module, wherein the second module is located upstream of the first module, wherein the second module encodes an shRNA for ApoE4 and is under the transcriptional control of a TRE-3G eukaryotic inducible promoter, and (ii) administering the agent to a mammal in a therapeutically effective amount to allow translation of the effector protein in selected cells of the mammal, thereby producing the protein in the cell, wherein producing the protein in the cell can be used to treat Alzheimer's disease in the mammal. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 :CellREADR design and implementation in mammalian cells
[0032] a.CellREADR is a single modular readrRNA molecule consisting of a 5'-sensor domain (sesRNA) and a 3'-effector domain (efRNA) separated by a T2a coding region. The sesRNA is complementary to the cellular RNA and contains an in-frame stop codon that prevents translation of the efRNA. Base pairing between the sesRNA and the target RNA recruits ADAR, which mediates A->I editing and converts the UAG stop codon to the UGG Trp codon, turning on translation of the effector protein. bd, b.CAG-tdT (top) expresses the tdTomato target RNA from the CAG promoter, and READR tdT-GFP (Bottom) Expression is driven by the CAG promoter and consists of the BFP coding region followed by sesRNA tdT and efRNA GFP c. Using CAG-tdT and READR tdT-GFP 293T cells transfected with both showed robust GFP expression co-localized with BFP and RFP (bottom). tdT-GFP (Top) or using CAG-tdT and expressing sesRNA with a scrambled coding sequence containing a stop codon Ctrl Comparison of READR Ctrl (Middle) Transfected cells show almost no GFP expression. Representative FACS analysis of GFP and RFP expression is shown on the right. d. Quantification of CellREADR efficiency by FACS. e.-g. Effect of target RNA levels on CellREADR. e. Expression vector used to quantify the effect of target RNA levels on CellREADR. In rtTA-TRE-ChETA (top), BFP-ChETA fusion target RNA is transcribed from TRE in a tetracycline concentration-dependent manner driven by constitutively expressed rtTA. READR ChETA-GFP (Bottom) Expression consists of the mCherry coding region and the subsequent sesRNA ChETA and efRNA GFP f. Using rtTA-TRE-ChETA and READR ChETA -GFP In co-transfected 293T cells, FACS analysis showed that increasing tetracycline concentration in the culture medium resulted in RFP + BFP + The percentage increase of g.GFP +The ratio of BFP to RFP+ increased with the increase of tetracycline concentration. CAG-ChETA constitutively expressing BFP-ChETA RNA was used as a positive control, and sesRNA was expressed Ctrl READR Ctrl As a negative control. hi, ADAR1 is required for CellREDAR function. Only sesRNA is expressed tdT , express sesRNA Ctrl and tdT, expressing sesRNA tdT and tdT or sesRNAdT and tdT and ADAR2 overexpressing wild-type 293T cells or ADAR1 KO FACS analysis of 293T cells (h). Arrows indicate GFP + / RFP + Population. i, Quantification of cell conversion rate. j, Electropherograms of Sanger sequencing show A-to-G conversion at the expected editing site in the different samples shown. k, Bar graph shows quantification of A-to-G conversion rate at the target editing site. Error bars in d, f, g, and k are mean ± sem, n = 3; n represents the number of independent experiments performed in parallel.
[0033] Figure 2 :sesRNA characteristics.
[0034] a, The optimal sesRNA length is about 200-300 nt. Using READR BFP-tdT-GFP and tdT as target RNA, testing sesRNAs of different lengths tdT To determine the optimal length, the conversion rate of cells was quantified in the FACS assay. b, The effect of mismatches between sesRNA and target RNA base pairing. The number of mismatches (top) and sesRNA in each case are shown. tdT c, Effect of sesRNA induction at different positions and sequences (e.g., different ChETA and tdT coding regions) within the target RNA expressed by the EF1a-ChETA-tdT vector; the promoter region was used as a negative control. The readrRNA efficiency is shown (below). d, To increase stringency, sesRNA tdT Designed to be in READR tdT-Luc The vector contains 1 to 3 stop codons (X-TAG). ef, only READR tdT-Luc Luminescence of 293T cells transfected (e) or co-transfected with CAG-tdT (f). g, Dual and triple sensor READR with sesRNA arrays ChETA / tdT-GFPSchematic diagram of the vectors, the sesRNA arrays targeting different regions of the ChETA-tdT fusion transcript expressed by EF1a-ChETA-tdT. h, Co-transfection of EF1a-ChETA-tdT and dual or triple RREADR tdT-GFP FACS analysis of 293T cells expressing the vector. Arrows indicate the GFP+ / RFP+ population. i. Quantification of various dual or triple READRs in (h) tdT-GFP Efficiency of carrier. j, using dual sensor READR ChETA / tdT-GFP or READR ChETA / tdT-Luc Scheme of vector cross-targeting cells expressing two target RNAs (ChETA and tdT); each sesRNA in the dual sensor array contains an editable stop codon. k, FACS analysis shows that the READR Cheta / tdT-GFP Co-transfection of 293T cells with CAG-ChETA or CAG-tdT resulted in almost no GFP translation, and only triple transfection resulted in GFP expression. Co-transfection of EF1a-ChETA-tdT (expressing ChETA-tdT fusion transcripts) was used as a positive control. Quantification is shown by FACS (l) and luciferase assay (m). Error bars in ac, ef, i and lm are mean ± sem n = 3, n represents the number of independent experiments performed in parallel.
[0035] Figure 3 .Sensing endogenous RNA using CellREADR.
[0036] a. Schematic representation of the genomic locus of the human EEF1A1 gene, showing the exon and intron structure (not to scale), pre-mRNA (middle) and mRNA (bottom). sesRNA EEF1A1 (1-7) were designed to sample EEF1A1 transcripts including the coding sequence (CDS). b, used to test sesRNA EEF1A1 Schematic diagram of the READREEF1A1-GFP vector (1-7); the BFP expression cassette labels all transfected cells. c, sesRNA in 293T cells EEF1A1 Quantification of the efficiency of (1-7). d, High sensitivity of CellREADR. Quantification of the efficiency of CellREADR for several endogenous cellular RNAs with different expression levels; TPM (transcripts per million) from RNAseq data is used to indicate cellular RNA expression levels. 1 to 3 sesRNAs were designed for each target. e, Using dual sensor READR EEF1A1 / ACTB-GFPSchematic diagram of the vector cross-targeting two endogenous RNAs (EEF1A1 and ACTB); each sesRNA in the dual sensor array contains an editable stop codon. EEF1A1 / Ctrl-GFP or READR Ctr1 / ACTB-GFP Quantification of efficiency showed that only READR Chet / atdT-GFP P transfection of 293T cells resulted in significant GFP expression. f, CellREADR did not alter the cellular transcriptome as determined by RNA sequencing. EEF1A1(7) sesRNA Ctrl (Top) Cells transfected with sesRNAPCNA or sesRNA Ctrl (Bottom) Comparison of transcriptomes between transfected cells. g. sesRNAEEF1A1 or sesRNA Ctrl (Top), sesRNA PCNA sesRNA Ctrl (Bottom) Volcano plot of differential gene expression analysis between the two groups. Genes with adjusted P values < 0.01 and log2 (fold change) > 2 were defined as significantly differentially expressed genes and marked in red. EEF1A A gene with significantly increased expression, OAS2, was detected in the group. h, Transcriptome-wide analysis of sesRNA by RNA sequencing EEF1A1 (above) or sesRNA ACTB (Bottom) Effects on A to I editing. Pearson correlation analysis was used to assess differential RNA editing rates. Error bars in CE are mean ± sem. n = 3, n represents the number of independent experiments performed in parallel.
[0037] Figure 4 CellREADR targeting, monitoring, and manipulation of mouse neuronal cell types a. Genomic structure of the mouse Ctip2 gene, with the locations of sesRNA3 and sesRNA8 as indicated. b. Schematic representation of single and binary AAV vectors used to target Ctip2 neurons in brain tissue. Ctip2-smFlag / tTA2 In the vector, the hSyn promoter drives mCherry and then encodes sesRNA Cti p 2 In the binary vector, the reporter vector is driven by the TRE promoter in response to the READR Ctip2-smFlag / tTA2 c, injection of READR Ctip2 (3)-smFlag / tTA2Coronal sections of S1 cortex transfected with AAV. Immunofluorescence using antibodies against FLAG (left) and CTIP2 (center) showed that READR-labeled cells (FLAG + , green) shows the interaction with CTIP2 + High colocalization of PN. d, Magnified view of the boxed area in (c). Arrowheads show representative co-labeled cells. e, READR delivered with a single vector Ctip2(3) f, In the S1 cortex co-injected with the dual AAV vector, READR Ctip2 Infected neurons express mCherry(f1). In a subset of these neurons, sesRNA Ctip2(3) Triggered translation of tTA2 and activation of mNeon expression in L5b PNs (f2). Specificity of mNeon expression in Ctip2 PNs was assessed by CTIP2 immunofluorescence (f3-5). f5 is the boxed region in f4. Arrowheads indicate co-labeled cells. g, READR delivered with binary vector Ctip2(3) Specificity. h, binary READR Cti p 2 (3) The efficiency was calculated as GFP in cells expressing mCherry and CTIP2. + Cell.il,READR Ctip2(3) Calcium imaging of specific cortical neuron types in vivo was achieved. Schematic diagram of left paw stimulation (i) and fiber photometry recording (j) of anesthetized mice. j, AAV-PTenhancer-tTA2 or AAV-Ctip2-CellREADR-tTA2 was co-injected with AAV-TRE-GCaMP6 into the upper limb area (SSp-ul) of the primary somatosensory cortex. k, Heat map of neuronal activity consistent with the onset of left paw stimulation. l, Average calcium signal consistent with the onset of left paw stimulation (two figures on the left). The peak Z score of the response is shown (right figure, n = 2 mice per group). The gray area represents 1 s of stimulation time. The black trace is from data consistent with the shuffled onset time. The shading around the mean represents ± sem. Data are mean ± sem. mp, READR Ctip2(3)Optogenetic manipulation of specific cortical neuron types in behaving mice was achieved. mn, Schematic diagram of optogenetic stimulation experiments with head-fixed mice (m) and virus injections (n). Two cameras were used to record evoked movements. The nose tip was the coordinate origin. The X, Y, and Z axes correspond to the medial-lateral, anterior-posterior, and dorsal-ventral axes, respectively. Reflective markers were attached to the dorsal surface of the left paw for tracking (red dots). n, AAV-PTenhancer-tTA2 or AAV-Ctip2-CellREADR-tTA2 was co-injected with AAV-TRE-ChRger2-eYFP into the caudal forelimb area (CFA). o, Velocity of the left paw before and after the onset of stimulation (n = 20 trials for PTenhancer mice; n = 16 trials for Ctip2CellREADR mice). The black trace represents the mean. The red line represents the onset of stimulation. The blue bar represents 500 ms of stimulation (see also Supplementary Video 1). p, Movement trajectories of the left paw during optogenetic stimulation (n = 20 trials for PT enhancer mice; n = 16 trials for Ctip2CellREADR mice). Lateral (left) and anterior (right) trajectories were normalized to the starting position of the left paw. Black traces represent the mean. Squares represent the position of the left paw when stimulation stopped.
[0038] Figure 5 .Targeting and recording of human cortical neuron types enabled by CellREADR a, Schematic diagram of the binary AAV vector used to target neuron types in human brain tissue. In the READR vector, the hSyn promoter drives the ClipF-Tag and subsequently encodes the sesRNA FOXP2 , smV5, and tTA2 sequences. In TRE3g-mNeon, the TRE promoter drives mNeon expression in response to tTA from the READR virus. b, Genomic structure of the human FOXP2 gene. Two sesRNAs were designed to target FOXP2 mRNA. c, READR targeting of human FOXP2 cells. Organotypic slices from the temporal neocortex were expressed with READR FOXP2(1) AAV-targeted upper layer FOXP2 cells (mNeon, naturally fluorescent) (c1). READR from the parietal neocortex FOXP2(2) Targeted deep-layer FOXP2 cells (c2). The insets in c1 and c2 show magnified views of the boxed areas. Dashed lines delineate the pia mater and white matter. d, READR FOXP2(2) Immunostaining of FOXP2 in labeled neurons. Arrowheads indicate neurons co-labeled with mNeon native fluorescence (left) and FOXP2 immunofluorescence (center); arrowheads indicate cells labeled only by mNeon. e, READR assayed by FOXP2 immunofluorescence FOXP2(2)Specificity. Error bars are mean ± sem. n = 2 biological replicates performed. f, Current clamp recording traces of three mNeon-labeled neurons (top). The input-output curves of the cells depict similar spike behaviors (top). g, Morphology of the labeled neurons recorded in (f) (blue curve). The patched cells were filled with biotin for post-recovery and visualized by silver staining under bright field. Brown arrowheads, cyan arrowheads, and purple arrowheads indicate cell soma, axons, and dendrites, respectively. h, SesRNA designed to target exon 2 of human VGAT mRNA. I, from co-infected AAV-READR VGAT ; TRE3g-mNeon and organotypic slices of human temporal neocortex visualized by native fluorescence 8 days after infection. jk, AAV-READR VGAT -Morphology of labeled interneurons. l, Colocalization of mNeon native fluorescence (left) with VGAT mRNA by in situ hybridization (center). Arrowheads indicate co-labeled neurons; arrowheads indicate cells labeled only by mNeon. m, READR assayed by VGAT mRNA in situ VGAT Specificity. Error bars are mean ± sem. n = 2 biological replicates performed. n, Current clamp recording traces (top) of three labeled neurons filled with biotin for post hoc recovery. Streptavidin dye was used for visualization. Input-output curves (bottom) depict different spiking behaviors (adapting (blue), fast (green), delayed onset (red)). o, READR recorded in (n) VGAT Mark the cell morphology.
[0039] Figure 6 Design and testing of single and dual CellREADR vectorsa,
[0040] Schematic diagram of a single CellREADR vector. Left: PGK-tdT expresses tdTomato target RNA from the PGK promoter. tdT-GFP Expression of sesRNA driven by CAG promoter tdT and efRNA GFP The vertical dotted lines represent tdT mRNA and sesRNA. tdT The complementary base pairing region between the two, and the sequence around the editable stop codon is shown on the right. At the editing site, the sesRNA tdT The editable adenine in (cyan) is mispaired with the cytosine in the tdT mRNA. TdTomato is a tandem repeat of two dTomato genes, so the tdT RNA contains two copies of the sesRNA tdTBase-paired target sequence. b.-d.READR tdT-G ' P Verification of the vector. tdT-GFP In 293T cells co-transfected with PGK-tdT (b), many cells turned on GFP translation and fluorescence (c. arrow in the upper figure). In cells co-transfected with the control empty vector, few cells showed GFP expression (c. arrow in the lower figure). GFP expression was further determined by Western blotting (d). e, Binary vector design for CellREADR luciferase assay. READR tdT-tTA2 sesRNA tdT and efRNA tTA2 , TRE-ffLuc expresses luciferase RNA upon activation of tTA2. f, Luciferase activity is significantly enhanced only in cells transfected with the three vectors in (e). Co-transfection of TRE-ffLuc with CAG-tTA2 constitutively expressing tTA2 was used as a positive control. g, Schematic READR tdT-GFP vector, in which sesRNA tdT A spacer sequence was inserted before the coding region. h, READRs encoding spacers of different lengths expressed with target RNA without (grey) or with (pink) tdT tdT-GFP The vector was transfected into 293T cells. Calculated as RFP + GFP + Quantification of conversion rate as a percentage of cells. i, Binary vector design for CellREADR assay. j, Representative images of GFP conversion using the binary vector in (i). Ctrl In cells co-transfected with the vector, a small amount of GFP was observed + The percentage of conversion is shown on the right. Error bars in F and H are mean ± SEM, n = 3 for F and n = 2 for H, where n represents the number of independent experiments performed in parallel.
[0041] Figure 7 .CellREADR enables RNA sensing-dependent gene editing and cell ablationa, used for the design of vectors for CellREADR-mediated and target RNA-dependent gene editing. In READR tdT-Cas9 / GFP, the CAG promoter drives BFP and subsequently encodes sesRNA tdTb, READR was quantified as the percentage of GFP in RFP- and BFP-expressing cells with or without tdT target RNA. tdT-Cas9 / GFP c, using U6b-gRNA DYRK1A -CAG-tdT and READR tdT-Cas9 / GFP Transfected cells show robust GFP expression colocalized with BFP and RFP (bottom). Cells transfected with READR tdT-Cas9 / GFP alone (top) show almost no GFP expression. d, SURVEYOR assay shows Cas9-mediated cleavage in the human DYRK1A locus. DYRK1A- CAG-tdT and READR tdT-Cas9 / GFP DNA cleavage was observed in cell lysates transfected with U6b-gRNA lacking tdT target RNA. DYRK1A No DNA cleavage was observed in the cell lysates transfected with READRtdT-Cas9 / GFP. CAG-Cas9 using U6b-gRNADYRK1 A cell lysate and 293T cell lysate without plasmid transfection were used as positive and negative controls, respectively. Arrows indicate cleavage products. e, Vector design for CellREADR-mediated and target RNA-dependent cell death induction. tdT-taCasp3-TEVp In the , the CAG promoter drives BFP and the subsequent sesRNA encoding tdT f, The level of apoptosis measured by luminescence was higher in cells transfected with READR compared to cells without tdT RNA. tdT -taCasp3-TEVp and EF1a-tdT. Error bars in b and f are mean ± sem. n = 3, n represents the number of independent experiments performed in parallel.
[0042] Figure 8 .CellREADR's Effect on Targeted mRNA
[0043] a, Quantitative PCR shows that CellREADR-mediated sesRNA expression does not affect the expression level of the target RNA. b, EEF1A1 mRNA and sesRNA EEF1A1-CDSBase pairing. EEF1A1 mRNA or sesRNA is indicated in blue and red, respectively. Peptides translated from EEF1A1 mRNA are highlighted in brown. Targeted regions of EEF1A1 mRNA were analyzed by RNAseq. c, The A to G change ratio of EEF1A1 mRNA at each adenosine position was quantified and displayed in a heat map. Two adenylate nucleotides (A107 and A115) showed a higher A to G editing rate (c). Off-target editing of two sensitive adenosines can induce potential amino acid changes (underlined in b). Error bars are mean ± sem. n = 3, n indicates the number of biological replicates performed.
[0044] Fig. 9 .Design and screening of sesRNAs targeting Fezf2 and Ctip2 RNA in vivo and in vitro.
[0045] ab, Genomic structures of mouse Fezf2 (a) and Ctip2 (b) genes, where the positions of various sesRNAs are as indicated. c, List of sesRNAs used for sesRNA screening and Fezf2 and Ctip2 target gene fragments. d, In the target vectors CAG-BFP-Fezf2 or CAG-BFP-Ctip2, a 200bp-3000bp genomic region of the Fezf2 or Ctip2 gene containing a sequence complementary to the sesRNA in (a, b) was cloned downstream of the BFP and T2a coding regions driven by the CAG promoter. In the READR vector, READR Fezf2-GFP or READR Ctip2-GFP Expression of the corresponding sesRNA shown in (a, b). e.-f. FACS analysis of 293T cells co-transfected with CAG-BFP-Fezf2 or CAG-BFP-Ctip2 target vectors to determine the expression of READR Fezf2 -GFP (e) or READR Ctip2-GFP (f) The efficiency is quantified as GFP conversion rate. g, Schematic diagram of the binary READR AAV vector. In the READR vector, the hSyn promoter drives mCherry and subsequently encodes sesRNA Cti p 2 , smFlag and tTA2 effector sequences. In the reporter vector, the TRE promoter drives mNeonGreen in response to tTA2 from the READR vector. h, injection of the binary READR Fezf2 Coronal sections of mouse cortex. mNeonG expresses READR Fezf2Labeled cells. Four Fezf2 sesRNAs were screened. i, Quantification of the specificity of the four Fezf2 sesRNAs in (h). For Fezf2 sesRNA in vivo screening, the specificity of each sesRNA was calculated by co-labeling with READR AAV and CTIP2 antibody (due to the lack of Fezf2 antibody); since Ctip2 represents a subpopulation of Fezf2+ cells (not shown), the CTIP2 antibody underestimates the specificity of Fezf2 sesRNA. SesRNA1 showed the highest specificity. j, Injection of dual READR Ctip2 Coronal sections of mouse cortex with vector. mNeonG represents cells labeled with binary READR. Eight Ctip2 sesRNAs were screened. k, Quantification of the specificity of eight sesRNAs in (j). Ctip2 AAV and CTIP2 antibodies (not shown) were co-labeled to calculate the specificity of each sesRNA. SesRNA3 and sesRNA8 showed the highest specificity.
[0046] Fig.10 .PNFezf2- and PNCtip2-type CellREADR targeting in the cortex of ADAR2-overexpressing mice
[0047] ab, Genomic structures of mouse Fezf2 (a) and Ctip2 (b) genes, with sesRNA positions as indicated. c, Schematic representation of binary AAV vectors used to target neuronal types. Fez f 2-tTA2 In the , the hSyn promoter drives ADAR2 and subsequently encodes sesRNA Fezf2(1) , T2a, and tTA2 effector sequence expression. In TRE-mRuby, the TRE promoter drives mRuby3 expression in response to tTA2 from the READR virus. d, Coronal section image from the brain of a Fezf2-CreER;LoxpSTOPLoxp-H2bGFP mouse showing Fezf2 + Distribution pattern of PNs in the S1 somatosensory cortex (d1). Rodrigo et al. Cellular anatomy of the mouse primary motor cortex Nature, Vol. 598, pp. 159-166 (2021). As previously described in Kim, Y. et al. Brain-wide mapsreveal stereotyped cell-type-based cortical architecture and subcorticalsexual dimorphism.Cell 171, 456-469.e422 (2017), Cre reporter transgenic mice were generated by hybridizing the 'knock-in' Cre driver with reporter mice (CAG-LoxP-STOP-LoxP-H2B-GFP). AAV READRFezf2 (1)-tTA2 and TRE-mRuby specifically labeled PNs (d2) were co-injected in L5b and L6. Co-labeling (d3) was performed by CellREADR AAV and H2bGFP, with an enlarged view in (d4). Arrows indicate co-labeled cells; arrowheads show neurons labeled with CellREADR AAV but not with Fezf2-H2bGFP (d4). e, Specificity of READRFezf2(1)-tTA2. f, Coronal sections of WT brains immunostained with CTIP2 antibody, showing Ctip2 + Distribution pattern of PNs in the S1 cortex (f1). AAV READR co-injected in L5b Ctip2(1 PNs specifically labeled with TRE-mRuby (f2). Co-labeling by CellREADR AAV and CTIP2 antibody (f3), with magnified view in (f4). Arrows show co-labeled cells; arrowheads show READR Ctip2(1) Mislabeled cells (f4). g, READR Cti p 2(1) Specificity. h, Axonal projection patterns of PNs infected with AAVREADRCtip2(1)-tTA2 and TRE-eYFP in the S1 cortex. Representative images showing projections to the striatum, thalamus, midbrain, pons, and medulla oblongata (arrows). i, Schematic locations of coronal sections are shown on the right.
[0048] Fig.11 .Expression levels and laminar distribution of cell type markers in mouse cortex.
[0049] a. Group plots of selected genes in transcriptomic cell type clusters based on the Allen Institute for Brain Science dataset. Gene expression levels and cortical distribution are shown. b, Gene expression levels of major cell type marker genes. These plots were generated using scRNAseq data40 .
[0050] Fig.12 CellREADR targeting of additional cortical neuron types in mice
[0051] a, Genomic structure of the mouse Satb2 gene, with the positions of sesRNAs as indicated. bc, By co-injection Figure 4 Cell labeling patterns in S1 using binary vectors as described in i. (b1) AAVsREADR in upper and deeper layers Satb2 and TRE-mNeon labeled cells. (b2). Satb2 mRNA in situ hybridization. (b3) READR Satb2 Co-labeling of Satb2 mRNA in the S1 cortex at P56 in the Allen Mouse Brain Atlas. + Percentage of cells with READR Satb2 f, Genomic structure of the mouse PlxnD1 gene, where the positions of the sesRNAs are as indicated. gh, Upper layers in S1 and L5a in AAVs READR PlxnD and TRE-mNeon labeled cells (g1). PlxnD1 mRNA in situ hybridization (g2). PlxnD1 Co-labeling with AAV and PlxnD1 mRNA (g3). h, Magnified view of the boxed area in (g3). Arrows indicate co-labeled cells. I, PlxnD1 mRNA expression in P56 S1 cortex from the Allen Mouse Brain Atlas. j, PlxnD1 measured in mNeon cells + Percentage of cells with READR PlxnD1 k, Genomic structure of the mouse Rorb gene, with sesRNA positions as indicated. l, AAVs READR in layer 4 Rorb and TRE-mNeon labeled cells (l1, l3). Laminar structure indicated by DAPI staining (l2). The mNeon labeling pattern is consistent with Rorb mRNA expression in the Allen Mouse Brain Atlas P56S1 cortex (m); due to the lack of specific antibodies against RORB and in situ probes for Rorb mRNA, the specificity of Rorb sesRNA remains to be rigorously quantified. n, Genomic structure of the mouse vGAT gene, where the location of the sesRNA is as indicated. op, Binary READR vGATand TRE-mNeon labeled cells (o1). vGAT mRNA in situ hybridization. (o2). vGAT Co-labeling of AAV and vGAT mRNA (o3). p, Magnified view of the rectangle in (o3). Arrows indicate co-labeled cells. q, vGAT mRNA expression in P56 S1 cortex from the Allen Rat Brain Atlas. r, Measured as vGAT in mNeon cells + Percentage of cells with READR vGAT Specificity.
[0052] Fig.13 Evaluation of the immune response of cortical cells after long-term expression of the CellREADR vector
[0053] a, Schematic diagram of the long-term effect evaluation of CellREADR in vivo. For each mouse, READR Ctip2(3) or CAG-tdT control AAV was injected into the S1 cortex and incubated for three months. Fresh brains were dissected and small pieces of cortical tissue at the injection site were collected. Quantitative PCR was performed immediately. S1 tissue from mice without virus injection was used as a control. b, Heat map of changes in expression levels of nine genes involved in glial activation and immunogenicity.
[0054] Fig.14 .AAV READR Ctip2 Axonal projection patterns of L5 / 6CFPNs targeted by TRE-ChRger2-eYFP in the caudal forelimb motor area
[0055] a, READR for optogenetic activation and axonal projection tracing Ctip2(3)-smFlag / tTA2 a, Schematic diagram of binary AAV vectors of TRE-ChRger2-eYFP. b, Axonal projection pattern of CFPN infected in CFA. Representative images show projections to the striatum (b2), thalamus (b3, b4), pons (b5), and medulla oblongata (b6, arrows). c, Schematic location of coronal sections in b.
[0056] Fig.15 CellREADR targeting of neuronal types in rats
[0057] a, Schematic diagram of the binary AAV vector for cell type targeting in rats. In the READR vector, the hSyn promoter drives the expression of mCherry followed by sequences encoding sesRNA, smFlag, and tTA2 effectors. Together with READR, the reporter vector drives the expression of mNeonG from the TRE promoter in response to tTA2 from the READR vector. b, Genomic structure of the rat vGAT gene, where the position of sesRNA is as shown. c, AAVs READRvGAT and TRE-mNeon injected into the deep cortex and hippocampus. Cells labeled by the binary vector are shown in the cortex (c1). c2, magnified view of the boxed area in (c1). Labeling of vGAT mRNA by in situ hybridization (c3). Co-labeling by mNeon and vGAT mRNA (c4). Arrows show co-labeled cells. d, AAV READR vGAT Cell labeling patterns in the CA1 region of the hippocampus after co-injection of TRE-mNeon and TRE-mNeon. e, Magnified view of the boxed area in (d). Arrows indicate co-labeled cells. fg, Measurement of vGAT in mNeon cells + Percentage of cells expressing READR in rat cortex (f) and hippocampus (g) vGAT h, Genomic structure of the rat Tle4 gene, where the sesRNA is located as indicated. ij, AAV READR co-injected into labeled cells (i1) concentrated in the deep layers of the rat motor cortex Tle4 and TRE-mNeon( Figure 4 i) Tle4 labeling by Tle4 antibody staining + PN (i2,3). j, Magnified view of the boxed area in (i). Arrows indicate cells co-labeled by CellREADR and TLE4 antibodies. k, Rat READR in rat cortex measured as the percentage of TLE4+ cells in mNeon cells Tle4 specificity.
[0058] Fig.16 . CellREADR vector targeting of neuronal types in isolated human cortical tissue
[0059] a, Schematic diagram of the organotypic platform for ex vivo human cortical tissue. b, Schematic diagram of the hSyn-eGFP viral construct used to drive extensive neuronal cell labeling. c. AAVrg-hSyn-eGFP-labeled cells are distributed in all layers and exhibit distinct morphologies (c1). The illustrations of c1 (c2) and c2 (c3, 4) depict many cells with pyramidal morphology, including prominent vertically oriented apical dendrites. d, FOXP2 expression in the human neocortex. FOXP2 mRNA expression pattern taken from the Allen Institute Human Brain Atlas (sample #4312), showing upper and deep layer expression (arrows) (d1). FOXP2 immunostaining (magenta dye) in the current study also shows upper and deep layer labeling (d2, 4). NeuN immunostaining (red) depicting cortical neurons (d3, 4). Dashed lines depict the pia mater and white matter. e, READR in organotypic sections derived from the same tissue used in d). FOXP2(1)Labeling. Overview of bright field and mNeon native fluorescence in organotypic slices shows highly restricted labeling compared to that observed in d. The inset of e2(e3) depicts the morphology of upper layer pyramidal neurons. f, READR FOXP2 Schematic diagram of two single vectors. In READRFOXP2 (1), the hSyn promoter drives the expression cassettes encoding ClipF, sesRNA1, smV5, and tTA2. FOXP2(2) In the figure, the hSyn promoter drives the expression cassettes encoding ClipF, sesRNA2, smFlag, and FlpO. g, READR was applied at DIV 1 FOXP2(2) Seven days after AAV, tissues were fixed and stained with antibodies against FOXP2 and FLAG. FOXP2(2) FLAG-labeled cells exhibit relatively small somata with short apical dendrites (arrowheads). Nonspecific background fluorescence signals (e.g., vessel-like outlines) are indicated by thin arrows in the middle panel. i, measured as V5 labeled by FOXP2 immunostaining, + Cells (for READR FOXP2(1) ) and FLAG + Cells (for READR FOXP2(2) ) Quantification of CellREADR specificity as a percentage of .
[0060] Fig.17 . In vivo epileptic CellREADR targeting of GABA neurons in macaque cortex.
[0061] a. Schematic diagram of the macaque vGAT gene. b. Binary CellREADR AAV vector. ce, Labeling of neurons with interneuron morphology in the macaque primary visual cortex after 2 months of AAV incubation.
[0062] Fig.18 . EpilepsymCellREADR targeting of human PV and SST neurons in ex vivo human neocortical tissue from epilepsy resected patients.
[0063] a. Human SST gene and sesRNA design. b. Binary AAV vectors for labeling and manipulating GABA neuron types. c. Human PV gene and sesRNA design. d. Examples of morphological labeling and firing patterns of human PV neurons. e. 14 of 15 neurons targeted by the PV sensor exhibited fast spikes characteristic of PV interneurons.
[0064] Fig.19 .CellREADR targeting of GLU and GABA neuronal types in macaques.
[0065] a. AAV-READRFOXP2; AAV-TRE3g-mNeon labeled putative FOXP2 cells in V1. The boxed area in b is enlarged to show GFP+ cones, with apical dendrites (open arrowheads) mainly located in L6 and axons mainly located in the white matter (closed arrowheads), suggesting their efferent parts. c. AAV-READRVGAT; AAV-TRE3g-mNeonon labeled putative GABA cells in V1. dg. Examples of multipolar cells from c with aspartate dendrites characteristic of multiple GABA IN proteins.
[0066] Fig. 20 .Cell-specific treatment for chronic pain
[0067] Binary expression vectors in which translation of the transcriptional activator tTA is gated by a NaV1.7 or NaV1.8 RNA sensor; tTA subsequently activates shRNA transcription of the NaV1.7 or NaV1.8 RNA.
[0068] Fig.21 .Cell-specific interventions in Alzheimer's disease
[0069] Schematic diagram of READR RNA consisting of sesRNA targeting AD marker RNA and effector RNA encoding tTA2, which are driven by the hSyn promoter. Upstream of this cassette, shRNA against ApoE4 RNA is driven by the TRE enhancer. DETAILED DESCRIPTION OF THE INVENTION
[0071] definition
[0072] In order to promote an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments, and specific language will be used to describe these preferred embodiments. However, it should be understood that this is not meant to limit the scope of the present disclosure, and such changes and further modifications to the present disclosure as shown herein are considered to be generally thought of by those skilled in the art to which the present disclosure relates.
[0073] Thus, one aspect of the present disclosure provides a modular readrRNA molecule comprising: (i) a 5' region containing a sensor RNA domain, the sensor domain comprising an ADAR-editable stop codon; and (ii) a 3' region containing an effector RNA (efRNA), the effector RNA being located downstream of and in frame with the sensor domain, wherein the sensor domain of the modular readrRNA molecule specifically binds to a cellular RNA encoded by a gene differentially expressed in a cell (preferably a cell or cell population of the cortex) through sequence-specific base pairing to form an RNA duplex, wherein the efRNA encodes a protein, and wherein the ADAR-editable stop codon acts as a translation switch, thereby allowing translation of the efRNA region to produce the effector protein.
[0074] In one aspect, the modular readrRNA molecule further encodes a self-cleaving 2A peptide located between the sensor domain and the effector RNA region. The self-cleaving 2A peptide is selected from the group consisting of: one or more of a T2A peptide, a P2A peptide, an E2A peptide, and a F2A peptide. Preferably, the 2A peptide is T2A.
[0075] In one aspect, the effector (efRNA) domain of the modular readrRNA encodes a detectable protein or detectable protein fragment (tag) and / or a transcriptional activator or repressor.
[0076] In one aspect, the genes differentially expressed in cortical cells are selected from the group consisting of: Fezf2, Ctip2, PlxnD1, Satb2, Rorb and vGAT.
[0077] Another embodiment of the present invention is a CellREADR "system" comprising at least two components, wherein the first component comprises a modular readrRNA molecule and wherein the second component comprises a gene that responds to a protein encoded by an effector domain. In one aspect of the CellREADR system, the protein encoded by the efRNA encoded by the modular readrRNA molecule comprises the tetracycline-dependent transcriptional activator tTA2, and wherein the sensor domain of the modular readrRNA molecule specifically binds to a cellular RNA encoded by the Ctip2 gene, and wherein the second component of the CellREADR system comprises a gene operably linked to a TRE-3G eukaryotic inducible promoter that responds to the tetracycline-dependent transcriptional activator tTA2. In one aspect of the CellREADR system, the efRNA protein encoded by the modular readrRNA molecule also comprises smFlag. In one aspect of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the calcium indicator GCaMP6s. In one aspect of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the calcium indicator GCaMP6s. In one aspect of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the light-activated ion channel rhodopsin-2.
[0078] Another embodiment of the present invention is to use CellREADR in response to mechanical stimulation of the forepaw. Ctip2 / 3 A method of stimulating GCaMP6s signaling in the forelimb sensory cortex in transduced mice (as measured by photometry) comprises co-infecting the mice with the CellREADR system described above.
[0079] Another embodiment of the present invention is to respond to CellREADR Ctip2 / 3 A method for stimulating forelimb movement by light stimulation of CFA of a transduced mouse comprising co-infecting the mouse with the CellREADR system described above. In another aspect, a second gene is operably linked to the TRE-3G eukaryotic inducible promoter, the second gene (eYFP) encoding enhanced yellow fluorescent protein.
[0080] Another embodiment of the invention is a delivery system comprising modular readrRNA molecules operably associated with a vehicle for administering the modular readrRNA to an organism, tissue or cell.
[0081] Another embodiment of the present invention is a delivery system comprising the above-described CellREADR system operably associated with a vehicle for administering the above-described CellREADR system to an organism, tissue or cell.
[0082] Another embodiment of the present invention is a delivery system, wherein the delivery vehicle is selected from the group consisting of nanoparticles, liposomes, vectors, exosomes, microbubbles, a gene gun, and a selective endogenous encapsidation for cellular delivery (SEND) system.
[0083] Another embodiment of the present invention is a delivery system comprising a recombinant viral vector, preferably one of adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus vector, vesicular stomatitis virus and combinations thereof.
[0084] Another embodiment of the present invention is a pharmaceutical composition comprising the above modular readrRNA molecule and / or the above CellREADR system and / or the above delivery system, and a pharmaceutically acceptable carrier, excipient and / or diluent.
[0085] Another embodiment of the present invention is a cell comprising the above modular readrRNA molecule and / or the above CellREADR system or the above delivery system, wherein preferably, the cell is a mammalian cell.
[0086] Another embodiment of the present invention is a kit comprising a kit containing the above modular readrRNA molecule and / or the above CellREADR system and / or the above delivery system.
[0087] Another embodiment of the present invention is a method for identifying GABAergic neurons in a mammalian cortex in vivo, comprising targeting vesicular GABA transporter (vGAT) mRNA in the mammalian cortex in vivo, the method comprising administering to the S1 barrel cortex and hippocampus of the mammal (i) a READR vGAT Binary AAV vector and (ii) reporter gene mNeon READRvGAT comprises [hSyn-mCherry-sesRNA] in a 5' to 3' transcriptional order (human Syn promoter, RNA encoding red fluorescent protein mCherry operably linked thereto, followed by a sesRNA encoding a target vGAT mRNA, a 2a protein, smFlag (smV5), a second 2a protein, a tetracycline-dependent transcription activator tTA2, and a sequence of W3SL). vGAT- smFlag-tTA2], wherein the reporter gene mNeon Contains [TRE3g-mNeon-WPRE],
[0088] wherein after administration, vGAT mRNA in the S1 barrel cortex and hippocampus of a mammal is co-labeled with a magenta dye and GFP, indicating that GABAergic neurons are identified in the mammalian cortex. In one aspect, the sesRNA targeting vGAT mRNA is complementary to all or part of exon 1 of vGAT mRNA.
[0089] Another embodiment of the present invention is a method for identifying GABAergic neurons in the cortex of a mammal in vivo, comprising targeting transducin-like enhancer protein 4 (Tle4) mRNA, the method comprising administering to the S1 barrel cortex of the mammal (i) a protein comprising READR vGAT Binary AAV vector and (ii) reporter gene mNeon , where the READR vGAT The reporter gene was expressed in a 5' to 3' transcriptional sequence (human Syn promoter, RNA encoding the red fluorescent protein mCherry operably linked thereto, followed by a sesRNA encoding Tle4 mRNA, a 2a protein, smFlag (smV5), a second 2a protein, a tetracycline-dependent transcriptional activator tTA2, and a sequence of W3SL), wherein the reporter gene mNeon The invention comprises [TRE3g-mNeon-WPRE], wherein after administration, Tle4 mRNA in the S1 barrel cortex of a mammal is co-labeled with a magenta dye and GFP, indicating that GABAergic neurons are identified in the mammalian cortex. In one aspect, the sesRNA targeting Tle4 mRNA is complementary to all or part of exon 15 of Tle4 mRNA.
[0090] Another embodiment of the present invention is a method for identifying cortical layers expressing human FOXP2, an evolutionarily conserved gene involved in the development of human language skills, in an organotypic culture platform, comprising administering READR FOXP2 / Reporter mNeon AAV (hSyn-ClipF–sesRNA with TRE3g-mNeon FOXP2 -smV5-tTA2), where 5 days after administration, mNeon-labeled cell bodies were observed in the upper and deep layers of the cortex of the organotypic culture platform, indicating that human foxp 2 was expressed in the upper and deep layers
[0091] Another embodiment of the invention is a method of inhibiting neural activity that promotes focal epileptic seizures in some cell types, comprising targeting a pathophysiological neural ensemble (PNE) comprising cell types involved in neural activity involved in seizure activity, wherein a marker of neural activity is a rapid upregulation of the immediate early gene (IEG) c-fos, the method comprising administering a READR operably linked to one of three effector genes c-fos , the effector gene is selected from the group consisting of: voltage-gated potassium channel kv1.1 (KCNA1), inhibitory DREADD (hM4D (Gi) inhibitory receptor) and chloride-permeable invertebrate glutamate receptor (eGluCL), wherein during epilepsy, upregulation of c-fos RNA will trigger effector translation to inhibit PNE activity. In one aspect, the effector gene is an inhibitory DREADD receptor, which is activated by the oral drug olanzapine. In another aspect, the effector gene is eGluCL, which is activated by the drug ivermectin. In another aspect, the effector gene is an inhibitory PSEM, which is activated by the drug varenicline.
[0092] Another embodiment of the present invention is a method for treating chronic pain, which comprises targeting nociceptors comprising RNA sensors (the RNA sensors targeting RNA encoded by voltage-gated sodium channels TRPV1 or NaV1.8 of dorsal root ganglia), and using CellReadR cell type-specific small hairpin RNA (shRNA) to mediate effector expression in a knockout approach to downregulate NaV1.7 and NaV1.8 mRNA in nociceptors.
[0093] Another embodiment of the present invention is a method for treating Alzheimer's disease, which targets marker genes / RNAs, including but not limited to marker genes / RNAs in astrocytes: aldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 1 (EAAT1); in microglia: C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119), ionized calcium binding adaptor molecule 1 (IBA-1), and using CellReadR cell type-specific small hairpin RNA (shRNA) to mediate effector expression to downregulate ApoE4.
[0094] As used herein, the term "stop codon" refers to a sequence of three nucleotides (trinucleotides) in DNA or messenger RNA (mRNA) that signals the cessation of protein synthesis in a cell.
[0095] A "codon" in messenger RNA corresponds to a nucleotide triplet that codes for an amino acid. Consecutive codons in RNA can be translated into a protein. In practice, the stop codon is located at the 3' end of one or more coding regions of the mRNA and signals the termination of translation by binding to a release factor, which causes the dissociation of the ribosomal subunits, thereby releasing the amino acid chain. There are 64 different trinucleotide codons: 61 that indicate amino acids and 3 that are stop codons (i.e., UAA, UAG, and UGA in RNA and TAA, TAG, and TGA in DNA).
[0096] As used herein, "editable stop codon" refers to a stop codon that can be edited by a cell from a stop codon to a translatable codon. Thus, in RNA, an editable stop codon as UAA, UAG or UGA can be edited by a cell to UII, UIG or UGI. The editable stop codon acts as a translation switch for any codon downstream of the editable stop codon. The editing of the stop codon occurs in cells in which endogenous ADAR enzymes are present.
[0097] When the sense RNA containing the editable stop codon forms dsRNA with the target RNA, thereby recruiting the endogenous ADAR enzyme, the "editing" of the stop codon occurs. ADAR acts on the stop codon and performs A to I editing, thereby converting, for example, the UAG stop codon to a UIG (tryptophan) codon, which allows the translation of downstream codons.
[0098] The term "ADAR" is a disambiguation that stands for adenosine deaminase acting on RNA. ADAR enzymes bind to double-stranded RNA (dsRNA) and convert adenosine to inosine (hypoxanthine) through deamination. ADAR proteins act post-transcriptionally, altering the nucleotide content of RNA. The conversion of adenosine to inosine (A to I) in RNA disrupts the normal A:U pairing, making the RNA unstable. Inosine is structurally similar to guanine (G), which results in inosine binding to cytosine (I:C). Inosine normally mimics guanosine during translation, but can also bind to uracil, cytosine, and adenosine, although it is not favored.
[0099] As used herein, "readrRNA" refers to a molecule having a 5' region and a 3' region, wherein the readrRNA molecule comprises, consists of, or consists essentially of: (i) a 5' region containing a sensor (ses) domain, the sensor domain comprising at least one ADAR-editable stop codon; and (ii) an effector RNA (efRNA) region, which is located downstream of the sensor domain and in frame with it.
[0100] In the readrRNA, an ADAR-editable stop codon is located within the sensor RNA and upstream of the in-frame effector coding region.
[0101] As used herein, "ADAR-editable stop codon" refers to a stop codon that can be edited by ADAR in a cell. Schneider, MF, Wettengel, J., Hoffmann, PC, & Stafforst, T. (2014). Optimal guide RNAs for re-directing deaminase activity of hADAR1 and hADAR2 intrans. Nucleic acids research, 42(10), e87. https: / / doi.org / 10.1093 / nar / gku272
[0102] As used herein, "sensor domain" refers to a group of contiguous nucleotides that form part of the readrRNA, wherein the sensor domain also includes at least one editable stop codon and a downstream effector domain. The sensor domain comprises contiguous nucleotides that are complementary to the RNA of a specific cell type through sequence-specific base pairing. The sensor domain may comprise a number of nucleotides, including at least 10 nucleotides to at least 1000 nucleotides or more. In some embodiments, the sensor domain comprises about 100 to about 900 nucleotides, consists essentially of about 100 to about 900 nucleotides, or consists of about 100 to about 900 nucleotides. In another embodiment, the sensor domain comprises about 200 nucleotides to about 300 nucleotides, or consists essentially of about 200 nucleotides to about 300 nucleotides or consists of about 200 nucleotides to about 300 nucleotides. The sensor domain may be 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 or more contiguous nucleotides in length.
[0103] At least one editable stop codon in the sensor domain is located anywhere within the sensor domain of the readrRNA. The sensor domain has a 5' to 3' orientation in the readrRNA molecule and includes a (5)' upstream portion and a (3)' downstream portion. The editable stop codon may be located in the upstream portion of the sensor domain or the downstream portion of the sensor domain. The editable stop codon may be located in the upstream portion of the sensor domain closer to the middle of the sensor domain, or the editable stop codon may be located in the downstream portion of the sensor domain closer to the downstream end of the sensor domain. For example, if the sensor domain is 600 nucleotides in length and is spatially divided into two halves, wherein the first nucleotide represents the 5' end of the sensor domain, the 300th nucleotide represents the middle of the sensor domain, and the last (600th) nucleotide of the sensor domain represents the 3' end of the sensor domain, then the editable stop codon may be located in the upstream portion of the downstream portion or closer to the middle of the sensor domain. If a sensor domain having the same approximate length is divided into four equal parts, the editable stop codon can be located in the first quarter of the sensor domain (nucleotides 1-250), the second quarter of the sensor domain (nucleotides 150-300), the third quarter of the sensor domain (nucleotides 300-450), or the fourth quarter of the sensor domain (nucleotides 450-600). Therefore, for a sensor domain of a given length, the editable stop codon can be located in a selected portion of the sensor domain. Typically, the editable stop codon can be located in the downstream half of the sensor domain or the downstream quarter of the sensor domain. The selected portion of the sensor domain containing the editable stop codon can be within 10-50 nucleotides of the 3' end of the sensor domain.
[0104] As used herein, "effector RNA (efRNA)" is an RNA that is translatable and encodes an effector protein.
[0105] An "effector protein" is a protein encoded by an effector RNA domain that has an effect on the cell in which it is expressed. An effector protein is translated from an effector RNA in a cell, and thus the effector protein, like the RNA encoding it, is introduced into a cell that may or may not contain the same endogenous protein. An effector protein is a protein that has an effect on the cell in which it is translated, or if secreted from a cell, on surrounding cells. Non-limiting examples of effector proteins include: an enzyme, a detectable protein, a cytokine, a toxin, a polymerase, a transcription or translation factor, a tumor suppressor, a neuronal activator or inhibitor, an apoptotic protein, or a physiological factor.
[0106] As used herein, "effector RNA (efRNA) region" refers to a portion of the readrRNA that includes the effector RNA, which is located downstream and in frame with the sensor domain.
[0107] The effector RNA (efRNA) can encode a target effector protein. The selection of the desired effector protein is entirely within the skill of those of ordinary skill in the art and depends on the context of the desired use of the readrRNA. For example, if a given disease needs to be treated, the effector protein can be selected based on the inhibitory effect of the effector protein on cells that are critical to the establishment and / or extension of the disease. For example, the effector module of CellREADR (efRNA) can be constructed to manipulate cells in a variety of ways, including enhancing activity and function, inhibiting activity and function, rescuing mutant cell function by reintroducing the complete form of the missing or mutant protein, changing and editing activity and function, reprogramming cell identity, fate and function, killing and deleting cell types, increasing or decreasing the production of a certain type of cell number, and cell type-specific genome editing and gene regulation.
[0108] Non-limiting examples of effectors are listed below in Table 1. Table 1 provides a non-limiting list of effector proteins (payloads) useful according to the present invention and their effect(s) on cells.
[0109] Table 1
[0110]
[0111] The term "payload" in the context of effector RNA "payload" refers to the protein encoded by the RNA encoding the effector protein.
[0112] As used herein, the phrase "cell type" is a somatic cell of an organism, a somatic cell of an organ, a somatic cell of a tissue, a cell population, or a cell line, or a somatic cell of a hybridoma, a somatic cell of a homogeneous cell population or a heterogeneous cell population, a cell that is resting or quiescent or activated, or transformed or diseased or stressed or inflamed or undergoing heat shock, or is part of the innate immune system, part of the natural immune system, a stem cell, a pluripotent stem cell, an intestinal stem cell, a stem cell, a fetal cell, a cell that contributes to homeostasis, a cell associated with the heart or blood vessels, a cell of the digestive system, a cell of the nervous system, a cell of the skeletal structure, or a cell of an organ, which can be identified by differential expression of RNA.
[0113] As one can imagine, each cell or group of cells is different, and single-cell RNA analysis provides evidence of this diversity regarding the cell's lineage, its activation state, its developmental state, its state as a result of interactions with other cells, tissues and organs and soluble molecules, and / or whether the cell is diseased, transformed or infected.
[0114] As used herein, the term "self-cleaving 2A peptide" or "2A peptide" refers to a class of 18-22 amino acid long peptides that can induce ribosome skipping during protein translation in cells. These peptides share the core sequence motif of DxExNPGP, are present in a wide range of viral families, and help produce polyproteins by causing ribosomes to be unable to form peptide bonds. Examples of suitable 2A peptides include, but are not limited to, T2A, P2A, E2A, F2A, etc. (Liu, Ziqing et al. "Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector." Scientific reports Vol. 7, 1 2193. May 19, 2017, doi: 10.1038 / s41598-017-02460-2). One such self-cleaving 2A peptide includes a T2A peptide.
[0115] Several 2A peptides have been identified in picornaviruses, insect viruses, and type C rotaviruses. As used herein, T2A is a 2A peptide identified in thoseasigna virus virus 2A; P2A is a 2A peptide identified in porcine Teschovirus-1 2A; E2A is a 2A peptide identified in equine rhinitis A virus (ERAV) 2A; and F2A is a 2A peptide identified as a self-cleaving 2A peptide in foot-and-mouth disease virus (FMDV). The following table provides the DNA and corresponding amino acid sequences of various 2A peptides. The underlined sequence encodes the amino acid GSG, which is an example of an optional addition to the natural 2A sequence, designed to improve cleavage efficiency; P2A represents porcine Teschovirus-1 2A; T2A, tetrasomic virus 2A; E2A, equine rhinitis A virus (ERAV) 2A; F2A, FMDV2A. This is modified from Table 1 of Kim JH et al. (High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice) PLoS One. 2011; 6(4): e18556 (published online on April 29, 2011. doi: 10.1371 / journal.pone.0018556.)
[0116] Table 2
[0117]
[0118] As used herein, "a sequence encoding a self-cleaving 2A peptide" is a nucleic acid, preferably RNA, encoding a self-cleaving 2A peptide as described above. According to the present invention, the sequence encoding a self-cleaving 2A peptide is usually located between the sensor domain and the effector RNA region.
[0119] The term "modular" when used in the context of the phrase "modular readrRNA molecule" refers to a recombinant readrRNA molecule comprising a nucleic acid sequence (preferably an RNA sequence) encoding a protein domain designed at the nucleic acid level, preferably at the RNA level, wherein different protein domains can be assembled in the recombinant readrRNA molecule in a desired order with a specified number of repeats (including 0).
[0120] As used herein, "CellREADR" stands for "Cellular Access by Endogenous ADARs [Adenosine Deaminases Acting on RNA] through RNA Sensing," which is designed as a single modular Readr RNA molecule consisting of a 5' sensor editing switch region (sesRNA) and a 3' effector protein (or protein fragment) coding region (efRNA), separated by a linker sequence encoding the self-cleaving peptide T2a and editing machinery ubiquitous in all animal cells (such as a stop codon editable by ADARs). CellREADR provides a mechanism for detecting the presence of cellular RNA and turning on the translation of effector proteins to monitor and manipulate the physiology, function and / or structure of cell types. The table below provides cell types of various tissues, showing the enriched mRNA.
[0121] Table 3
[0122]
[0123]
[0124]
[0125]
[0126]
[0127]
[0128] As used herein, a "CellREADR system" includes the following components: (i) a sensor RNA domain comprising a set of consecutive nucleotides complementary to a portion of a selected cellular RNA, (ii) an effector RNA (efRNA) domain encoding an effector protein, the efRNA domain being located downstream of and in frame with the sensor RNA domain, (iii) an ADAR-editable stop codon located within the sensor RNA domain or between the sensor RNA domain and the effector RNA domain, and (iv) a second protein-encoding nucleic acid or gene, optionally including a genetic control element, wherein (iv) may or may not be physically linked to the sensor RNA and effector RNA domains. The CellREADR system may include an exogenous gene (DNA or RNA) that is not physically linked to the readrRNA (e.g., on a separate vector). The CellREADR system may include a cell containing a readrRNA nucleic acid, a nucleic acid encoding a second protein, for delivery to a multicellular organism, a plant, an animal, or a human.
[0129] As used herein, "delivery system" refers to a system comprising a vehicle for administering modular readrRNA molecules and / or CellREADR system, wherein the vehicle includes but is not limited to nanoparticles, liposomes, vectors, exosomes, microbubbles, gene guns, SEND systems, and combinations thereof.
[0130] The "SEND system" is an mRNA delivery system that includes humanized virus-like particles (VLPs) based on reverse transcription factors present in the human genome (Segel M et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021; 373: 882-889. doi: 10.1126 / science.abg6155). The vectors of this delivery system include, but are not limited to, recombinant viral vectors, such as adeno-associated viruses (AAV), adenoviruses, and retroviruses. Slow virus, herpes virus vectors, vesicular stomatitis viruses, and combinations thereof. In one embodiment, the viral vector includes an AAV vector.
[0131] As used herein, “capable of forming a duplex with” means that the “corresponding consecutive nucleotide segment” can base pair with the consecutive nucleotide segment of the sensor domain RNA.
[0132] As used herein, "corresponding segments" means sequences that are identical in nucleotide length and match by base pairing.
[0133] A “segment” refers to a length of contiguous nucleotides of at least 15 bases or longer; longer includes 20 bases, 25 bases, 30 bases, 40 bases, 50 bases, 60 bases, 75 bases, 100 bases, 125 bases, 150 bases, 175 bases, 200 bases, 225 bases, 250 bases, 275 bases, 300 bases, 325 bases, 350 bases, 375 bases, 400 bases, 425 bases, bases, 450 bases, 475 bases, 500 bases, 525 bases, 550 bases, 575 bases, 600 bases, 625 bases, 650 bases, 675 bases, 700 bases, 725 bases, 750 bases, 775 bases, 800 bases, 825 bases, 850 bases, 875 bases, 900 bases, 925 bases, 950 bases, 975 bases, 1000 bases and longer.
[0134] As used herein, a "translation switch" is a component of a readrRNA molecule that contains an ADAR-editable stop codon component, which binds to a complementary target RNA through an upstream sensor RNA to form a double-stranded RNA structure, resulting in subsequent ADAR-mediated editing of the AUG stop codon, thereby leading to the translation of a downstream RNA encoding an effector protein.
[0135] As used herein, "cellular RNA" refers to RNA that is present in a given cell, whether that RNA is endogenous to the cell (i.e., transcribed from a gene endogenous to the cell) or is present in the cell because it is transcribed from a gene that has been introduced into the cell or from a pathogen (such as a virus, bacterium, fungus, or another microorganism) that has infected the cell.
[0136] As used herein, "cellular RNA of a cell" means an RNA present in a cell that is identifiable by virtue of having specific characteristics because it is known to be present in cells having those specific characteristics.
[0137] As used herein, "cell state determining cellular RNA" refers to one or more RNA sequences present in a selected cell or target cell population, the presence of which identifies the state of a given cell, including but not limited to a specified cell physiology, a specified cell development stage, a specified cell transformation, or a cell activation state.
[0138] That is, the specific physiology of a cell is largely determined by the expression of its unique RNA transcript repertoire. A unique RNA transcript repertoire is a means of identifying a specific cell or target cell population, or identifying a specific activation state of a specific cell or target cell population, or identifying a specific developmental state of a specific cell or target cell population, or identifying any of a variety of physiological states of a cell or a specific cell or target cell population.
[0139] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also encompasses amino acid polymers that have been modified (e.g., by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component).
[0140] In the context of the polypeptides and molecules provided herein, the terms "fusion", "fused", "combination" and "connected" are used interchangeably herein. These terms refer to the connection of two or more protein components by any means including chemical conjugation or recombinant means. For example, if a promoter or enhancer affects the transcription of a coding sequence, it is operably connected to the sequence. Generally, "operably connected" means that the DNA sequences being connected are continuous and in the reading phase or frame. As used herein, the term "in-frame" or "in frame" refers to two or more open reading frames (ORFs) being connected to form a continuous longer ORF in a manner that maintains the correct reading frame of the original ORF. Therefore, the resulting recombinant molecule is a single protein containing two or more segments, and the fragments correspond to the polypeptides encoded by the original ORFs (the segments are not usually connected in this way in nature).
[0141] In the context of polypeptides, a "linear sequence" or "sequence" is the order of amino acids in a polypeptide in the amino-terminal to carboxyl-terminal direction, wherein residues adjacent to each other in the sequence are contiguous in the primary structure of the polypeptide. A "partial sequence" is a linear sequence of a portion of a polypeptide known to contain additional residues in one or both directions.
[0142] "Heterologous" means derived from an entity that is genotypically different from the rest of the entity to which it is compared. For example, a glycine-rich sequence removed from its native coding sequence and operably linked to a coding sequence other than the native sequence is a heterologous glycine-rich sequence. The term "heterologous" as applied to polynucleotides and polypeptides means that the polynucleotide or polypeptide is derived from an entity that is genotypically different from the rest of the entity to which it is compared.
[0143] The terms "polynucleotide", "nucleic acid", "nucleotide" and "oligonucleotide" can be used interchangeably. They refer to a polymeric form of nucleotides of any length, which can be deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of genes or gene fragments, loci (locus) defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. Polynucleotides may contain modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, the nucleotide structure can be modified before or after polymer assembly. The nucleotide sequence can be interrupted by non-nucleotide components. The polynucleotides can be further modified after polymerization, for example, by conjugation with a labeling component.
[0144] The phrases "complementary to" or "complement of a polynucleotide" refer to a polynucleotide nucleic acid molecule having a complementary sequence, wherein the complement has a base sequence in a 5' to 3' or 3' to 5' direction that base pairs with a nucleic acid having an inverse base sequence. As described herein, the sensor RNA is complementary to the specified target RNA except for a mandatory mismatch codon (preferably AUG in the sensor RNA).
[0145] In the context of a sensor domain, the phrase "portion complementary to a cellular RNA" refers to consecutive nucleotides of the sensor nucleic acid domain that are capable of base pairing with corresponding consecutive nucleotides of the cellular RNA.
[0146] In the context of a sensor domain, the phrase "a portion complementary to a messenger RNA (mRNA)" refers to the consecutive nucleotides of the sensor nucleic acid domain that are capable of base pairing with the corresponding consecutive nucleotides of the mRNA.
[0147] The term "cellular RNA" refers to a nucleic acid composed of nucleotides in a cell, which are essentially ribonucleotides, but may include deoxyribonucleotides. The types of cellular RNA include, but are not limited to, mRNA, rRNA, tRNA, and microRNA. The cellular RNA has a length sufficient to form a nucleic acid duplex with a sensor RNA containing a mismatch, thereby attracting ADAR editing and repairing the mismatch. Therefore, the length of the cellular RNA is at least 10 residues, and the length may be 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000 nucleotides or longer.
[0148] "Recombinant" as applied to a polynucleotide means that the polynucleotide is the product of various combinations of in vitro cloning, restriction and / or ligation steps, and other processes that result in a construct that may be expressed in a host cell.
[0149] The terms "gene" or "gene fragment" are used interchangeably herein. They refer to a polynucleotide containing at least one open reading frame that can encode a specific protein after transcription and translation. The term "gene" includes not only an open reading frame, but also at least one promoter that is operably linked to the open reading frame so as to initiate transcription of the open reading frame in the presence of appropriate transcription factors. The gene or gene fragment can be genomic or cDNA, as long as the polynucleotide contains at least one open reading frame, which can cover the entire coding region or a segment thereof. A "fusion gene" is a gene composed of at least two heterologous polynucleotides linked together.
[0150] "Homology" or "homologous" refers to sequence similarity or interchangeability between two or more polynucleotide sequences or two or more polypeptide sequences. When using a program such as BestFit to determine sequence identity, similarity or homology between two different amino acid sequences, the default settings can be used, or a suitable scoring matrix such as blosum45 or blosum80 can be selected to optimize identity, similarity or homology scores. Preferably, homologous polynucleotides are hybridized under stringent conditions defined herein, and have at least 70%, preferably at least 80%, more preferably at least 90%, more preferably 95%, more preferably 97%, more preferably 98%, and even more preferably 99% sequence identity with those sequences.
[0151] As used herein, "treatment", "therapy" and / or "treatment regimen" refers to a clinical intervention performed in response to a disease, disorder or physiological condition exhibited by a patient or to which the patient may be susceptible. The purpose of treatment includes alleviating or preventing symptoms, slowing down or stopping the development or deterioration of a disease, disorder or illness and / or alleviating a disease, disorder or illness. As used herein, the terms "prevent", "preventing", "prevention", "prophylactic treatment" and the like refer to reducing the probability of developing a disease, disorder or illness in a subject who does not suffer from a disease, disorder or illness but has a risk of developing a disease, disorder or illness or is susceptible to developing a disease, disorder or illness. The term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to produce a beneficial or desired biological and / or clinical result.
[0152] An effective amount as used herein in various contexts also includes an amount sufficient to delay the development of disease symptoms, alter the course of a symptomatic disease (e.g., but not limited to, slowing the progression of disease symptoms), or reverse disease symptoms. Therefore, it is generally not feasible to specify an exact "effective amount." However, for any given situation, a suitable "effective amount" can be determined by one of ordinary skill in the art using only routine experimentation.
[0153] The effective amount, toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective to 50% of the population). The effect of any particular dose can be monitored by appropriate bioassays, such as assays of tumor growth and / or size, etc. The dose can be determined by the physician and adjusted as necessary to accommodate the observed therapeutic effect.
[0154] As used herein, the term "administering" an agent, such as a therapeutic entity, to an animal or cell is intended to refer to the distribution, delivery, or application of a substance to an intended target. With respect to a therapeutic agent, the term "administering" is intended to refer to contacting a therapeutic agent with a subject or distributing, delivering, or applying the therapeutic agent to a subject by any suitable route for delivering the therapeutic agent to a desired location in the body of an animal, including delivery by parenteral or oral routes, intramuscular injection, subcutaneous / intradermal injection, intravenous injection, intrathecal administration, oral administration, transdermal delivery, topical administration, and administration by intranasal or respiratory routes.
[0155] The term "biological sample" as used herein includes, but is not limited to, a sample comprising tissue, cells, and / or biological fluids isolated from a subject. Examples of biological samples include, but are not limited to, tissue, cells, biopsies, blood, lymph, serum, plasma, urine, saliva, mucus, and tears. A biological sample can be obtained directly from a subject (e.g., by blood or tissue sampling) or from a third party (e.g., received from an intermediary such as a healthcare provider or laboratory technician).
[0156] As used herein, the term "disorder and / or disease" includes, but is not limited to, any abnormal disorder and / or condition that affects the structure or function of a part of an organism. It may be caused by external factors, such as infectious diseases, or by internal dysfunctions, such as cancer, cancer metastasis, genetic diseases / mutations (congenital and environmental), etc.
[0157] As used herein, a monogenic somatic disease comprising an underlying inherited mutation in a gene refers to a monogenic disease caused by a variation in a single gene. The variation may be present on one or both chromosomes in a pair of chromosomes. Non-limiting examples of monogenic diseases are cystic fibrosis, Huntington's disease, and sickle cell disease.
[0158] As known in the art, cancer is generally considered to be uncontrolled cell growth. The method of the present invention can be used to treat any cancer and any metastasis thereof, including but not limited to carcinoma, lymphoma, blastoma, sarcoma and leukemia. More specific examples of such cancers include breast cancer, prostate cancer, colon cancer, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, salivary gland cancer, mesothelioma, kidney cancer, vulvar cancer, pancreatic cancer, thyroid cancer, liver cancer, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphoblastic leukemia, acute myeloid leukemia, Ewing's sarcoma and peripheral neuroepithelioma.
[0159] As used herein, "contacting" (e.g., as in "contacting a sample") refers to contacting a sample or cell directly or indirectly in vitro, ex vivo, or in vivo (i.e., in a subject as defined herein). Contacting a sample can include adding a compound (e.g., a readrRNA molecule provided herein and / or a delivery system comprising a readrRNA molecule provided herein) to a sample, or administering to a subject. Contacting encompasses administration to a solution, a cell, a tissue, a mammal, a subject, a patient, or a human. In addition, contacting a cell includes adding an agent to a cell culture.
[0160] As used herein, the terms "subject" and "patient" are used interchangeably herein and refer to humans and non-human animals. The term "non-human animal" disclosed herein includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. The methods and compositions disclosed herein can be used for samples in vitro (e.g., on isolated cells or tissues) or in vivo in a subject (i.e., in vivo, such as a patient).
[0161] The terms "decrease", "reduced", "reduction" and "inhibit" are all used herein to indicate a reduction in a statistically significant amount. In some embodiments, "reduce", "reduction" or "decrease" or "inhibit" generally refers to a reduction of at least 10% compared to a reference level (e.g., in the absence of a given treatment or agent), and may include, for example, a reduction of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% or more. As used herein, "reduce" or "inhibit" does not encompass complete inhibition or reduction compared to a reference level. "Complete inhibition" is 100% inhibition compared to a reference level. The reduction may preferably be to a level that is within the acceptable normal range for individuals without a given disorder.
[0162] The terms "increased", "increase", "enhancement" or "activation" are all used herein to indicate an increase in a statistically significant amount. In some embodiments, the terms "increased", "increase", "enhancement" or "activation" may represent an increase of at least 10% compared to a reference level, such as at least about 20% compared to a reference level, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% increase or up to (and including) 100% increase or any increase between 10% and 100%, or at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times or at least about 10 times increase compared to a reference level, or any increase between 2 times and 10 times or higher. In the context of a marker or symptom, "increase" is a statistically significant increase in this level.
[0163] The central nervous system (CNS) has three main components: the brain, the spinal cord, and the neurons (or nerve cells).
[0164] It is one of two parts of the nervous system. The other is the peripheral nervous system, which consists of nerves that connect the brain and spinal cord to the rest of the body.
[0165] The major cell types of the central nervous system include neurons, glial cells (astrocytes, oligodendrocytes, ependymal cells, and microglia), choroid plexus cells, cells associated with blood vessels and coverings. The peripheral nervous system includes efferent neurons (motor neurons), afferent neurons (sensory neurons), and Schwann cells.
[0166] As used herein, "subject" refers to a person or an animal. Typically, the animal is a vertebrate, such as a primate, a rodent, a livestock or a game animal. Primates include chimpanzees, crab-eating monkeys, spider monkeys and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Livestock and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species such as house cats, canine species such as dogs, foxes, wolves, avian species such as chickens, emus, ostriches and fish such as trout, catfish and salmon. In some embodiments, the subject is a mammal, such as a primate, such as a human. The terms "individual", "patient" and "subject" are used interchangeably herein.
[0167] Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of cancer. The subject can be male or female.
[0168] The subject may be a subject who has been previously diagnosed or identified as having or suffering from a disease (e.g., cancer) or one or more complications associated with such a disease that requires treatment, and who has optionally received treatment for the disease or one or more complications associated with the disease. Alternatively, the subject may also be a subject who has not been previously diagnosed with a disease or one or more complications associated with the disease. For example, the subject may be a subject who exhibits one or more risk factors for the disease or one or more complications associated with the disease, or a subject who does not exhibit risk factors.
[0169] A "subject in need of treatment" for a particular disorder can be a subject suffering from the disorder, diagnosed with the disorder, or at risk of developing the disorder.
[0170] In some embodiments, the polypeptide described herein (or nucleic acid encoding such a polypeptide) can be a functional fragment of one of the amino acid sequences described herein. As used herein, a "functional fragment" is a fragment or segment of a peptide that retains at least 50% of the activity of a wild-type reference polypeptide according to an assay described herein below. A functional fragment may comprise conservative substitutions of the sequences disclosed herein.
[0171] In some embodiments, the polypeptides described herein can be variants of the sequences described herein. In some embodiments, the variants are conservatively modified variants. For example, conservative substitution variants can be obtained by mutations of natural nucleotide sequences. "Variants" as described herein are polypeptides that are substantially homologous to natural or reference polypeptides, but due to one or more deletions, insertions or substitutions, they have an amino acid sequence different from the amino acid sequence of a natural or reference polypeptide. The DNA sequence encoding the variant polypeptide encompasses sequences that contain one or more nucleotide additions, deletions or substitutions compared to a natural or reference DNA sequence, but encodes variant proteins or fragments thereof that retain activity. A variety of PCR-based site-directed mutagenesis methods are known in the art and can be applied by ordinary technicians.
[0172] In some embodiments, the polypeptide may include one or more amino acid substitutions or modifications. In some embodiments, substitution and / or modification can prevent or reduce proteolytic degradation and / or extend the half-life of the polypeptide in a subject. In some embodiments, the polypeptide can be modified by conjugating or fusing the polypeptide to other polypeptides or polypeptide domains (such as, non-limiting examples of transferrin (WO06096515A2), albumin (Yeh et al., 1992), growth hormone (US2003104578AA); cellulose (Levy and Shoseyov, 2002); and / or Fc fragments (Ashkenazi and Chamow, 1997)). The references in the preceding paragraphs are incorporated herein by reference in their entirety.
[0173] As used herein, the term "nucleic acid" or "nucleic acid sequence" refers to any molecule, preferably a polymeric molecule, incorporating ribonucleic acid, deoxyribonucleic acid or its analog units. Nucleic acids can be single-stranded or double-stranded. A single-stranded nucleic acid can be a nucleic acid strand of a denatured double-stranded DNA. Alternatively, it can be a single-stranded nucleic acid that is not derived from any double-stranded DNA. On the one hand, the nucleic acid can be DNA. On the other hand, the nucleic acid can be RNA. Suitable DNA can include, for example, genomic DNA or cDNA. Suitable RNA can include, for example, mRNA.
[0174] The term "expression" refers to the cellular processes involved in producing RNA and protein and, when appropriate, secreting protein, including (where applicable) but not limited to, for example, transcription, transcript processing, translation, and protein folding, modification, and processing. Expression may refer to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from one or more nucleic acid fragments of the invention and / or the translation of mRNA into polypeptides.
[0175] In some embodiments, the expression of one or more biomarkers, one or more targets, or genes / polypeptides described herein is tissue specific. In some embodiments, the expression of one or more biomarkers, one or more targets, or genes / polypeptides described herein is global. In some embodiments, the expression of one or more biomarkers, one or more targets, or genes / polypeptides described herein is systemic.
[0176] "Expression products" include RNA transcribed from a gene, and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" means a nucleic acid sequence that is transcribed (DNA) into RNA in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as the 5' untranslated region (5'UTR) or "leader" sequence and the 3'UTR or "trailer" sequence, as well as intervening sequences (introns) between individual coding segments (exons).
[0177] "Operably linked" refers to an arrangement of elements in which the components so described are configured to perform their usual functions. Thus, control elements operably linked to a coding sequence are capable of affecting the expression of the coding sequence. Control elements do not have to be adjacent to the coding sequence, as long as they are able to direct its expression. Thus, for example, there may be intervening non-translated but transcribed sequences between a promoter sequence and a coding sequence, and the promoter sequence may still be considered to be "operably linked" to the coding sequence. In addition, they need not be physically linked.
[0178] "Marker" in the present specification refers to an expression product, such as a nucleic acid or polypeptide, that is differentially present in a sample taken from a subject with diabetes or cancer compared to a comparable sample taken from a control subject (e.g., a healthy subject). The term "biomarker" can be used interchangeably with the term "marker".
[0179] In some embodiments, the methods described herein relate to measuring, detecting or determining the level of at least one marker. As used herein, the term "detection" or "measurement" refers to observing a signal from, for example, a probe, a marker or a target molecule to indicate the presence of an analyte in a sample. Any method known in the art for detecting a specific labeling moiety can be used for detection. Exemplary detection methods include, but are not limited to, spectral methods, fluorescent methods, photochemical methods, biochemical methods, immunochemical methods, electrical methods, optical methods or chemical methods. In some embodiments of either aspect, measurement can be quantitative observation.
[0180] In some embodiments of any aspect, the polypeptides, nucleic acids, or cells described herein may be engineered. As used herein, "engineered" refers to aspects that have been artificially manipulated. For example, a polypeptide is considered "engineered" when at least one aspect of the polypeptide (e.g., its sequence) has been artificially manipulated to be different from that which occurs in nature. As is common practice and understood by those skilled in the art, the progeny of an engineered cell are still generally referred to as "engineered," even if the actual manipulations were performed on a previous entity.
[0181] The term "exogenous" refers to a substance present in a cell other than its natural source. When used herein, the term "exogenous" may refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or a polypeptide, which is introduced into a biological system in which the nucleic acid or polypeptide is not usually present by an artificial process, and people hope to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, "exogenous" may refer to a nucleic acid or polypeptide that has been introduced into a biological system such as a cell or organism by an artificial process, in which the nucleic acid or polypeptide is present in a relatively low amount, and people hope to increase the content of the nucleic acid or polypeptide in the cell or organism, such as to produce ectopic expression or level. In contrast, the term "endogenous" refers to a substance that is natural to a biological system or cell. As used herein, "ectopic" refers to a substance that is present in an unusual position and / or in an unusual amount. Ectopic substances can be substances that are usually present in a given cell, but exist in a much lower amount and / or at different times. Ectopic also includes substances that are non-naturally present or expressed in the natural environment of a given cell, such as polypeptides or nucleic acids.
[0182] In some aspects described herein, the nucleic acid sequence encoding a given polypeptide described herein or any module thereof is operably linked to a vector. As used herein, the term "vector" refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector may be viral or non-viral. The term "vector" includes any genetic element that can replicate and transfer a gene sequence to a cell when associated with an appropriate control element. Vectors may include, but are not limited to, cloning vectors, expression vectors, plasmids, bacteriophages, transposons, cosmids, chromosomes, viruses, and virions.
[0183] In some embodiments of any aspect, the vector is recombinant, for example, it comprises sequences derived from at least two different sources. In some embodiments of any aspect, the vector comprises sequences derived from at least two different species. In some embodiments of any aspect, the vector comprises sequences derived from at least two different genes, for example, it comprises a fusion protein or a nucleic acid encoding an expression product, the nucleic acid being operably linked to at least one non-natural (e.g., heterologous) genetic control element (e.g., promoter, sensor domain, activator, enhancer, response element, etc.).
[0184] As used herein, the term "expression vector" refers to a vector that directs RNA or polypeptide expression from a sequence linked to a transcriptional regulatory sequence on the vector. The expressed sequence is usually, but not necessarily, heterologous to the cell. The expression vector may contain additional elements, for example, the expression vector may have two replication systems, allowing it to be maintained in two organisms, for example, in human cells for expression, and in prokaryotic hosts for cloning and amplification.
[0185] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin and has the ability to be packaged into viral vector particles. Viral vectors may contain nucleic acids encoding polypeptides described herein to replace non-essential viral genes. Vectors and / or particles can be used for the purpose of transferring any nucleic acid into cells in vitro or in vivo. Various forms of viral vectors are known in the art.
[0186] It should be understood that in some embodiments, the carrier described herein can be combined with other suitable compositions and therapies. In some embodiments, the carrier is an additional type. The use of a suitable additional carrier provides a form of high copy number extrachromosomal DNA in a subject to maintain the target nucleotide, thereby eliminating the means of the potential impact of chromosome integration.
[0187] In some embodiments of any aspect, preventive treatment methods are described herein. As used herein, "preventive" refers to the timing and intent of treatment related to a disease or symptom, i.e., treatment is performed before clinical detection or diagnosis of a specific disease or symptom to protect the patient from the effects of the disease or symptom. Preventive treatment can encompass reducing the severity or onset of a disease or symptom, or helping to recover from a disease or symptom more quickly. Thus, the methods described herein can be preventive for metastasis or tumor formation. In some embodiments of any aspect, preventive treatment is not to prevent all symptoms or signs of a disease.
[0188] As used herein, "combination" refers to a group of two or more substances used together (e.g., for administration to the same subject). The two or more substances may be present in the same preparation in any molecular or physical arrangement, such as in a mixture, solution, admixture, suspension, colloid, emulsion. The preparation may be a homogeneous or heterogeneous mixture. In some embodiments of either aspect, the two or more active compounds may be composed of the same or different superstructures, such as nanoparticles, liposomes, carriers, cells, scaffolds, etc., and the superstructures are present in solutions, mixtures, blends, suspensions together with solvents, carriers, or some of the two or more substances. Alternatively, the two or more substances may be present in two or more separate preparations, such as in a kit or package containing multiple preparations in separate containers for administration to the same subject.
[0189] A kit is a collection of materials or components, including at least one medicament as described herein. The exact nature of the components configured in the kit depends on its intended use. In some embodiments of either aspect, the kit includes instructions for use. "Instructions for use" generally include a tangible representation of the technology used when describing the components of the kit (e.g., to treat a subject or for administering to a subject). Still according to the present invention, "instructions for use" may include a tangible representation of the preparation (usually for the intended purpose) of at least one reagent described herein, such as dilution, mixing or incubation instructions, etc. Optionally, the kit also includes other useful components, such as measuring tools, diluents, buffers, syringes, pharmaceutically acceptable carriers or other useful appliances easily identified by those skilled in the art.
[0190] The materials or components assembled in the kit can be provided to the practitioner for storage in any convenient and suitable manner to maintain its operability and practicality. For example, the components can be in dissolved, dehydrated or lyophilized form; they can be provided at room temperature, refrigerated or frozen temperature. The components are usually contained in one or more suitable packaging materials. As used herein, the phrase "packaging material" refers to one or more physical structures for containing the contents of the kit (such as the composition of the present invention, etc.). The packaging material is formed by known methods, preferably to provide a sterile, contaminant-free environment. The packaging can also preferably provide a light-proof, moisture-proof and oxygen-proof environment. As used herein, the term "packaging" refers to a suitable solid matrix or material, such as glass, plastic, paper, foil, polyester (such as polyethylene terephthalate or Mylar), etc., which can accommodate a single kit component. Thus, for example, the package can be a glass bottle for containing an appropriate amount of a composition, the composition comprising a certain volume of at least one reagent described herein. The packaging material usually has an external label, which indicates the contents and / or use of the kit and / or its components.
[0191] As used herein, the term "nanoparticle" refers to a particle having a diameter or width of about 1 to 1,000 nanometers. The term "nanoparticle" includes nanospheres; nanorods; nanoshells; and nanoprisms; these nanoparticles can be part of a nanonetwork. The term "nanoparticle" also encompasses liposomes and lipid particles having nanoparticle sizes. Exemplary nanoparticles include lipid nanoparticles or ferritin nanoparticles. Lipid nanoparticles may include a variety of components, including, for example, ionizable lipids (such as MC3, DLin-MC3-DMA, ALC-0315 or SM-102), pegylated lipids (such as PEG2000-C-DMG, PEG2000-DMG, ALC-0159), phospholipids (such as DSPC) and cholesterol.
[0192] Exemplary liposomes can include, for example, DSPC, DPPC, DSPG, cholesterol, hydrogenated soybean phosphatidylcholine, soybean phosphatidylcholine, methoxy polyethylene glycol (mPEG-DSPE) phosphatidylcholine (PC), phosphatidylglycerol (PG), distearoylphosphatidylcholine, and combinations thereof.
[0193] As used herein, the term "administering" refers to placing a compound disclosed herein in a subject's body by a method or approach that results in the agent being at least partially delivered to a desired site. Pharmaceutical compositions comprising compounds disclosed herein can be administered by any suitable approach that produces effective treatment for a subject. In some embodiments, administration includes human physical activity, such as injection, intake action, application action, and / or operation of a delivery device or machine. Such activity can be performed by, for example, a medical professional and / or a subject being treated.
[0194] As used herein, "contacting" refers to any suitable means for delivering or exposing an agent to at least one cell. Exemplary delivery methods include, but are not limited to, direct delivery to a cell culture medium, perfusion, injection, or other delivery methods known to those skilled in the art. In some embodiments, contacting includes human physical activity, such as injection; actions of dispensing, mixing, and / or decanting; and / or operation of a delivery device or machine.
[0195] The term "statistically significant" or "significantly" refers to statistical significance, generally meaning a difference of two standard deviations (2SD) or greater.
[0196] Except in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein are to be understood as modified in all instances by the term "about." When used in conjunction with a percentage, the term "about" may mean mean ± 1%.
[0197] As used herein, the term "comprising" means that there may be other elements in addition to the defined elements given. The use of "comprising" means inclusion rather than limitation.
[0198] The term "consisting of" refers to the compositions, methods, and respective components described herein, which do not include any elements not recited in the description of the embodiment.
[0199] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect one or more basic and novel or functional characteristics of the embodiments of the invention.
[0200] As used herein, the term "specific binding" refers to a chemical interaction between two molecules, compounds, cells and / or particles, wherein the first entity binds to a second target entity with greater specificity and affinity than to a third, non-target entity. In some embodiments, specific binding may refer to an affinity of the first entity for the second target entity being at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, or greater than the affinity for a third, non-target entity. An agent specific for a given target is one that exhibits specific binding to that target under the assay conditions used.
[0201] Unless otherwise defined herein, the scientific and technical terms used in conjunction with the present application should have the meanings commonly understood by those of ordinary skill in the art to which the present disclosure belongs. It should be understood that the present invention is not limited to specific methods, schemes and reagents described herein, etc., so this can vary. The terms used herein are only to describe specific embodiments, rather than to limit the scope of the present invention, which is limited only by the claims. Definitions of commonly used terms in immunology and molecular biology can be found in the following references: The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-0911910421); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Werner Luttmann's Immunology, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (editors), WWNorton&Company, 2016 (ISBN 0815345054,978-0815345053); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: ALaboratory Manual, 4th Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch(ed.)Elsevier, 2013(ISBN0124199542);Current Protocols in Molecular Biology(CPMB),Frederick M.Ausubel(ed.),John Wiley and Sons,2014(ISBN 047150338X,9780471503385),Current Protocols in Protein Science(CPPS),John E. Coligan (editor), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are incorporated herein by reference in their entirety.
[0202] The chemotherapeutic agent used can be easily identified by one skilled in the art (e.g., see Physicians' Cancer Chemotherapy Drug Manual 2014, Edward Chu, Vincent T. DeVita Jr., Jones & Bartlett Learning; Principles of Cancer Therapy, Harrison's Principles of Internal Medicine, Chapter 85 in 18th Edition; Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents and Cancer Pharmacology, Abeloff's Clinical Oncology, Chapters 28-29 in 2013 Elsevier; and Fischer DS (ed.): The Cancer Chemotherapy Handbook, 4th Edition, St. Louis, Mosby-Year Book, 2003).
[0203] mCherry is a basic (constitutively fluorescent) red fluorescent protein published in 2004, derived from a species of Discosoma. It is reported to be a very fast-maturing monomer with low acid sensitivity; virally expressed mCherry is pseudo-colored magenta.
[0204] SmV5 refers to spaghetti monster V5;
[0205] smFLAG refers to Spaghetti Monster FLAG: 10 copies of the epitope tag FLAG-(DYKDDDDK)
[0206] tTA2 is a tetracycline-dependent transcriptional activator.
[0207] W3SL is a truncated woodchuck hepatitis posttranscriptional regulatory element and polyadenylation signal cassette (Choi et al., 2014). Choi JH, Yu NK, Baek GC, Bakes J, Seo D, Nam HJ, Baek SH, Lim CS, Lee YS, Kaang BK (2014).
[0208] eYFP is enhanced yellow fluorescent protein.
[0209] The PT enhancer is the mscRE4 enhancer, which marks L5 pyramidal tract (PT) neurons, a subset of CFPNs.
[0210] Calcium-saturated GCaMP6 is 27% brighter than its parent fluorescent protein, enhanced GFP (EGFP).
[0211] PlxnD1 (intracerebro-IT PNs in L2 / 3 and L5a), Satb2 (IT PNs across upper and lower layers), Rorb (L4 pyramidal neurons), and vGAT (pan-GABAergic neurons).
[0212] Fezf2 is a FEZ family zinc finger 2 gene. Diseases associated with FEZF2 include some fetal alcohol syndrome and thymic dysplasia.
[0213] Ctip2tip2 / Bcl11b is a dual-acting (repressor / activator) zinc-finger transcription factor that couples epigenetic regulation to gene transcription during development in various tissues. The transcription factor COUP TF1-interacting protein 2 (CTIP2) plays a key role in axonal extension and pathfinding of submental projection neurons in the cerebral cortex (Arlotta et al., 2005). Here, we report that Ctip2 is uniquely expressed by MSNs in the striatum, specifically marking this key neuronal population from the early postmitotic phase. Loss of Ctip2 function results in a failure of MSN differentiation, disruption of the plaque matrix organization of MSNs, and distinct changes in the expression of multiple genes, including a novel molecular identifier for the patch compartment. Defects in plaque aggregation also result in abnormal dopaminergic innervation of the striatum. Finally, altered expression of molecules involved in cell repulsion and ectopic appearance in mutant striatum strongly suggest that loss of Ctip2 disrupts normal mechanisms of cell repulsion during development. Journal of Neuroscience16January 2008,28(3)622-632; DOI:doi.org / 10.1523 / JNEUROSCI.2986-07.2008.
[0214] The cerebrocortical projection neurons (CFPNs) that constitute the cortical output pathway include PlxnD1 (intracerebro-IT PNs in L2 / 3 and L5a), Satb2 (IT PNs spanning upper and lower layers), Rorb (L4 pyramidal neurons), vGAT (pan-γ-aminobutyric acid neurons),
[0215] hSyn refers to the human synapsin 1 gene promoter, which is recognized in the art to confer highly neuron-specific long-term transgene expression from adenoviral vectors in adult rat brain.
[0216] TRE-3G refers to a eukaryotic inducible promoter; TRE consists of a concatemer of Tet operator (tetO) sequences fused to a minimal promoter, (usually the minimal promoter sequence is derived from the human cytomegalovirus (hCMV) immediate early promoter); in the absence of Tc or Dox, tTA binds to TRE and activates transcription of the target gene.
[0217] mNeonGreen is a basic (constitutively fluorescent) green / yellow fluorescent protein published in 2013, derived from the European lancelet (Branchiostoma lanceolatum).
[0218] WPRE is the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) that increases transgene expression from a variety of viral vectors, although the exact mechanism is unclear. WPRE is most effective when it is located downstream of the transgene, close to the polyadenylation signal.
[0219] The dTomato gene is a gene encoding dTomato, which is a basic (constitutively fluorescent) orange fluorescent protein derived from a certain species of Discosoma.
[0220] tdTomato is a genetic fusion of two copies of the dTomato gene; tdTomato is an exceptionally bright red fluorescent protein.
[0221] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.
[0222] Detailed Description
[0223] The present invention is based in part on the discovery of bifunctional RNA molecules (readrRNA) that allow (i) targeting of selected somatic cells based on their transcriptional profile and (ii) translation of a desired effector protein encoded by the RNA molecule in the selected cells, the translation of the effector protein being achieved by RNA editing mediated by adenosine deaminases acting on RNA (ADARs).
[0224] ADAR-mediated RNA editing
[0225] RNA editing is a widespread post-transcriptional process that alters the sequence of RNA encoded by a DNA template and is ubiquitous in all metazoan cells. In the animal kingdom, the most prevalent form of RNA editing is the conversion of adenosine to inosine (A to I), catalyzed by the ADAR (adenosine deaminases acting on RNA) family of enzymes, which has three members in mammals (ADAR1, ADAR2, ADAR3). The edited inosine is then base-paired with cysteine and recognized as guanosine (G) by various cellular machinery. ADAR-mediated AI editing is ubiquitous in all metazoan cells. See Figure 3 .
[0226] There are millions of ADAR editing sites in the transcriptome of humans and animals, and only a small fraction of these edits occur in coding mRNAs, changing protein properties. The vast majority are located in noncoding regions, which may affect RNA splicing, microRNAs, and shRNA functions. However, their most important role is to protect cells from innate immune responses to self-produced dsRNAs, while allowing the immune system to destroy viral dsRNAs during infection.
[0227] readrRNA
[0228] "readrRNA" refers to an RNA-based molecule having a 5' region and a 3' region, wherein the readrRNA molecule comprises, consists of, or consists essentially of: (i) a 5' region comprising a sensor (ses) domain comprising at least one ADAR-editable stop codon; and (ii) an effector RNA (efRNA) region, which is located downstream of the sensor domain and in the same frame as it. The bifunctional readrRNA of the applicant's invention allows the recruitment of ADAR deaminases to edit one or more specific sites in the readrRNA by forming dsRNAs with mismatches with target RNAs expressed in selected somatic cells. After ADAR-mediated removal of the stop codon from the readrRNA molecule, translation of the downstream operably linked effector protein encoded by the readrRNA occurs in the selected somatic cell. Figure 4 In the absence of target RNA in selected somatic cells, the readrRNA remains inert in the cell.
[0229] Because readrRNAs detect or “sense” target RNAs in selected somatic cells, readrRNAs are an integral component of the system encompassed by CellREADR (Cellular Access via RNA Sensing by Endogenous ADARs), a programmable RNA-sensing technology that utilizes ADAR (adenosine deaminases acting on RNA)-mediated RNA editing to couple the detection of cell-type-defining RNAs to the translation of one or more effector proteins in somatic cells.
[0230] Cell type defining RNA
[0231] RNA is a central and ubiquitous mediator of genetic information that underlies the diversity of cell types and cell states that together shape tissue architecture and biological function across species and lifespans. Despite advances in RNA sequencing and the accumulation of large amounts of transcriptome datasets in the life sciences, the lack of technologies to observe and manipulate cell types using RNA remains a daunting bottleneck in biology and medicine. (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0232] Cell types are the product of evolution and are the basic functional units of organisms. The entire repertoire in the brain and body is established from a single fertilized egg (zygote) through a series of sequential and parallel developmental events coordinated in space and time. This developmental program executes a remarkable implementation plan that, through evolution, reveals the identity of all cell types encoded in the genome. Transcriptional and epigenetic regulatory programs are unfolded from the genomic sequence and drive a series of cascades of cell proliferation and differentiation processes, leading to the expression of different cellular phenotypes. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0233] RNA expression profiles arguably underlie all phenotypic features of a cell at the time or state in which the cell is characterized and are a snapshot of the cell at one time. A key distinction is whether the RNA expressed in a selected cell represents a specific cell state—a transient or dynamic response characteristic of a cell to its environment—or a cell type, as cell types can exist in different states. Cell-type-specific changes in RNA expression associated with different cell states can be seen during the circadian cycle, variable metabolic states, development, aging, or in behavioral, pharmacological, or diseased states (Mayr et al., 2019; Morris, 2019). (Zeng et al., 2019) https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0234] A single-cell transcriptome is only a one-time snapshot of a cell. However, one can compare transcriptomes collected from different time points or different behavioral, physiological, or pathological states. The distinction between cell type and cell state is particularly challenging during development because cells are constantly changing their state, and at certain key time points they may switch their cell type identity. However, although not absolute, it is reasonable to assume that changes in the transcriptome are more continuous during cell state transitions, while they tend to be more abrupt or discrete when cells switch types. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0235] For the definition of cell types to be meaningful, it is ideally relevant to the context of the cell type. Therefore, in addition to defining cell types based on their cell type defining RNA, cell types are also defined by relating their RNA expression to anatomical and functional information. So far, it has been shown that transcriptome types have a good correspondence with their spatial distribution patterns. Since spatial distribution patterns are defined during development, this suggests that the transcriptome can preserve developmental programs. (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0236] Systematic single-cell transcriptomic, epigenomic, and spatially resolved transcriptomic analyses with high temporal resolution, coupled with lineage tracing and other phenotypic characterizations, have tremendous potential to capture the key gene sets and genomic regulatory networks involved in these series of events and begin to dissect the extremely complex spatial and temporal transitions of cell types and states that lead to the adult stage repertoire of cell types (Allaway et al., 2021; Bandler et al., 2022; Bhaduri et al., 2021; Cao et al., 2019b; Chen et al., 2022; Delgado et al., 2022; Di Bella et al., 2021; Klingler et al., 2021; LaManno et al., 2021; Romanov et al., 2020; Schmitz et al., 2022; Sharma et al., 2020; Shekhar et al., 2022; Tiklová et al., 2019; Zhu et al., 2018) (Zeng et al., 2018). https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0237] Hierarchical organization of transcriptomically defined cell types
[0238] As used herein, the term "brain cell" refers to any cell type found in the mammalian brain.
[0239] Within each of these major brain structures, there are multiple regions and subregions, each with many cell types. The basic structure of the mammalian brain (Swanson, 2000, 2012) consists of the telencephalon, diencephalon, mesencephalon (midbrain), and rhombencephalon (hindbrain). (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0240] The telencephalon (composed of five major brain structures: (1) cortex, (2) hippocampal formation [HPF], (3) olfactory area, (4) cortical sub-plate, and (5) cerebral nuclei). The telencephalon and diencephalon (including the thalamus and hypothalamus) are collectively called the forebrain. The midbrain is divided into the tectum and tegmentum. The rhombencephalon (hindbrain) is divided into the pons, medulla, and cerebellum. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0241] In the cortex, the first (highest) order of division is the separation of neurons and various non-neuronal cell classes ( Figure 2 A). For neurons, the second level of branching is driven by major brain structures / regions, and the third level includes the various cell subclasses and types within each major brain structure, although there may be crossover or sharing of cell types between brain structures due to cell migration during development. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0242] The cortex consists of multiple cortical areas (including the visual cortex and the motor cortex), each of which mediates sensory, motor, or associative functions. In each of these areas, there are two neuronal classes (glutamatergic and GABAergic) based on the primary neurotransmitters they release, as well as several non-neuronal classes. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031).
[0243] Most glutamatergic excitatory neurons have long-range axonal projections to other cortical and / or subcortical areas. Based on their layer specificity and long-range projection patterns, they are divided into nine subclasses: L2 / 3 intra-telencephalic projections [IT], L4 / 5IT, L5 IT, L6 IT, Car3 IT, L5 extra-telencephalic projections [ET], L5 / 6 proximal projections [NP], L6 corticothalamic projections [CT], and L6b. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0244] The axonal projections of GABA inhibitory neurons are mostly confined to local areas. They are divided into six subclasses named after standard marker genes: Lamp5, Sncg, Vip, Sst, Sst-Chodl and Pvalb. (Zeng https: / / doi.org / 10.1016 / j.cell .2022.06.031).
[0245] Within each glutamatergic or GABAergic subclass, as well as within each non-neuronal class, there are several transcriptomic clusters or types, resulting in a total of 110 transcriptomic cell types per cortical region (Brain Initiative CellCensus Network, 2021; Tasic et al., 2018). This organization is highly consistent with existing knowledge about cortical cell types that have been extensively studied in a variety of phenotypic patterns over the past 50 years (Harris and Shepherd, 2015; Tremblay et al., 2016; Yuste et al., 2020; Zeng and Sanes, 2017), indicating that single-cell transcriptomics alone can faithfully capture the overall cell type organization at the class and subclass level. (Zeng et al., 2017) https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0246] However, within the cortex, cell types that are either specific to cortical regions or shared between regions have been identified. Shared cell types often show gradient distribution or gradient gene expression across regions with both discrete and continuous variations between types. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0247] There are discrete variations between subclasses and major types of cells that are typically located in higher branches of the hierarchy. Continuous variation is often found in closely related transcriptomic clusters or subtypes at lower branches, such as many IT neuron types that span cortical depths from L2 / 3 to L6 ( Figure 2 C). Cells at either end of the continuum have distinct transcriptome profiles, but the transition from one end to the other is gradual among the cells that make up the continuum. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0248] Integration of transcriptomics and MERFISH, a spatially resolved transcriptomics approach, revealed the spatial organization of cell types in the mouse motor cortex (Zhang et al., 2021a). The main findings of this study are that in addition to the laminar distribution of glutamatergic neuron subclasses as expected, even GABAergic types within each subclass exhibited layer-selective localization, and the continuous variation between individual glutamatergic or GABAergic types was closely correlated with their continuous distribution along cortical layers / depths (a prominent example of which was that all excitatory L2 / 3-L6 IT types were arranged along the cortical depth from L2 / 3 to L6). (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031 ).
[0249] However, it is often unclear whether cell types defined by different phenotypic features are consistent with each other or which feature is the correct one to define a cell type.
[0250] By coupling the targeting of specific RNA transcripts with the expression of encoded effector molecules (such as fluorescent proteins), the cellular readrRNA system provides a system for simultaneous transcript-based and spatial / morphological monitoring of cell types and their states.
[0251] The invention described herein is based on Watson-Crick base pairing and RNA editing, and CellREADR 1) has inherent and absolute specificity for cellular RNAs and cells defined by RNA expression; 2) is easy to design, build, use, and propagate (e.g., DNA vectors); 3) is infinitely scalable for targeting all RNA-defined cell types in any tissue; 4) is generalizable to a library of "cellular medical devices" for most animal species, including humans; 5) is comprehensive for most cell types and tissues, 6) is universal across animal species, 7) is applicable to human biology and medicine, and 8) is programmable to achieve cross-targeting of cells defined by two or more RNAs and multiplexed targeting and manipulation of several cell types in the same tissue.
[0252] CellREADR Technology
[0253] The core of CellREADR technology is readrRNA, which is an RNA sequence-specific molecular sensor-switch that is effectively connected to the effector molecule. In other words, a single modular readrRNA contains a 5'-triggered sense-editing-switch domain (sesRNA) and a 3'-triggered effector domain (efRNA). The target specificity of sesRNA is due to its interaction with the complementary sequence on the target mRNA. The degree of complementarity determines whether there is ADAR-mediated editing of sesRNA. SesRNAs that are completely complementary to the target RNA induce ADAR-mediated editing of sesRNAs at the stop codons that can be edited by ADAR.
[0254] ReadrRNA can be produced from conventional DNA expression vectors. These vectors consist of a promoter, a DNA box encoding sesRNA and efRNA, and a 3' untranslated region, which can be assembled by conventional DNA synthesis and molecular cloning. In one embodiment, the sesRNA encoding box can be about 200-300 base pairs, and the effector gene box can be about 1-2 thousand base pairs. These expression vectors can be easily packaged into various viral particles. ReadrRNA can also be produced by direct single-stranded oligonucleotide synthesis, if necessary, by incorporating chemically modified nucleotides.
[0255] Modular readrRNA
[0256] Thus, one aspect of the present disclosure provides a modular readrRNA molecule comprising, consisting of, or consisting essentially of: (i) a 5' region comprising a sensor domain comprising at least one ADAR-editable stop codon; and (ii) an effector RNA (efRNA) region located downstream of the sensor domain and in the same frame as the sensor domain. The term "modular" when used in the context of the phrase "modular readrRNA molecule" refers to a recombinant readrRNA molecule comprising a combination of a much smaller number of connected structural units, each of which encodes a protein molecule that functions independently.
[0257] The modular design of readrRNA molecules, in which different protein-coding domains are designed at the RNA level and assembled in the recombinant readrRNA molecules in the desired order and with a specified number of repetitions, enables the production of readrRNA molecules with different properties. The translation machinery also has high fidelity, which enables the desired readrRNA molecules to have a specified amino acid sequence.
[0258] In general, readrRNA molecules are composed of modular domains that confer specific functions, including but not limited to facilitating interactions between cells, sensing environmental stimuli, and enabling responses to environmental stimuli, including enabling spatiotemporal input / output in biological systems.
[0259] Modular readrRNA sensor domains
[0260] The sensor domain (sesRNA) comprises a set of nucleotides that are complementary to RNA present in a specific cell type and can detect a specific cell type by base pairing with the RNA sequence. The sensor domain may comprise many nucleotides. In some embodiments, the sensor domain comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1000 nucleotides. In some embodiments, the sensor domain comprises a range of about 100 to about 900 nucleotides. In another embodiment, the sensor domain comprises a range of about 200 nucleotides to about 300 nucleotides. Preferably, the sensor domain (sesRNA) comprises about 200 nucleotides, is complementary to RNA of a specific cell type, and can therefore detect RNA of a specific cell type by base pairing.
[0261] The sensor domain also includes one or more ADAR-editable stop codons that act as a translation switch (referred to herein as sense-editing-switch RNA (sesRNA)). Thus, the sensor domain functions as a sense-editing switch RNA (sesRNA). The sensor RNA comprises a nucleotide sequence complementary to a cellular RNA.
[0262] The modular readrRNA molecule may also include a sequence encoding a self-cleaving 2A peptide. In such embodiments, the 2A peptide is located between domains, preferably between the sensor domain and the effector RNA region and / or between additional domains / regions that may be present in the readrRNA molecule or CellREADER system, as further discussed herein.
[0263] In-frame effector RNA (efRNA) coding region of modular readrRNA
[0264] Downstream of the sensor domain is an in-frame effector RNA (efRNA) coding region, and is optionally separated by a sequence encoding a self-cleaved 2A peptide. Effector RNA (efRNA) can encode a target effector protein, such as a marker that allows visualization of labeled cells. Effector RNA (efRNA) can encode an effector protein that changes the physiology of a cell. For example, in the case of treating a disease caused by a mutation in a single gene, the encoded effector protein can be a correct copy of the mutant gene. In the case of treating a disease by providing a certain protein, whether the protein is endogenous or exogenous to the organism, the protein can be encoded in the effector region.
[0265] The choice of a given efRNA depends on the desired use of the readrRNA molecule (e.g., treatment of disease, study of proteins / pathways, etc.) and can be readily determined by one skilled in the art. For example, effector modules of CellREADR (efRNA) can be constructed to manipulate cells in a variety of ways, including enhancing activity and function, inhibiting activity and function, rescuing mutant cell function by reintroducing intact forms of missing or mutant proteins, altering and editing activity and function, reprogramming cell identity, fate and function, killing and deleting cell types, increasing or decreasing the production of a certain type of cell number, and cell type-specific genome editing and gene regulation.
[0266] In cells expressing the target RNA, sesRNA forms dsRNA, which recruits endogenous ADAR enzymes. At the stop codon, A to I editing converts the stop codon to a TI(G)G tryptophan codon, turns on translation of efRNA, and produces the effector protein. The resulting fusion protein contains the N-terminal peptide, T2A, and the C-terminal effector, which is then self-cleaved by T2A to release the functional effector protein. In cells that do not express the target RNA, readrRNA remains inert.
[0267] The protein encoded by efRNA may include any protein that participates in or can affect cell replication, gene expression and / or transcription / translation. Suitable examples include, but are not limited to, transcription activators, transcription inhibitors, and DNA recombinases.
[0268] Effector proteins include, but are not limited to, A) enzymes, such as proteases, phosphatases, glycosylases, acetylases or lipases, B) proteins that mimic the functions of host cell proteins, C) transcription factors, D) protein partners that promote protein-protein interactions, D) proteins that change the structure and function of host cells, such as by promoting infection (virulence factors or toxins) and / or by triggering defense responses, and / or promoting morphogenesis (Cachat, E., Liu, W., Hohenstein, P. et al. Library of mammalian effector modules for synthetic morphology. J Biol Eng 8, 26 (2014). https: / / doi.org / 10.1186 / 1754-1611-8-26 ).
[0269] For example, exemplary effector proteins are listed in Table 4 below.
[0270]
[0271]
[0272] Thus, effector functions may affect the activity of innate immune cell responses including phagocytosis, secretion of cytokines, trafficking or promotion functions, migration, survival and proliferation of immune cells.
[0273] Thus, the encoded effector molecules can be transactivators or transsensor domains that stimulate or repress the expression of target genes, respectively, by binding to their promoter / enhancer regions, whether endogenous or exogenous genes administered as part of the cellular posterior system.
[0274] Transcriptional activators are proteins or small molecules that bind to one or more specific regulatory sequences in DNA (or RNA in the case of retroviruses) and stimulate transcription of one or more nearby genes. Most activators enhance the binding of RNA polymerase (forming a closed complex) or the transition to an open complex required for transcription initiation. Most activators interact directly with subunits of RNA polymerase.
[0275] Transcriptional repressors are sequence-specific DNA-binding proteins that are generally thought to function by recruiting corepressor complexes, which consist of multiple proteins, including histone-modifying enzymes.
[0276] As used herein, "modulated" means regulated in the sense of activation or inhibition.
[0277] As used herein, pathogens include organisms that cause disease in humans, including but not limited to bacteria, viruses, parasites, insects, algae, prions, and fungi.
[0278] CellREADR system 2 reporter genes
[0279] Another aspect of the present disclosure provides a CellREADR system comprising at least two components, a first component comprising a modular readrRNA molecule as described herein and optionally one or more additional components comprising a response gene operatively linked (although not physically linked in this embodiment) to a protein encoded by the efRNA of the readrRNA molecule (e.g., a transcriptional regulator, e.g., AP1 and SP1). This enables the readrRNA molecule to activate, increase, decrease or inhibit transcription of another protein encoded on a physically separate exogenously added nucleic acid molecule (such as a caspase molecule that causes cell death).
[0280] ADAR-mediated programmability and cross-targeting
[0281] The sensor and effector modules are combined and easily programmable, which allows each cell type to be manipulated in a variety of ways and to manipulate multiple cell types in a tissue simultaneously, each cell type being manipulated in a specific and coordinated manner. As described above, in some embodiments, the modular readrRNA molecule comprises, consists of, or consists essentially of a 5' sensor-editing-switch region (sesRNA) and a 3' effector coding region (efRNA), which are separated by an optional continuous sequence encoding a self-cleaving peptide 2A. In some embodiments, the sesRNA comprises about 200 to about 300 nucleotides, which are complementary to a specific cell type RNA, so that a specific cell type RNA can be detected by base pairing, and also comprises one or more ADAR editable stop codons that act as a translation switch, and wherein the downstream is an in-frame effector coding region to produce various target effector proteins.
[0282] In cells expressing the target RNA, sesRNA forms dsRNA with the target RNA, which recruits endogenous ADAR enzymes. At the stop codon, A to I editing converts the stop codon into a TI(G)G tryptophan codon, turning on the translation of efRNA and producing effector proteins. The resulting fusion protein contains an N-terminal peptide, 2A, and a C-terminal effector, which then self-cleaves by 2A to release a functional effector protein. Importantly, in cells that do not express the target RNA, readrRNA remains inert. Therefore, since ADAR is endogenous to the cell, modular readrRNA molecules can be deployed as single RNA molecules and can be easily assembled into viral vectors (e.g., AAV vectors).
[0283] In some cases, one or more ADAR proteins are not highly expressed in cells, or in some cases are not present. In such cases, the present invention provides for the addition of ADAR proteins (e.g., ADAR2) to be included in modular readrRNA molecules and / or added to the system via separate vectors. The most fundamental feature of CellREADR is that it is entirely based on RNA sequences and operates through Wollerson-Crick base pairing, which confers many highly desirable properties, including but not limited to, (i) inherent and absolute specificity for cellular RNA; (ii) easy to design, build, use and share (DNA vectors); (iii) an infinitely expandable library of "cellular medical devices"; (iii) comprehensive for most cell types and tissues; (iv) universal across animal species; and (v) human biology and medicine. Therefore, a comprehensive and combinatorial CellREADR sensor-effector library can be established for the identification, characterization and manipulation of cell types across organ systems and animal species.
[0284] The programmability of the modular readrRNA molecules provided herein confers additional capabilities. Accordingly, another embodiment of the present disclosure provides programmability for modular readrRNA molecules and / or cross-targeting using modular readrRNA molecules as provided herein.
[0285] First, two or more RNA sensors can be designed to detect two or more individual cellular RNAs to achieve cross-targeting of two or more specific cell types. Second, the same RNA sensor can be linked to different effectors to label, record, and manipulate the same cell type. Third, a queue of multiple RNA sensors can be designed to target several cell types in the same tissue, each expressing a different effector, to coordinate tissue functional modules. Fourth, RNA sensors can be designed to detect different threshold levels of target RNA to monitor and manipulate different cell states defined by RNA levels.
[0286] In one embodiment, the present disclosure provides two sensors designed to detect two separate cellular RNAs to achieve cross-targeting of more specific cell types. On the one hand, each sensor module has a stop codon, and the effector molecule can only be expressed when both are removed. In one embodiment, each sensor comprises at least one stop codon. In another embodiment, the same sensor can be used to express different effectors to mark, record and operate the same cell type. In yet another embodiment, multiple sensors are designed to target several cell types in the same tissue, each cell type expressing different effectors, thereby coordinating module tissue functions.
[0287] Thus, the RNA sensing domain has the ability to detect any cellular RNA, thereby providing access to any RNA-defined cell type and cell state in any human tissue. The effector domain has the ability to encode any protein, thereby providing the ability to monitor, manipulate, and edit many cellular properties.
[0288] Universality of targeting cell types and cell states
[0289] RNA sensor domains can detect RNA markers that define cell type and cell state. Recent advances in single-cell RNA sequencing are generating large datasets in all human and animal tissues. 1,2,3 Several major efforts are underway to advance this, including the Human Cell Atlas Project ( humancellatlas.org) ; commonfund.nih.gov / hubmap Human Biomolecular Atlas Program; Brain Active Cell Census Network ( biccn.org / ) ; and Allen Brain Atlas ( portal.brain-map.org / ).
[0290] All single-cell transcriptome datasets are publicly available. RNA markers for most, if not all, major human cell types will be identified 1,2,3 In addition, RNA markers of many diseased cell states will be identified 4 All of these RNA markers can be used by CellREADR to target cell types and cell states. Table 5 lists some of these markers.
[0291] Table 5
[0292]
[0293]
[0294] References
[0295] 1.Regev A,Teichmann SA,Lander ES,Amit I,Benoist C,Birney E,Bodenmiller B,Campbell P,Carninci P,Clatworthy M,Clevers H,Deplancke B,DunhamI,Eberwine J,Eils R,Enard W,Farmer A,Fugger L, B,Hacohen N,HaniffaM,Hemberg M,Kim S,Klenerman P,Kriegstein A,Lein E,Linnarsson S,Lundberg E,Lundeberg J,Majumder P,Marioni JC,Merad M,Mhlanga M,Nawijn M,Netea M,Nolan G,Pe'er D,Phillipakis A,Ponting CP,Quake S,Reik W,Rozenblatt-Rosen O,Sanes J,Satija R,Schumacher TN,Shalek A,Shapiro E,Sharma P,Shin JW,Stegle O,StrattonM,Stubbington MJT,Theis FJ,Uhlen M,van Oudenaarden A,Wagner A,Watt F,WeissmanJ,Wold B,Xavier R,Yosef N;Human Cell Atlas Meeting Participants.(2017) The Human Cell Atlas. Elife.2017Dec5;6:e27041.doi:10.7554 / eLife.27041.PMID:29206104.
[0296] 2.Osumi-Sutherland D,Xu C,Keays M,Levine AP,Kharchenko PV,Regev A,Lein E,Teichmann SA.(2021) Cell type ontologies of the Human Cell Atlas. NatCell Biol.2021Nov;23(11):1129-1135.doi:10.1038 / s41556-021-00787-7.Epub2021Nov 8.PMID:34750578Review.
[0297] 3.Haniffa M,Taylor D,Linnarsson S,Aronow BJ,Bader GD,Barker RA,CamaraPG,Camp JG,Chédotal A,Copp A,Etchevers HC,Giacobini P, B, Guo G, Hupalowska A, James KR, Kirby E, Kriegstein A, Lundeberg J, Marioni JC, Meyer KB, Niakan KK, Nilsson M, Olabi B, Pe'er D, Regev A, Rood J, Rozenblatt-Rosen O, Satija R, Teichmann SA, Treutlein B, Vento-Tormo R, Webb S; Human Cell Atlas Developmental Biological Network. (2021) A roadmap for the Human Developmental Cell Atlas. Nature. 2021 Sep; 597(7875): 196 - 205. doi: 10.1038 / s41586 - 021 - 03620 - 1. Epub 2021 Sep 8. PMID: 34497388.
[0298] 4. Jagadeesh KA, Dey KK, Montoro DT, Mohan R, Gazal S, Engreitz JM, Xavier RJ, Price AL, Regev A. (2022) Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. Nat Genet. 2022 Oct; 54(10): 1479 - 1492. doi: 10.1038 / s41588 - 022 - 01187 - 9. Epub 2022 Sep 29. PMID: 36175791
[0299] Delivery
[0300] CellREADR can be used as a single RNA molecule because ADARs are endogenous to the cell. And it can be easily assembled into an AAV viral vector within 4.7Kb. In fact, the entire readrRNA has several thousand bases, depending on which specific sensors and effectors are integrated into the molecule, so it can be delivered to the cell through a delivery system. In cells expressing the target RNA, sesRNA forms dsRNA with the target, which recruits ADARs to assemble the editing complex. At the editable stop codon, ADAR converts A to I, which pairs with the corresponding C in the target RNA. This A->G substitution converts the TAG stop codon to a TI(G)G tryptophan codon, thereby turning on the translation of efRNA. In-frame translation produces a fusion protein containing an N-terminal peptide, 2A (if used), and a C-terminal effector, which then self-cleaves through 2A and releases the functional effector protein (see, for example Figure 1 a). The readrRNA remains inert in cells that do not express the target RNA.
[0301] Through the present disclosure and the knowledge in the art, the modular readrRNA molecules provided herein or any of their components, nucleic acid molecules thereof and / or nucleic acid molecules encoding or providing their components, and any CellREADR system provided herein can be delivered by various delivery systems. Examples of such delivery systems include, but are not limited to, DNA or RNA transfection methods: chemical reagents (PEI, lipofectamine, calcium phosphate, etc.) or electroporation, DNA expression vectors can be packaged into liposome nanoparticles. ReadrRNA can be transcribed or synthesized in vitro and packaged into liposome nanoparticles, nanoparticles, liposomes, recombinant viral vectors (viral vectors: adeno-associated virus (AAV), lentivirus and vesicular stomatitis virus are preferred viral vectors), electroporated exosomes, microbubbles, gene guns, selective endogenous encapsidation (SEND) system for cell delivery (an mRNA delivery system containing humanized virus-like particles (VLPs) based on retrotranscription elements present in the human genome) (Segel M, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021; 373: 882-889. doi: 10.1126 / science.abg6155), combinations thereof, and the like.
[0302] Modular readrRNA molecules and / or any RNA (e.g., sesRNA, efRNA, etc.) and / or any auxiliary protein and / or CellREADR system can be delivered using a suitable vector, such as a plasmid or recombinant viral vector, such as adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus vector, vesicular stomatitis virus and other viral vectors or combinations thereof. Proteins, such as sesRNA, efRNA, efRNA response genes, protein encoding or non-coding RNA (e.g., sgRHA, shRNA, etc.), CellREADR systems, etc. can be packaged into one or more vectors such as plasmids or viral vectors. For example, in some embodiments, a second expression vector comprising an efRNA response gene operatively linked to a protein encoded by efRNA is co-delivered with a readrRNA molecule and / or CellREADR system, wherein the successful translation of the modular readrRNA molecule and the effector RNA results in the successful binding and activation of the reporter product. In some embodiments, the efRNA response gene comprises a reporter gene (e.g., a reporter gene includes but is not limited to GFP, mRuby, mCherry, ChR2, DTA, Gcamp, TK, interferon, etc.). In other embodiments, the efRNA response gene comprises a second effector gene.
[0303] For bacterial applications, if applicable, phage can be used to deliver nucleic acids encoding any components of the modular readrRNA molecule system described herein to bacteria. Exemplary phages include, but are not limited to, T4 phage, μ, λ phage, T5 phage, T7 phage, T3 phage, Φ29, M13, MS2, Qβ, and ΦX174. In such embodiments, it may be necessary to add exogenous ADARs.
[0304] In some embodiments, the carrier, such as a plasmid or a recombinant viral vector, is delivered to the target tissue by, for example, intramuscular injection, intravenous administration, transdermal administration, intranasal administration, oral administration, or mucosal administration. This delivery can be carried out by a single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose delivered herein may vary greatly depending on a variety of factors, such as carrier selection, target cells, organisms, tissues, the general condition of the subject to be treated, the degree of conversion / modification sought, route of administration, mode of administration, type of conversion / modification sought, etc.
[0305] In some embodiments, the recombinant viral vector comprises an adenoviral vector, which may contain at least 1×10 5 A single dose of adenovirus particles (also called particle units, PUs) is preferably at least about 1 x 10 6 adenoviral particles, at least about 1x107 adenoviral particles, at least about 1x10 8 adenoviral particles and at least about 1x10 9 adenovirus particles.
[0306] In some embodiments, delivery is carried out by recombinant adeno-associated virus (rAAV) vector. For example, in some embodiments, modified AAV vectors can be used for delivery. Modified AAV vectors can be based on one or more of several capsid types, including AAV1, AV2, AAV5, AAV6, AAV8, AAV 8.2. AAAV9, AAV rhlO, modified AAV vectors (e.g., modified AAV2, modified AAV3, modified AAV6) and pseudotyped AAV (e.g., AAV2 / 8, AAV2 / 5 and AAV2 / 6), AAV-PHP.eB and any variants thereof, AAV-PHP.S and any variants thereof, AAV-PHP.V1 and any variants thereof, etc. Exemplary AAV vectors and techniques that can be used to produce rAAV particles are known in the art.
[0307] In some embodiments, delivery is carried out by plasmid. The dosage can be the number of plasmids sufficient to elicit a reaction. In some cases, the appropriate amount of plasmid DNA in the plasmid composition can be about 0.1 to about 2 mg. Plasmids generally include (i) a promoter; (ii) a sequence encoding a modular readrRNA molecule and / or a CellREADR system provided herein, each of which is operably connected to a promoter (e.g., the same promoter or a different promoter); (iii) a selection marker; (iv) a replication initiation site; and (v) a transcription terminator located downstream of (ii) and operably connected thereto. Plasmids can also encode other RNA components, but one or more of these components can be encoded alternatively on different vectors. The frequency of administration is within the scope of a medical or veterinary practitioner (e.g., a physician, a veterinarian) or a person skilled in the art.
[0308] In those cells / systems where ADAR proteins are not expressed or expressed at low levels (e.g., bacterial cells and certain plant cells), the plasmid (alone or a plasmid expressing the modular readrRNA molecules and / or CellREADR system provided herein) may also comprise a sequence encoding an ADAR gene (e.g., Adar1, Adar2, etc.).
[0309] Exogenous ADARs or engineered ADARs (i.e., with improved functionality) can improve the efficiency of the CellREADR system. Exogenous ADARs can be introduced into animal (or plant) cells by:
[0310] 1) Deliver ADAR1 or ADAR2 by transfection or viral infection (AAV, lentivirus, etc.) using separate constructs / DNA vectors (from Readr constructs) with CMV, CAG promoters.
[0311] 2) In the same CellReader construct / DAN vector, ADAR1 or ADAR2 is placed in front of the SesRNA sequence and delivered into cells by transfection or viral infection.
[0312] 3) Using CellReadr DNA vectors or RNA, ADAR1 or ADAR2 mRNA is delivered into cells via LNP.
[0313] 4) Use CellReadr DNA vectors or RNA to deliver ADAR1 or ADAR2 proteins into cells via LNPs or VLPs (virus-like particles).
[0314] In another embodiment, delivery is by liposome or lipid transfection preparation, etc., and can be prepared by methods known to those skilled in the art. For example, such methods are described in, for example, WO 2016205764 and U.S. Patents Nos. 5,593,972, 5,589,466 and 5,580,859 (each of which is incorporated herein by reference in its entirety).
[0315] In some embodiments, delivery is via nanoparticles or exosomes. For example, exosomes have been shown to be particularly useful in delivering RNA.
[0316] A further means of introducing one or more components of the modular readrRNA molecule system provided herein into a cell is to use a cell penetrating peptide (CPP). In some embodiments, the cell penetrating peptide is connected to the modular readrRNA molecule. In some embodiments, the modular readrRNA molecule and / or any of its components are combined with one or more CPPs to effectively transport them into a cell (e.g., a plant protoplast). In some embodiments, the modular readrRNA molecule and / or any of its components are encoded by one or more circular or non-circular DNA molecules, which are combined with one or more CPPs for cell delivery.
[0317] CPP is a short peptide of less than 35 amino acids, derived from proteins or from chimeric sequences that can transport biomolecules across cell membranes in a receptor-independent manner. CPP can be a cationic peptide, a peptide with a hydrophobic sequence, an amphipathic peptide, a peptide with a proline-rich and antimicrobial sequence, and a chimeric or dichotomous peptide. Examples of CPP include, for example, Tat (a nuclear transcription activator protein required for HIV type 1 virus replication), penetratin, Kaposi's fibroblast growth factor (FGF) signal peptide sequence, integrin 3 signal peptide sequence, polyarginine peptide Args sequence, guanine-rich molecular transporter, and sweet arrow peptide.
[0318] Another method for introducing one or more components of the modular readrRNA molecule system provided herein into a cell is to use SEND (see, e.g., Segel, M. et al., 2021. Science 373:6557; 882-889 (the contents of which are hereby incorporated by reference in their entirety). In such embodiments, a retrovirus-like protein (such as PEG10) (which directly binds to its own mmRNA in an extracellular virus-like capsid and secretes it) is pseudotyped with a fusion gene to deliver a functional mRNA cargo (i.e., a modular readrRNA molecule provided herein) to a mammalian cell.
[0319] Other embodiments of the present disclosure provide modifications of modular readrRNA molecules as provided herein. Such modifications may be used for any purpose, such as enhanced stability, the ability of modular readrRNA molecules to escape the immunity of a subject, etc. For example, in the case where the modular readrRNA molecule comprises a circular RNA molecule, one such modification may include N6-methyladenosine modification. For example, the inclusion of the N6-methyladenosine reader YTHDF2 sequence enables chelation of N6-methyladenosine-circular rRNA, thereby allowing inhibition of innate immunity (see, e.g., Chen, YG et al., (2019) Molecular Cell (76): 1; 96-109, the contents of which are hereby incorporated by reference in their entirety). In other embodiments, such modifications may include replacing uridine with pseudouridine to help escape the subject's immune system (see. For example, Dolgin, E. (2021) Nature 597; 318-324, the contents of which are hereby incorporated by reference in their entirety).
[0320] Pharmaceutical composition
[0321] In another aspect, the present disclosure provides compositions comprising one or more modular readrRNA molecules described herein, or delivery systems comprising modular readrRNA molecules provided herein (referred to herein alone or together as "molecules") and suitable carriers, excipients, or diluents. The exact nature of the carrier, excipient, or diluent will depend on the intended use of the composition, and may range from suitable or acceptable for veterinary use to suitable or acceptable for human use. The composition may optionally include one or more additional compounds and / or therapeutic agents.
[0322] The pharmaceutical compositions can be in a form suitable for nearly any route of administration including, for example, topical, ophthalmic, oral, buccal, systemic, intranasal, injectable, transdermal, rectal, vaginal, etc., or in a form suitable for administration by inhalation or insufflation.
[0323] Alternatively, other drug delivery systems may be used. Liposomes and emulsions are well-known examples of delivery vehicles that can be used to deliver one or more molecules. Certain organic solvents, such as dimethyl sulfoxide (DMSO), may also be used, although usually at the expense of greater toxicity.
[0324] If desired, the pharmaceutical composition may be present in a package or dispenser device which may contain one or more unit dosage forms containing one or more of the molecules. For example, the package may comprise metal or plastic foil, such as a blister pack. The package or dispenser device may be accompanied by instructions for administration.
[0325] One or more molecules described herein, or pharmaceutical compositions thereof, are generally used in an amount effective to achieve the desired result, e.g., in an amount effective to treat or prevent the specific disease being treated. A therapeutic benefit refers to the eradication or amelioration of the underlying condition being treated and / or the eradication or amelioration of one or more symptoms associated with the underlying condition, such that the patient reports feeling or condition improved, although the patient may still be suffering from the underlying disease. A therapeutic benefit also generally includes stopping or slowing the progression of a disease, whether or not an improvement is achieved.
[0326] Determining the effective dose of one or more molecules for a specific use and mode of administration is completely within the capabilities of those skilled in the art. The effective dose can be preliminarily estimated based on in vitro activity and metabolic assays. For example, the initial dose of a compound for an animal can be formulated to achieve a circulating blood or serum concentration of a metabolite active compound (e.g., efRNA product) equal to or higher than the IC50 of a specific compound measured in an in vitro assay. The dose calculated to achieve such circulating blood or serum concentrations by considering the bioavailability of a specific compound through a desired route of administration is completely within the capabilities of the technician. The initial dose of a compound can also be estimated based on in vivo data (such as an animal model). Animal models for testing the efficacy of active metabolites in treating or preventing the above-mentioned various diseases are well known in the art. Animal models suitable for testing the bioavailability of a compound and / or metabolizing it into active metabolites are also well known. Ordinary technicians can routinely modify this type of information to determine the dosage of a specific compound suitable for human administration.
[0327] The dosage will depend, among other factors, on the activity of the active compound, the bioavailability of the compound, its metabolic kinetics and other pharmacokinetic properties, the mode of administration, and the various other factors described above. The dosage and interval can be adjusted individually to provide a plasma level of one or more compounds and / or one or more active metabolite compounds sufficient to maintain a therapeutic or preventive effect. For example, the compound may be administered once a week, several times a week (e.g., every other day), once a day, or multiple times a day, depending, among other factors, on the mode of administration, the specific indication being treated, and the judgment of the prescribing physician. In the case of local administration or selective uptake (such as local topical administration), the effective local concentration of one or more compounds and / or one or more active metabolite compounds may be independent of the plasma concentration. A skilled technician can optimize the effective dosage without undue experimentation.
[0328] Cell manipulation
[0329] To monitor and / or alter the physiology of a target cell or cell population, one or more target cells are identified based on differential expression of one or more RNA transcripts of one or more cells by the SES component of the readrRNA. Through ADAR-mediated editing, one or more operably linked effector molecules are translated and can fluorescently label the cell and / or produce some desired change in cell physiology, including cell death.
[0330] In addition to the physical linkage of the SES component of the readrRNA to the encoded effector of the readrRNA, the target cell may also contain a second nucleic acid entity under the control of the encoded effector of the readrRNA, comprising a system called the CellREADR system. For example, the effector of the readrRNA can encode a transactivator that can activate a gene encoded on the second nucleic acid entity, wherein the second nucleic acid entity is endogenous to the cell, encodes a gene under the control of the transactivator, and the gene is endogenous to the cell, and / or wherein the second nucleic acid entity is exogenously added to the cell and encodes one or more genes under the control of the transactivator, and the gene is exogenous and / or endogenous to the cell.
[0331] The transactivator or sensor domain can also silence or reduce the expression of a specified endogenous gene in the cell by controlling the expression of an exogenous gene encoding a silencing tight hairpin loop (shRNA). It should also be noted that, in addition to being located on a second nucleic acid entity, the gene under the control of the transactivator can optionally be located on the readrRNA molecule itself. In the case where the cell contains a mutant gene that ultimately causes a patient's disease or condition, the effector can encode a functional gene and / or cause the expression of a nucleic acid encoding a functional gene.
[0332] Thus, cells or tissues express modular readrRNA molecules, and systems comprising such modular readrRNA molecules. Therefore, another aspect of the present disclosure provides cells comprising the modular readrRNA molecules provided, or delivery systems comprising the modular readrRNA molecules provided herein. The readrRNA molecules provided herein can be expressed in prokaryotic and eukaryotic cells. In some embodiments, cells include eukaryotic cells. In one embodiment, eukaryotic cells include mammalian cells or plant cells.
[0333] Another aspect of the present disclosure provides an animal model or a plant model comprising the cells provided herein.
[0334] treat
[0335] The present disclosure also encompasses methods comprising the readrRNA molecules provided herein and in the examples below.
[0336] Another aspect of the present disclosure provides a method for detecting the presence or dynamics of cell state-determining cellular RNA and / or turning on the translation of one or more effector proteins, the method comprising, consisting of, or essentially consisting of the following steps: detecting the target effector RNA / hybridizing the target effector RNA with a modular readrRNA molecule provided herein, or a delivery system comprising a modular readrRNA molecule provided herein, or a pharmaceutical composition provided herein, wherein the sensor domain detects and binds to a specific cell type RNA through sequence-specific base pairing, and one or more ADAR-editable stop codons act as a translation switch, thereby allowing translation of the effector RNA encoding the effector protein.
[0337] In some embodiments, the effector protein is located intracellularly.
[0338] The dynamic state of detection / assessment cells is crucial for detecting diseases in individuals for diagnosis. The dynamic state of detection / assessment cells is crucial for targeted treatment of individual diseases by providing therapeutic agents specifically to designated targeted cells, wherein the therapeutic agents can be the most effective and have reduced pleiotropic side effects. However, effector molecules can then play a role outside designated cells (e.g., in the case of secretory cytokines and interleukins and T-cars).
[0339] Another aspect of the present disclosure provides a method of treating a condition and / or disease in a subject in need thereof, the method comprising, consisting of, or consisting essentially of the following steps: administering to the subject a modular readrRNA molecule provided herein or a delivery system comprising a modular readrRNA molecule provided herein, thereby treating the condition and / or disease in the subject.
[0340] In some embodiments, the disorder and / or disease is selected from the group consisting of cancer, infectious disease, genetic disease, and the like.
[0341] As used herein, "treatment" of an illness and / or disease is to improve any condition or symptom associated with the illness and / or disease. As measured by any standard technique, this reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99% or more compared to an equivalent untreated control. A variety of means for administering the compositions described herein to a subject are known to those skilled in the art. Such methods may include, but are not limited to, oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, skin, topical, injection or intratumoral administration. Administration may be local or systemic. In some embodiments of either aspect, administration is subcutaneous.
[0342] Examples of somatic cell type-specific gene therapy include cell type-specific complementation of normal mRNA / protein in monogenic diseases including, but not limited to, muscular dystrophy, cystic fibrosis, congenital deafness, Duchenne muscular dystrophy, familial hypercholesterolemia, hemochromatosis, neurofibromatosis type 1 (NF1), sickle cell disease, and Tay-Sachs disease.
[0343] Treatment of cancer: (e.g., solid tumors; leukemias) includes the use of readrRNA and cellREADR to detect cancer cells by their upregulated and / or aberrant forms of RNA and eliminate cancer cells by expression of one or more cell death proteins, including but not limited to caspases, programmed cell death protein 1, caspase 8, Bcl-2 associated X protein, PDL-L1, caspase 3, CFLAR, Bcl-xl, SMAC / Diablo, Diablo homolog, Bcl-2 homolog antagonist killer, FADD, BECN1, death receptor 5, PDCD6, RIP1 kinase, RIP3 kinase and granzyme; or receptors that recruit immune killer cells, including but not limited to CD16, chemokine receptors (CCR2, CCR5, CXCR3 and CX3CR1) and β2-integrin LFA-1.
[0344] readrRNA and cellREADR can be used to treat liver diseases (with the advantage of delivery by lipid nanoparticles via the portal vein, etc.), including but not limited to chronic hepatitis B, hepatitis C, non-alcoholic steatohepatitis (NASH); heart disease, and infectious diseases (including but not limited to latent viral infections (intracellular parasites) and drug-resistant infections such as Epstein-Barr virus, herpes, tuberculosis, prions, Zika virus, HIV
[0345] readrRNA and cellREADR can be used to treat chronic pain: Widespread impact; e.g. diabetic neuropathy; NIDA, NINDS HEAL Initiative) > Non-addictive pain treatment. Through targeted local AAV vector injection, readrRNA and cellREADR can modulate ion channel and receptor expression in specific sensory neuron and glial cell types in peripheral ganglia.
[0346] ReadrRNA and cellREADR can be used to treat epilepsy, which is currently usually treated by surgical removal of brain tissue. Epilepsy is often caused by abnormal neural activity of certain neuronal cell types. That is, epilepsy is characterized by hypersynchrony of neural activity in pathological brain networks. Brain circuits include a variety of excitatory and inhibitory cell types, each of which makes unique contributions to information processing and excitation-inhibition balance. At different stages of epilepsy (onset, maintenance), neural activity of some cell types promotes epileptic seizures while other cell types inhibit epileptic seizures. Using readrRNA and cellREADR to perform cell-type-specific regulation of brain circuit activity through one or more RNA sensors-one or more effectors (such as druggable GPCRs, ion channels, etc.) is a promising method for controlling and treating epilepsy. Therefore, readrRNA and cellREADR can be used for cell-type targeted regulation of neural activity to inhibit and treat epilepsy.
[0347] Reagent test kit
[0348] The present disclosure also provides a kit comprising a composition provided herein and for implementing the subject method provided herein. For example, in one embodiment, the subject kit may comprise, consist of, or consist essentially of one or more of the following substances: (i) a modular readrRNA molecule provided herein; (ii) a CellREADR system provided herein; (iii) a delivery system comprising a modular readrRNA and / or a CellREADR system provided herein; (iv) a cell comprising a modular readrRNA and / or a CellREADR system and / or a delivery system containing a modular readrRNA and / or a CellREADR system provided herein; and / or (v) a pharmaceutical composition provided herein.
[0349] In other embodiments, the kit may also include other components. Such components may be provided alone or in combination, and may be provided in any suitable container such as a vial, a bottle or a test tube. Examples of such components include, but are not limited to, (I) one or more additional reagents, such as one or more dilution buffers; one or more reconstitution solutions; one or more washing buffers; one or more storage buffers, one or more control reagents, etc., (ii) one or more control expression vectors or RNA polynucleotides; (iii) one or more reagents for in vitro production and / or maintenance of molecules, cells, delivery systems, etc. provided herein; and the like. Components (e.g., reagents) may also be provided in a form that can be used for a specific assay, or in a form that requires the addition of one or more other components before use (e.g., in a concentrated or lyophilized form). Suitable buffers include, but are not limited to, phosphate buffered saline, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. Kit components may also be provided alone or in combination, and may be provided in any suitable container such as a vial, a bottle or a test tube. In some embodiments, the kit disclosed herein comprises one or more reagents for the embodiments disclosed herein.
[0350] In addition to the above-mentioned components, the subject test kit may also include the use of the components of the test kit to implement the instructions for the subject method. The instructions for implementing the subject method are usually recorded on a suitable recording medium. For example, the instructions can be printed on a substrate (such as paper or plastic, etc.). Therefore, the instructions can be present in the test kit as a package insert, present in the label (i.e., associated with packaging or subpackaging) of a test kit container or its components, etc. In other embodiments, the instructions are present on a suitable computer-readable storage medium (such as CD-ROM, disk, flash drive, etc.) as an electronic storage data file. In other embodiments, actual instructions are not present in the test kit, but provide the means (such as through the Internet) of obtaining instructions from a remote source. The example of this embodiment is to include a test kit comprising a website where instructions can be viewed and / or instructions can be downloaded therefrom. Like the instructions, the means for obtaining the instructions are recorded on a suitable substrate.
[0351] Another aspect of the present disclosure provides all that is described and shown herein.The following examples are provided by way of illustration and not limitation. Example
[0352] The following general method is common to the working examples
[0353] Supplementary Video 1. Optogenetic Activation of Mice Injected with Binary CellREADR Viral Vectors
[0354] Injected with binary READR Ctip 2 / 3 / Reporter ChR g er2-eYFP Optogenetic activation of AAV in mice (CFA, 0.5 s) induced a stepping movement of the forelimbs. The upward movement consisted of sequential elbow, wrist, and finger flexion, followed by extension.
[0355] Supplementary Video 2. Optogenetic Activation of Mice Injected with Binary PT Enhancer Viral Vector
[0356] Injection of PTenhancer / Reporter ChRger2-eYFP Optogenetic activation of AAV in mice (CFA, 0.5 s) induced elbow extension accompanied by finger extension.
[0357] Methods used in the working example
[0358] Plasmids: All constructs were generated using standard molecular cloning procedures. The vector backbone was linearized using restriction digestion and DNA fragment inserts were generated using PCR or gBlock synthesis (IDT). Information for all plasmids is included in Table 6. All sesRNA inserts were generated by gBlock synthesis (IDT) and the sesRNA sequences used in this study are included in Table 7.
[0359] Cell culture and transfection
[0360] HeLa cell line was obtained from A. Krainer laboratory (Cold Spring Harbor Laboratory). Mouse neuroblastoma Neuro-2a (N2a) cells were purchased from Millipore-Sigma (Sigma, Cat. 89121404). HEK293T and KPC1242 cell lines were obtained from D. Fearon laboratory (Cold Spring Harbor Laboratory). HEK293T, Hela and N2a cell lines were cultured in Dulbecco's modified Eagle's medium (Corning, 10-013-CV) containing 10% fetal bovine serum (FBS) (Gibco, Cat. 16000036) at 37 ° C and 5% CO2. 1% penicillin-streptomycin was supplemented in the culture medium. Cells were transfected with Lipofectamine 2000 (Invitrogen, Cat. 11668019) DNA transfection reagent according to the manufacturer's instructions. For interferon treatment, medium containing 1 nM recombinant mouse interferon-β (R&D, Cat. 8234-MB) was used and replaced every 24 hours during transfection. For tetracycline treatment, medium containing the specified tetracycline concentration was used 24 hours after transfection instead of medium without tetracycline, and continued for 48 hours before analysis. For apoptosis assay, cells were incubated for 72 hours after transfection, and RealTime-GloTM Annexin V apoptosis and necrosis assay (Promega JA1011) was used to quantify apoptosis levels.
[0361] SURVEYOR assay
[0362] PCR of genomic DNA (primers for DYRK1A, forward: GGAGCTGGTCTGTTGGAGAA; reverse: TCCCAATCCATAATCCCACGTT) was used to amplify the Cas9 target region from a heterogeneous population of modified and unmodified cells, and the PCR products were slowly annealed to generate heteroduplexes. The reannealed heteroduplexes were cleaved by SURVEYOR nuclease, while the homoduplexes remained intact (IDT: Alt-R Genome Editing Detection Kit). The Cas9-mediated cleavage efficiency (% indel) was calculated based on the fraction of DNA 31 that was cleaved.
[0363] animal
[0364] Mice aged 6 to 20 weeks (both male and female) were used for this study. Wild-type mice were purchased from Jackson Laboratory (C57BL / 6J, 000664). Fezf2-CreER and Rosa26-LoxpSSTOLoxp-H2bGFP mice were previously described 39,56 To mark Fezf2+ Cortical pyramidal neurons were injected with 200 mg / kg dose of tamoxifen (T56648, Sigma) by intraperitoneal injection two days before AAV injection. Long Evans rats (Rattus norvegicus, 12 weeks old, 50-250 g) were obtained from Charles River. All animals were maintained in a 12h:12h light:dark cycle, with a maximum of 5 animals per cage for mice and a maximum of 1 animal per cage for rats. All animal maintenance and experimental procedures were performed according to the guidelines established by Cold Spring Harbor Laboratory and Duke Medical Center.
[0365] Construction of ADAR1 knockout cell line
[0366] ADAR1 knockout cell line was generated by CRISPR-Cas9 genome editing. gRNA was cloned into pSpCas9(BB)-2A-puro(pX459)(Addgene, Cat.62988). gRNA sequences were 5'GGATACTATTCAAGTCATCTGGG 3'(gRNA1) and 5'GTTATTTGAGGCATTTGATG 3'(gRNA2). In short, ADAR1 knockout cells were produced with two gRNAs targeting exon 2, which are shared by ADAR1-p110 and ADAR1-p150 isoforms. HEK293T cells were seeded into 6-well plates and transfected with a plasmid mixture of 1ug of pX459-gRNA1 and pX459-gRNA2 using Lipofectamine 2000 (Thermo Fisher Scientific, Cat.11668019). On the second day, all culture media containing transfection reagents were removed and replaced with fresh culture media supplemented with puromycin (final concentration of 2ug / ml). Fresh culture media containing puromycin was replaced with old culture media every two days for a total of three times. The remaining cells after puromycin selection were harvested with TrypLE (Gibco, Cat.12605036) and distributed in 96-well plates, 1 to 2 cells per well. The ADAR1 deficiency of amplified single clones was screened by Western blotting, and the destruction of the ADAR1 genomic locus was confirmed by Sanger sequencing.
[0367] Flow cytometric analysis
[0368] Two days after transfection, cells were harvested with TrypLE (Gibco, Cat. 12605036), distributed in 96-well round-bottom plates, and centrifuged at 500 rpm for 1 min at 4°C. The supernatant was removed, the cells were resuspended with 1% PFA buffer, and incubated overnight or longer at 4°C. The cells were then resuspended with 200ul flow cytometry staining buffer (Invitrogen, Cat. 00-4222-26) and analyzed using LSR Fortessa (BD Biosciences). Fortessa was operated with FACSDIVA (BD Biosciences) software. Data analysis was performed using FlowJo 10 (FlowJo, LLC). For sorting, cells were subjected to the same procedure as flow cytometry analysis, but without 1% PFA treatment, and were processed using BD FACSAria (BD Biosciences).
[0369] CellREADR efficiency of exogenous or endogenous transcripts
[0370] To determine CellREADR efficiency using fluorescent reporter genes, HEK293T cells or HEK293T ADAR1 knockout cells were first seeded in 24-well plates. After 24 hours, cells were co-transfected with a total of 1.5 μg of plasmid. 48 hours after transfection, cells were collected, fixed with 1% PFA and prepared for FACS analysis. To calculate CellREADR efficiency from FACS data, fluorescent proteins expressed by the spacer (e.g., Figure 1 b- Figure 1 Cells expressing the READR vector were gated using the BFP in d, and the efficiency was calculated as the ratio of double-positive cells expressing both efRNA and target RNA among all cells expressing the target RNA within the gate. Figure 1 h and Figure 2 ), the ratio was directly calculated as the ratio of double positive cells expressing both efRNA and target RNA among cells expressing target RNA. For some controls, CellREADR efficiency was calculated as the percentage of cells expressing efRNA among all counted cells.
[0371] sesRNA design
[0372] The following procedure is used for sesRNA design: 1) sesRNA is complementary to a specific cellular coding or noncoding RNA sequence, i.e., antisense; 2) the optimal length of sesRNA is 200-300 nucleotides; 3) readRNA consists of sesRNA and efRNA arranged in a continuous translation reading frame; 4) one or more stop codons (TAG) are located near the center of the sesRNA (within about 80220 nucleotides from the 5' end); 5) a 5'-CCA-3' sequence is found in the target RNA, which is complementary to the 5'-TGG-3' sequence in the sesRNA; then 5'-TAG-3' is replaced with 5'-T GG-3', so that when the sesRNA base pairs with the target RNA, a mismatch AC will be introduced; 6) To ensure that there are no other stop codons in the sesRNA, all other TAG, TAA, and TGA sequences in the sesRNA are converted to GAG, GAA, and GGA, respectively; preferably, the converted stop codon is not close to the TAG defined in step 5 (i.e., more than 10 bp away from it); 7) There should be no ATG (start codon) after the TAG defined in step 5 to exclude the possibility of accidental translation initiation; 8) sesRNA can target any region of the cell transcript, including exons, introns, UTR regions, or mature mRNA after splicing. 9) Avoid sesRNAs with complex secondary structures.
[0373] A to I editing rate of CellREADR
[0374] To evaluate the A to I editing rate, HEK293T cells were seeded in 12-well plates. 48 hours after transfection, cells were collected and RNA was extracted. RNA was purified with RNeasy Mini kit (Qiagen Cat.74106) and converted into cDNA using TaqManTM reverse transcription reagent (Thermo Fisher, N8080234). PCR products covering the entire sesRNA region were generated with CloneAmp HiFi PCR premix (Takara, catalog number 639298), and the PCR products were purified with NucleoSpin gel and PCR Clean-up kit (Takara, catalog number 74061) for Sanger sequencing. Editing efficiency was calculated as the ratio of Sanger peak height G / (A+G). Three biological replicates were performed.
[0375] Whole-transcriptome RNA sequencing analysis
[0376] The expression readrRNA with a red fluorescent protein (tdTomato) expression cassette Ctrl or readrRNA PCNA 、readrRNA EEF1A1-CDSThe plasmid was transfected into 293T cells. RFP was enriched by FACS sorting 48 hours after transfection. + Cells (approximately 5×10^5) were cultured and RNA was purified using the RNeasy Mini kit (Qiagen Cat.74106). To prepare the library, RNA samples were treated with the TrueSeqStranded mRNA library Prep kit (Illumina, 20020594) and the TrueSeq RNA Single Index (Illumina, 20020492). Deep sequencing analysis was performed on the IlluminaNextSeq500 platform at the NGS Bioinformatics Center of Cold Spring Harbor Laboratory. FastQC was applied to the RNA-seq data to check the sequencing quality. All samples that passed the quality check were mapped to the reference genome (GRCh38-hg38). Genes were annotated using STAR (version 2.7.2) and RSEM (version 1.3.2). TPM values were calculated based on RSEM. For all genes with a read count above zero for at least one library, DESeq2 was used to compare the average expression values of biological replicates between samples to detect differentially expressed genes. 36 Genes with corrected p-value < 0.01 and fold change > 2 or < 0.5 were identified as significantly differentially expressed. For global A to G editing rate analysis, A to G editing rate calculation was performed using the RNA Editing Detection Pipeline (REDP), a python wrapper of REDItool 37 Parameters were set to default values. The alignment step was done using STAR v2.7.8a with default and coordinate ordering parameters. The genome reference from Gencode GRCH38.p13 was used and concatenated with known sequences from target genes including EEF1A1 and PCNA.
[0377] Western blotting
[0378] Primary antibodies against ADAR1 (Santa Cruz, sc-271854, 1:500), GFP antibody (Cell Signaling Technology, Cat. 2956, 1:10000), and β-actin antibody (Cell Signaling Technology, Cat. 3700, 1:10000) were used in this study. A standard Western blotting protocol was used. Briefly, approximately 2×10 6 cells, and an equal amount of each lysate was loaded for SDS-PAGE. Then, the sample proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories) and immunoblotted with primary antibodies against ADAR1 or GFP, followed by secondary antibody incubation (1:10,000) and exposure.
[0379] Luciferase complementation assay
[0380] 48 hours after transfection, HEK293T cells expressing the firefly luciferase gene were washed in PBS, collected by grinding and transferred to a 96-well plate. Promega luciferase assay system (Promega, E1500) was used. Firefly luminescence was measured using a SpectraMax multi-mode microplate reader (Molecular Devices).
[0381] qRT-PCR
[0382] RNA was extracted and purified using the RNeasy Mini kit (Qiagen Cat. 74106). RNA was converted to cDNA using TaqMan™ reverse transcription reagent (Thermo Fisher, N8080234). qRT-PCR was performed using Taqman probes on the QuantStudio 6Flex real-time PCR system. The housekeeping gene TBP was used for normalization. Gene probes were purchased from Thermo Fisher Scientific. (Thermo Fisher Scientific EEF1A1: Hs01591985, PCNA: Hs00427214, XIST: Hs00300535, ACTB: Hs03023943, Mda5: Mm00459183_m1, Rig-I: Mm01216853_m1, Ifnb1: Mm00439552_s1, Il6: Mm00446190_m1, Ccl2: Mm00441242_m1, Fgf2: Mm01285715_m1, Cd40: Mm00441891_m1, Iba1: Mm00479862_g1, Cxcl10: Mm00445235_m1). The housekeeping gene TBP (ThermoFisher Scientific, human TBP: Hs00427620, mouse Tbp: Mm01277042_m1) was used for normalization.
[0383] Virus production
[0384] In order to produce READR and reporter viruses, HEK293T was transiently transfected with READR or reporter plasmids, AAV serotype plasmids and pHelper (Catalog 24765, Polysciences Inc.) using PEI MAX. After 72 hours of transfection, cells were collected in cell culture medium and centrifuged at 4,000rpm for 15 minutes. The supernatant was discarded, and the precipitate was resuspended in cell lysis buffer and frozen and thawed three times with dry ice / ethanol bath. The cell lysate was centrifuged at 4,000rpm for 20 minutes. The contaminated DNA in the supernatant was removed by adding Benzonase and incubated at 37 for 30 minutes. The crude virus solution was loaded onto the iodixanol density gradient and rotated at 60,000rpm for 90 minutes using a Beckman Ti70 rotor. After centrifugation, 3-4ml crude virus preparations were collected from 40-60% of the layer with an 18-gauge needle connected to a 10ml syringe. The crude virus solution was concentrated to 200-250 μl using an Amicon Ultra-15 centrifugal filter (100 kDa), washed once with 8 ml PBS, and concentrated to an appropriate volume. Aliquots were stored at -80 °C before use. Mouse and rat READR and reporter viruses were packaged into AAV-DJ or AAV-PHP.eB serotypes. PT enhancer-tTA2 virus was packaged into PHP.eB using a vector from Addgene (#163480). Human READR and reporter viruses were packaged into AAV2-Retro serotype. pAAV(DJ)-hSyn-Adar2-sesRNA Fez f 2 -tTA2 and pAAV(PHP.eB)-hSyn-ADAR2-sesRNA Ctip2(1) -tTA2 was packaged by Vigene Inc.).
[0385] Immunohistochemistry
[0386] Mice or rats were anesthetized (using Avertin) and then perfused intracardially with saline followed by 4% paraformaldehyde (PFA) in 0.1M PBS buffer. After fixation overnight at 4°C, the brains were rinsed three times and cut into 50 μm thick sections using a Leica 1000s vibrating microtome. The sections were placed in PBS 1X blocking solution containing 10% normal goat serum (NGS) and 0.1% Triton-X100 for 1 hour and then incubated with primary antibodies diluted in blocking solution overnight at 4°C. Anti-CTIP2 ((1:1000, Aves, GFP-1020), anti-CTIP2 (1:250, Abcam 18465) were used. Anti-TLE4 (1:500, Scbt: sc-365406); anti-Rorb (1:300, Novus Biologicals NBP1-82532) were used; the sections were rinsed three times in PBS and incubated with the corresponding secondary antibodies (1:500, Life Technologies) for 1 h at room temperature. The sections were dry-mounted on slides using Fluoromount (Sigma, F4680) mounting medium.
[0387] For human tissue, cortical slices were fixed in 4% PFA overnight after viral expression peaked, or after patch clamp recordings, then rinsed in PBS and stored in PBS containing azide for 1-7 days. For biotin recovery, tissues were permeabilized in PBS containing 10% TritonX100, 5% NGS, 100uM glycine, and 0.5% BSA for 30 minutes at room temperature on a shaking plate. Both primary and secondary antibodies were incubated at 4°C for 24 hours. Biotin was either directly generated with streptavidin conjugated to Alexa647 or indirectly generated by enzyme metallography with peroxidase-labeled streptavidin treated with a silver ion substrate that deposited metallic silver at the active site. Recovered cells were imaged on a Keyence BZ-X800 with a 10X or 20X objective. Large field images of native mNeon fluorescence were made on a Leica SP8 upright confocal microscope. For immunohistochemical labeling of FOXP2 and NeuN, the tissue was cryoprotected in 30% sucrose for at least 24 hours and then re-sectioned at 40 μm using a sliding microtome. The floating sections were permeabilized in PBS containing 1% TritonX100, 5% NGS and 100 μM glycine at room temperature for 30 minutes and labeled overnight with primary antibodies (rabbit anti-FOXP2 Abcam #16046 1:500, rat anti-Flag 1:500 Novus NBP1-06712, mouse anti-NeuN Ab1:500, Cell Signaling #94403S) at 4 o'clock. For secondary antibodies, tissues were incubated either with biotinylated anti-rabbit Ab (1:1000, ThermoFisher 31822) for 2 h at room temperature, followed by incubation with streptavidin AlexaFluor647 for 1 h at room temperature (FOXP2) or with goat anti-mouse Ab (1:1000, ThermoFisher 32723) for 2 h at room temperature (NeuN).
[0388] In situ hybridization
[0389] All probes were purchased from Molecular Instruments (mouse Satb2 cat#PRM128, mouse PlxnD1 cat#PRK885, mouse Fezf2 cat#PRA339, mouse vGAT cat#PRE853, rat vGAT cat#PRN024, and human VGAT cat#PRM351). After PFA perfusion fixation and sucrose protection, the mouse brain was cut into 50 μm thick slices. In situ hybridization chain reaction was performed by free floating method in 24-well plates. First, the brain slices were exposed to hybridization buffer containing the probe HCR probe set at 37 degrees for 24 hours. The brain slices were washed with probe wash buffer, incubated with amplification buffer, and amplified at 25. Amplified for 24 hours. On the 3rd day, the brain slices were washed and counterstained if necessary.
[0390] Stereotaxic virus injection
[0391] 2% isoflurane delivered by inhalation with a constant airflow (0.4L / min) is anesthetized in 8-week-old or larger adult mice. Ketoprofen (5mg / kg) and dexamethasone (0.5mg / kg) are subcutaneously administered as preemptive analgesia and prevention of cerebral edema, and lidocaine (2-4mg / kg) is used. Mice are fixed in a stereotaxic head frame (Kopf Instruments, 940 series or Leica Biosystems, Angle Two). Stereotaxic coordinates are determined. An incision is made on the scalp, a small burr hole is drilled in the skull, and the brain surface is exposed. A 20-30 μm drawn glass pipette tip containing the virus suspension was lowered into the brain; a single or mixed virus volume of 500 nl was delivered to the injection site at 300 um and 700 um (1:1 volume) using a Picospritzer (General Valve Corp) at a rate of 30 nl / min; the pipette was kept in place for 10 min before being retracted to prevent backflow, after which the incision was closed with nylon sutures (Ethilon nylon sutures, Ethicon Inc. Germany) or Tissuelue (3M Vetbond), and the animal was kept warm on a heating pad until fully recovered. For rat Tle4 cell type targeting, READR Tle4 A 3:1 mixture of READR and reporter gene AAV was stereotaxically injected into the cortex (0 mm posterior, 3.5 mm lateral), with a volume of 1000 ul injected at -2 mm ventral and 1000 ul injected at -1 mm ventral, respectively. vGATA 3:1 mixture of 1:1 and reporter gene AAV was stereotaxically injected into the cortex (-4 mm posterior, 3.5 mm lateral), with 1000 ul injected at -2.5 mm ventral and 1000 ul injected at -1.5 mm ventral, respectively. After 3 weeks of virus incubation, further immunohistochemistry or in situ hybridization experiments were performed.
[0392] Mouse Physiology
[0393] -Stereotaxic surgery and viral injections. All surgeries were performed under sterile conditions and body temperature was maintained with a heating pad. Standard surgical procedures were used for stereotaxic injections and fiber optic implantation. Mice were anesthetized with isoflurane (2-5% at the beginning and 0.8-1.2% during the rest of the surgery) and placed in a stereotaxic frame and on a heating pad maintained at 34-37°C. Ketoprofen (5 mg / kg) was administered intraperitoneally (IP) as an analgesic before and after surgery, and lidocaine (2%) was administered subcutaneously under the scalp before surgery. The scalp and connective tissue were removed to expose the back of the skull. The skin was pushed aside and the skull surface was cleaned with saline. A digital mouse brain atlas was connected to the stereotaxic frame to guide the identification and targeting of different brain regions (Angle Two stereotaxic system, Leica Biosystems). The following coordinates were used for injection and implantation in SSp-ul: -0.09 from bregma, 2.46 mm lateral to midline; CFA: 0.37 mm from bregma, 1.13 mm lateral to midline.
[0394] For viral injection, a small burr hole was drilled in the skull to expose the brain surface. A 20-30 μm pulled glass pipette tip containing the virus suspension was placed into the brain; a 500 nl volume was delivered at a rate of 10-30 nl / min using a Picospritzer (General Valve Corp); the pipette was kept in place for 5 min to prevent backflow and then retracted. The injection depth was 700 μm. The optical fiber (200 μm in diameter; NA, 0.39) was then implanted into CFA or SSp-ul for optogenetic activation or fiber photometry, respectively. The implanted optical fiber tip contacted the brain surface. To fix the optical fiber to the skull, a silicone adhesive (Kwik-Sil, WPI) was applied to cover the hole, followed by a layer of dental cement (C&B Metabond, Parkell), then black; instant glue (Loctite 426) and dental cement (Ortho-Jet, Lang Dental). A titanium head bar was fixed to the skull around lambda using dental cement. Mice were transferred to a heating pad until fully recovered. Further experiments with optogenetic activation or fiber photometry were performed after 8 weeks of viral incubation.
[0395] -In vivo optogenetic activation. Mice were first briefly anesthetized with isoflurane (2%) and a reflective marker was attached to the back of their left paw. The mice were then transferred to a tube with their heads fixed on a stage and allowed to fully recover from anesthesia before stimulation began. A fiber-coupled laser (5ms pulse, 10-20mW; λ=473nm) was used to stimulate at 20 and 50Hz for 0.5s. The stimulation interval was 9.5s. Two cameras (FLIR, FL3-U3-13E4C-C), a frontal camera and a side camera, were mounted on the stage to capture high frame rate (100Hz) video. The two cameras were synchronized by a TTL signal controlled by a custom MATLAB program. The video and TTL signal status were acquired simultaneously using the workflow in the Bonsai software. Four LED lights were used for illumination (two for each camera).
[0396] -Behavioral video analysis. Both cameras were calibrated using the Camera Calibrator application in MATLAB. For left paw tracking using MATLAB, images from the videos were smoothed with a Gaussian low-pass filter (spec 9, sigma 1.8). The centroid of the reflective markings on the paw was first detected by a combination of brightness and hue thresholds and then tracked by a feature-based tracking algorithm (PointTracker from Computer Vision Toolbox). Tracking results were manually verified and errors were corrected accordingly. Trials in which the mouse made spontaneous movements before stimulus onset (within 0.5 s) were excluded from further analysis.
[0397] - Paw stimulation. To stimulate the left paw, mice were lightly anesthetized with isoflurane (0.75-1%). Body temperature was maintained using a feedback-controlled heating pad. A piezo bender (BA4510, PiezoDrive) driven by a micro piezoelectric actuator (PDu100B, PiezoDrive) was insulated with Kapton tape, to which a blunt needle was glued. The needle tip was attached to the back of the paw and the paw was stimulated with vibration (100 Hz, sine wave, 1 s). The stimulation interval was 10 s.
[0398] -In vivo fiber photometry and data analysis. A commercial fiber photometry system (Neurophotometrics) was used to record calcium activity from SSp-ul. A patch cord (core diameter 200 μm; Doric Lenses) was used to connect the photometry system and the implanted optical fiber. The intensity of the blue light (λ = 470 nm) used for GCaMP excitation was adjusted to about 60 μW at the tip of the patch cord. An isoabsorption control signal was obtained using violation light (λ = 415 nm, about 60 μW at the tip) to detect artifacts that are independent of calcium. The emitted signal was bandpass filtered and focused on the sensor of the CMOS camera. The photometric signal and the start of stimulation were calibrated based on a TTL signal generated by a multifunction I / O device (PCIe-6321, National Instruments). The average value of the signal from the ROI was calculated and saved using Bonsai software and exported to MATLAB for further analysis.
[0399] To process the recorded photometric signals, an adaptive iteratively reweighted penalized least squares algorithm ( https: / / at github.com / zmzhang / airPLS) Baseline correction is performed on each signal to eliminate the slope and low-frequency fluctuations in the signal. The median and standard deviation of the 5-s baseline period are used to normalize the baseline-corrected signal on a trial-by-trial basis (Z score). Robust linear regression is used to fit the normalized 415-nm excited iso-absorptive signal to the normalized 47-nm excited GCaMP signal. Finally, the normalized iso-absorptive signal is scaled using the parameters of the linear regression, and is regressed from the normalized GCaMP signal to obtain a calcium-dependent signal.
[0400] Human organotypic sample preparation
[0401] Human neocortical tissue (frontal, parietal, temporal) was obtained from pediatric and adult patients (N=6; 6-60 years) undergoing brain resection for epilepsy. Informed consent for tissue donation was obtained under Duke University IRB protocol 00103019.
[0402] Tissue preparation generally follows the literature 41 ,57 ,58The dissecting solution contained (in mM): 75 sucrose, 87 NaCl, 25 glucose, 26 NaHCO3, 2.5 KCl, 1.2 NaH2PO4, 10 MgCl2, 0.5 CaCl2, bubbled with 95 / 5% O2 / CO2 (pH 7.4). The cortex was carefully dissected under ice-cold (~4C) oxygenated dissecting solution to remove the pia mater. Individual gyri were blocked for sectioning and cut at a thickness of 300um on a Leica VT1200. The sections were rinsed in Hank's buffered saline and plated on PTFE membranes (Millipore, catalog number PICMORG50) in 6-well plates. The tissue was placed in the wells of the literature. 40 Cultivate in the conditioned medium described in. In the first 7 days in vitro, the conditioned medium also contains antibiotics / antimycotics (1X, Gibco by ThermoFisher), and contains cyclosporin (5ug / mL) during the entire culture period. HEPES (20mM) is added to the culture medium in the first hour after slicing. AAV retro-grade (AAV-rg) virus is suspended in the conditioned medium and directly applied to the slice surface by a pipette on the day of plating. The expression of mNeon reporter gene is monitored from DIV 3, and the tissue is used for immunohistochemistry and patch clamp experiments between DIV 6 and DIV 14.
[0403] Electrophysiology of human organotypic samples
[0404] Cultured human neocortical tissue was transferred to a heated recording bath (32-34°C) on the stage of an Olympus BX-50 upright microscope. The recording solution contained (in mM): 118 NaCl, 3 KCl, 25 NaHCO3, 1 NaH2PO4, 1 MgCl2, 1.5 CaCl2, 30 glucose fully saturated with 95 / 5% O2 / CO2. Borosilicate patch pipettes were pulled with a resistance of 4.0-5.5 MΩ and filled with an internal solution containing the following ingredients (in mM): 134 K-gluconate, 10 HEPES, 4 ATP-triphosphate magnesium salt, 3 GTP-triphosphate sodium salt, 14 creatine phosphate, 6 KCl, 4 NaCl, adjusted to a pH of 7.4 with KOH. Biotin (0.2%) was added to the internal solution to allow morphological identification after recording. Patched cells were kept in whole-cell mode for at least 12 minutes to ensure complete filling with biotin. Using Axopatch 700B amplifier (Molecular Devices) under visual guidance, cells expressing mNeon were patch clamped. Data were digitized with (Digidata 1550B) and recorded with pClamp 10 (Molecular Devices). Membrane voltage was recorded at 100 kHz and low-pass filtered at 10 kHz. Liquid junction potential was uncorrected. Pipette capacitance and series resistance were compensated at the beginning of each recording, and the stability of the recording configuration was checked regularly. Intrinsic membrane properties were measured with -10pA current steps. The firing base intensity (Firing rheobase) was measured using a ramp current with a duration of 1s and a final amplitude of 100-300pA. The input-output curve was generated by a series of current steps, which started from -50pA and increased in increments of 10pA until the maximum trigger rate was reached. NeuroMatic and internal program analysis data were used in Igor Pro (Wavemetrics).
[0405] Microscopy and image analysis
[0406] Imaging of cells in tissue culture was performed on a ZEISS Axio Observer (CSHL St. Giles Advanced Microscopy Center). Serially mounted brain sections were imaged on a Zeiss LSM 780 or 710 confocal microscope (CSHL St. Giles Advanced Microscopy Center) and a Nikon Eclipse 90i fluorescence microscope, using x63 and x5 objectives for embryonic tissue and x20 objectives for adult tissue, and on a Zeiss Axioimager M2 system equipped with MBF Neurolucida software (MBF) using an x5 objective. Quantification and image analysis were performed using Image J / FIJI software. Statistics and graphing were performed using GraphPad Prism 9.
[0407] statistics
[0408] Unpaired two-tailed Student's t-test was used for comparison between groups. Statistical analysis was performed using Prism 9 (GraphPad Software, Inc.). Statistical significance of whole transcriptome RNA-seq data was analyzed using DESeq2.
[0409] Any references, publications, online resources, patents and / or non-patent literature mentioned herein are hereby incorporated by reference in their entirety.
[0410] Overview of cell type access via programmable RNA sensing
[0411] Different cell types in multicellular organisms are essential intermediates for genome construction and coordination of organismal phenotypes. Deciphering the organizational logic of this biological information flow and its changes in disease requires methods that allow specific and comprehensive analysis of cell types in different species. The following examples describe CellREADR (cell access by endogenous ADAR through RNA sensing), which combines the detection of RNA that determines the type of somatic cell with the translation of the desired effector protein through RNA editing mediated by adenosine deaminase (ADAR) acting on RNA. The following examples show that when delivered by viral vectors, CellREADR senses specific RNA sequences to translate reporter proteins in different neuronal types in human and mouse cell lines and in the mouse cerebral cortex. This RNA programmable technology highlights the potential to discover, monitor and edit animal cell types in a specific, simple, universal and universal way across organ systems and species, and has wide applications in biology, medicine and biotechnology.
[0412] Example I. CellREADR design and validation in mammalian cells
[0413] RNA editing is a widespread and powerful posttranscriptional mechanism that is essential to the metazoan gene regulatory toolkit, which involves recoding, splicing, microRNA targeting, and other RNA processing and cellular processes [20, 21]. The most common form of RNA editing is the conversion of adenosine to inosine (A->I), catalyzed by ADARs; inosine is recognized by the cellular machinery as guanosine (G)
[21] . ADARs recognize and are recruited to segments of base-paired double-stranded (ds) RNA
[20] and can therefore operate as sequence-guided base editing machines and have been used for transcriptome editing [22-26]. Because ADARs are ubiquitous in animal cells
[27] , CellREADR was designed as a single and modular reader RNA molecule ( Figure 1 a). The 5' region of the readrRNA contains a sensor domain of approximately 300 nucleotides that is complementary to the RNA of a specific cell type, thereby detecting the RNA of a specific cell type through sequence-specific base pairing. The sensor domain contains one or more ADAR-editable stop codons that act as a translation switch; this leads to the nomenclature of this region as sense-editing-switch RNA (sesRNA). Downstream and in-frame of the sesRNA is a sequence encoding the self-cleaving peptide 2A, followed in-frame by an effector RNA (efRNA) region encoding various effector proteins. Depending on the specific sensor and effector, the entire readrRNA is several thousand bases long and can therefore be delivered to cells via viral vectors or liposome nanoparticles. In cells expressing the target RNA, the sesRNA forms a dsRNA with the target, which recruits ADARs to assemble an editing complex. At the editable stop codon, ADAR converts A to I, which pairs with the opposite C in the target RNA. This A->G substitution converts the TAG stop codon to a TI(G)G tryptophan codon, thereby turning on the translation of the efRNA. In-frame translation produces a fusion protein containing the N-terminal peptide, 2A, and the C-terminal effector, which is then self-cleaved by 2A and releases the functional effector protein ( Figure 1 a). The readrRNA is expected to remain inert in cells that do not express the target RNA.
[0414] Example 2. Operability in human cells
[0415] A proof-of-principle format of CellREADR was established and tested in a human 293T cell line. An expression vector (PGK-tdT) was used to express the tdTomato gene as an exogenous target RNA and label transfected cells. Next, a READR vector (READRtdT-GFP) expressing a readrRNA was designed, which consists of a 5' sensor region of a tdT sequence embedded with a TAG stop codon (sesRNAtdT), a 2A coding sequence, and a 3' coding box for green fluorescence (GFP) ( Figure 6 Co-transfection of READRtdT-GFP and PGK-tdT resulted in GFP expression in the tdT+ cell subpopulation ( Figure 6 To confirm this result, the GFP coding region of the READR vector was replaced with the coding region of a tetracycline-inducible transcriptional activator (tTA2), which drives the expression of the firefly luciferase gene (Luc) from the tetracycline response element (TRE) promoter ( Figure 6 Co-transfection of READRtdT-tTA2 and TRE Luc with PGK-tdT resulted in significant induction of luminescence compared to the empty vector control ( Figure 6 When co-transfected with the empty PGK vector, sparse and weak GFP or luciferase expression was observed from READRtdT-GFP or READRtdT-tTA2 / TRE Luc alone, respectively ( Fig.10 b- Fig.10 f), which may be caused by occasional read-through of stop codons in sesRNA
[28] .
[0416] Example 3. Spacer
[0417] The spacer sequence reduces readrRNA leakage according to one embodiment of the present disclosure. Inclusion of an in-frame spacer of approximately 600 bp before the sesRNA almost eliminates residual GFP translation. Figure 2 a. Figure 6 g and Figure 6 i is a schematic READRtdT-G'P vector, in which a spacer sequence is inserted before the sesRNAtdT coding region. Figure 6 J is a representative FACS analysis of GFP and RFP expression in 293T cells transfected with READRtdT-G'P vectors encoding variable spacer lengths in the presence (upper) or absence (lower) of tdT target RNA expression. Figure 6 j); In the presence of tdT target RNA, longer spacers reduce the efficiency of readrRNA ( Figure 6 h), which shows Figure 6Quantification of transformation efficiency calculated as the percentage of GFP+ cells among RFP+ cells is shown in J.
[0418] Example 4. Quantification
[0419] To characterize CellREADR efficiency more quantitatively, a BFP coding cassette was inserted upstream of the sesRNAtdT region in READRtdT-GFP, which served as a spacer and marker for all READRtdT-GFP-transfected cells and CAG-tdT-transfected cells ( Figure 1 b, Figure 1 c). The efficiency of CellREADR was calculated as the ratio of GFP+ cells in RFP+ cells gated against BFP+ cells in FACS analysis. In the absence of tdT target RNA, READRtdT-GFP showed no leaky GFP expression. In the presence of tdT RNA, the efficiency of READRtdT-GFP was 15.2% ( Figure 1 c, Figure 1 d), whereas a control READR vector expressing sesRNACtrl with a scrambled coding sequence containing a stop codon showed no GFP translation.
[0420] Example 5. CellREADR efficiency is related to target RNA levels
[0421] Next, it was checked whether the efficiency of CellREADR is related to the target RNA level. The efficiency of READRtdT-GFP increases with the increase of CAG-tdT vector amount in 293T cell transfection. A tetracycline inducible expression vector was further designed, in which the ChETA (variant of light-gated channel rhodopsin-2) coding sequence was fused to blue fluorescent protein (BFP) and driven by TRE, so the BFP fluorescence level indicates the Cheta transcription level, which is related to the tetracycline concentration in the culture medium. The increase of tetracycline concentration and BFP expression level improves the efficiency of READRCheta-GFP in a Cheta RNA-dependent manner. Figure 1 e- Figure 1 f. Using constitutive promoter-driven BFP-Cheta expression, the efficiency of READRCheta-GFP was as high as 41.5%. These results demonstrate the target RNA level dependence and robustness of CellREADR. To demonstrate the ability of effector RNA to mediate physiological functions, we constructed READRtdT-Cas9 (to express Cas9 protein for genomic DNA editing29) and READRTDT-taCas3 / TEV (to express functional caspase 3 for programmed cell death30). Efficient gene editing was induced only in the presence of tdT target RNA ( Figure 7a- Figure 7 d) and increased apoptosis ( Figure 7 e- Figure 7 f).
[0422] Example 6. Role of ADAR Proteins in CellREADR Function
[0423] To examine the role of ADAR proteins in CellREADR function, an ADAR1 knockout (KO) 293T cell line was generated using CRISPR. Since ADAR1 is highly expressed in 293T cells, while ADAR2 is barely expressed, ADAR1KO293T essentially represents an ADAR-null cell line. Removal of ADAR1 largely abolished READRtdT-GFP functionality ( Figure 5 h, Figure 5 i), which is functionally activated by the p110 or p150 ADAR1 isoforms and the ADAR2 protein ( Figure 5 h, Figure 5 i) Exogenous expression of ADAR2 rescued the READR tdT-GFP The efficiency is increased by about 25-30% ( Figure 5 h, Figure 5 i). Sanger sequencing confirmed the A to I / G edit at the expected site, which converted the TAG stop codon to a TGG tryptophan codon ( Figure 5 j, Figure 5 k). Since ADAR expression can be induced by interferon stimulation [32,33], we further confirmed that ADAR1-p110 and ADAR1-p150 ADARs were induced by interferon stimulation in wild-type 293T cells and demonstrated a corresponding increase in READRtdT-GFP efficiency.
[0424] Example 7. CellREADR functions in various cells
[0425] In addition to 293T cells, CellREADR functionality was demonstrated in several other cell lines derived from different tissues or species, including human HeLa, mouse N2a, and mouse KPC1242 cell lines. Collectively, these results suggest that by utilizing endogenous ADARs, CellREADR can couple the detection of cellular RNA with the translation of effector proteins in a specific, efficient, and robust manner.
[0426] Example 8. sesRNA properties endow CellREADR with programmability
[0427] Since sesRNA is a key component of CellREADR, we used the ADAR2-overexpressing READRAdar2-tdT-GFP vector as a robust assay to exploit several properties of sesRNA. We found that sesRNAs shorter than 100 nucleotides were largely ineffective, while sesRNAs of increasing length were positively correlated with CellREADR efficiency, with an optimal length of 200-250 nt.
[0428] Example 9. The role of mismatch in programmability
[0429] In terms of sequence mismatches with the target RNA, the approximately 200 nt sesRNA tolerated up to 10 mismatches (5% of the sequence length) or in-frame indels without a significant reduction in READRAdar2-tdT-GFP efficiency ( Figure 2 by; this feature confers flexibility to sesRNA design (see Methods).
[0430] However, mismatches near the editing site significantly reduced the efficiency of CellREADR. In order to explore the effect of the position along the target transcript on sesRNA design, the EF1a-Cheta-tdT expression vector was used and 5 sesRNAs targeting the promoter, different coding regions and 3'UTR were tested. Except for one targeting the promoter, all 4 sesRNAs targeting the transcript region showed robust efficiency. Finally, it was tested whether the inclusion of more stop codons could further increase the stringency of sesRNA (i.e., reduce basic translation in the absence of target RNA). Using luciferase as a sensitive indicator of leaky translation, sesRNA with two stop codons showed reduced leakage with comparable efficiency compared to sesRNA with one stop codon, although 3 stop codons significantly reduced efficiency ( Figure 2 d- Figure 2 f). Taken together, these results suggest strategies to enhance the stringency, efficiency, and flexibility of CellREADR.
[0431] Example 10. CellREADR is inherently programmable
[0432] Based on Watson-Crick base pairing, CellREADR is inherently programmable, endowing the potential for cross-targeting of two or more cellular RNAs for more specific cell type definition. To explore this property, dual- or triple-sesRNA arrays targeting different regions of the same transcript were designed. All sesRNA arrays tested exhibited robust CellREADR efficiency, comparable to that of a single sesRNA.
[0433] To examine the possibility of cross-targeting of two target RNAs, a sesRNA array consisting of sesRNAtdT and sesRNACheta (sesRNAtdT / Cheta) arranged in tandem was designed. Although a single target RNA, tdTomato or Cheta, could not induce GFP or Luc expression using readrRNAtdT / Cheta, significant GFP expression or enhanced luminescence was observed when both tdTomato and Cheta vectors were transfected, respectively. This result demonstrates the potential for cross-cell type targeting based on the programmability of CellREADR. Figure 2 .
[0434] Example 11. Endogenous RNA sensing by CellREADR
[0435] Compared with synthetic genes expressing exogenous RNA, endogenous genes usually have more complex genomic structures, including many exons, introns and regulatory elements; transcribed endogenous RNA undergoes multiple complex post-transcriptional steps, such as splicing and chemical modification, before being processed into mature mRNA. In order to test the ability of CellREADR to target endogenous RNA in cells, we first selected the housekeeping gene EEF1A1, which is highly expressed in 293T cells, and systematically designed a set of sesRNAs targeting its various exons, introns, 5' and 3' UTRs and mRNAs. Figure 3 . These sesRNAs efficiently sensed all expected EEF1A1 regions to turn on efRNA translation; exons were better targets than UTRs and introns. Notably, sesRNAs complementary to mRNA regions connected by two exons achieved efficacy comparable to those contained in exons, indicating that CellREADR acts on mRNA as well as pre-mRNA. After cell transfection, CellREADR efficiency for EEF1A1 RNA increased with longer incubation times. Several other endogenous RNAs were further tested in 293T cells, including highly expressed ACTB, moderately expressed PCNA, and the long noncoding RNA XIST. Robust CellREADR efficiency was observed for all of these RNAs ( Figure 3 d). Exogenous ADAR2 overexpression resulted in a modest increase in CellREADR efficiency of approximately 30% ( Figure 3 c, Figure 3 d). Taken together, these results suggest that endogenous ADARs enable efficient and robust CellREADR function on endogenous RNAs.
[0436] Example 12. Effect of CellREADR on Targeted Transcript Levels
[0437] CellREADR does not alter the levels of targeted transcripts measured by quantitative PCR (qPCR) ( Figure 3 e); This result also excludes the possible role of RNA interference induced by readrRNA. EEF1A sesRNA PCNA The transcriptome profiles of 293T cells expressing scrambled sesRNACtrl and 293T cells expressing scrambled sesRNACtrl were further analyzed by RNA sequencing to evaluate the transcriptome effects of CellREADR. Correlation analysis showed that sesRNAEEF1A or sesRNAPCNA expression had no significant effect on the global transcriptome ( Figure 3 f), DESeq2 analysis showed that sesRNA EEF1A sesRNA PCNA Group and sesRNA Ctrl There were no significant differences in gene expression between the groups, indicating that CellREADR had no significant effect on the cellular transcriptome.
[0438] Example 13. Further sensing of endogenous RNA by CellREADR
[0439] Compared with synthetic genes expressing exogenous RNA, endogenous genes usually have more complex genomic structures, including numerous exons, introns, and regulatory elements; transcribed endogenous RNA undergoes multiple complex post-transcriptional steps, such as splicing and chemical modification, before being processed into mature mRNAs34. To examine the ability of CellREADR to detect endogenous RNA in cells, we first selected EEF1A1, a housekeeping gene highly expressed in 293T cells, and systematically designed a set of sesRNAs targeting its various exons, introns, 5' and 3' UTRs, and mRNAs. Figure 3 a. Figure 3 b). These sesRNAs efficiently sense all expected EEF1A1 regions to turn on efRNA translation; exons appear to be better targets than introns ( Figure 3 c). Notably, sesRNAs complementary to the mRNA region connected by two spliced exons achieved efficiencies comparable to those contained within the exons, indicating that sesRNAs can be designed to target both pre-mRNA and mRNA sequences. After cell transfection, CellREADR efficiency for EEF1A1 RNA increased with longer incubation times.
[0440] Example 14. Sensitivity
[0441] To examine the sensitivity of CellREADR to target RNA levels, several other endogenous RNAs were further tested in 293T cells, including highly expressed ACTB, moderately expressed PCNA, and long noncoding RNA XIST. Several endogenous RNAs with expression levels ranging from high (ACTB, PCNA), moderate (TP53, XIST) to low (HER2, ARC) were selected. Robust CellREADR efficiency was observed for all these RNAs ( Figure 3 d). Exogenous ADAR2 overexpression resulted in a modest increase in CellREADR efficiency of approximately 30% ( Figure 3 c, Figure 3 d). CellREADR can reliably detect even low levels of ARC RNA, albeit at a much lower efficiency. Taken together, these results indicate that endogenous ADARs enable efficient and robust CellREADR function for endogenous RNAs.
[0442] Summary of Examples 1-14.
[0443] CellREADR was tested in human and mouse cell lines by setting up a reporter RNA editing assay in human 293 cells, where the target RNA is made from an RFP expression vector, the sensor RNA is antisense to the RFP target, and then the tTA transcriptional activator, which activates and amplifies GFP expression in a third vector. When transfected into cells, the sensor RNA pairs with the RFP RNA, and ADAR is recruited to edit the stop codon, turning on tTA translation that activates GFP, thereby turning the cells from red to green. Editing can also be quantified by fluorescence-activated cell sorting [FACS] assay, where the upper right quadrant is the RFP / GFP-positive cells.
[0444] This conversion was ADAR-mediated, as it did not occur in an ADAR1 knockout cell line and could then be rescued by expression of Adar2. Sanger sequencing demonstrated that this was indeed due to an increase in the expected AI(G) transition of the stop codon.
[0445] The system was also applicable to human Hela cells, mouse N2a cells, and to endogenous RNA in cells. When different regions of the Ef1a gene and pre-mRNA were used as targets, exons and coding regions were found to be better perceived targets than introns and untranslated regions. In addition, this also applied to five other cellular RNAs, including non-coding RNAs.
[0446] Example 15. Neuronal Cell Type Targeting Using CellREADR
[0447] CellREADR, which is used to access specific cell types in animal tissues (including neuronal tissues and cells), includes a single vector system and a binary vector system ( Figure 4 b) In a single vector system, i.e., a single READR vector contains, for example, the hSyn promoter that drives transcription of genes encoding the mCherry red fluorescent protein and subsequently sesRNA and efRNA encoding smFlag and tTA2. This single READR vector directly couples RNA detection to effector gene expression; its efficiency and specificity are assessed by co-localization of mCherry, smFlag, and target mRNA or protein.
[0448] The binary system includes an additional reporter vector containing a TRE promoter that drives mNeongreen (mNeon) or other effector proteins ( Figure 4 b). Binary vectors provide amplification of effector gene expression and combinatorial flexibility to express different effector genes in different cell types by pairing READR and reporter vectors.
[0449] In vitro targeting of Fezf2 or Ctip2
[0450] A panel of READR vectors targeting mRNAs that define the major glutamatergic projection neuron (PN) types of the mouse cerebral cortex were first tested and screened in 293T cells by co-expressing a single sesRNA targeting a neuronal RNA sequence (in this case, Ctip2 and Fezf2 sequences). Fig. 9 a. Fig. 9 b. Fig. 9 d). The zinc finger transcription factor Fezf2 labels the vast majority of layer 5b (L5b) and L6 cortical projection neurons (CFPNs) that constitute the cortical output pathway, whereas Ctip2 primarily labels a subset of L5b / L6 CFPN neurons 38,39 In the presence of exogenous Fezf2 or Ctip2 target sequences, all sesRNAs exhibited variable but significant CellREADR efficiencies in 293T cells ( Fig. 9 e- Fig. 9 f).
[0451] In vivo targeting of Fezf2 or Ctip2
[0452] AAV vectors were used to deliver these sesRNAs into the mouse cortex by local injection into the somatosensory cortex (S1) or motor cortex (M1). When delivered with the binary vector, Fezf2sesRNA1 showed 86.4% specificity, and Ctip2sesRNA3 and 8 achieved over 90% specificity as determined by Ctip2 antibody staining. Fig. 9 j- Fig. 9 k).
[0453] Ctip2sesRNA3 was the focus of the following experiments. When the primary somatosensory mouse cortex (S1 cortex) was transfected with a single READRAAV Ctip2 / 3 During infection, FLAG immunofluorescence is concentrated in the deep layers ( Figure 4 c); Co-localization of CTIP2 and FLAG immunolabeled cells ( Figure 4 c, Figure 4 d) showed a specificity of 94.1% ( Figure 4 e) Using binary READR Ctip2 / 3 / Reporter mNeon In the S1 cortex co-infected with AAV reporter gene mNeon AAV, mCherry expression from the READR vector labeled cells across cortical layers, while mNeon expression from the reporter gene vector specifically labeled L5b and some L6 neurons ( Figure 4 f); CTIP2 immunofluorescence showed a specificity of 90.4% ( Figure 4 g) READR calculated as the ratio of GFP cells in mCherry and Ctip2 double positive cells Ctip2 / 3 The efficiency reaches 84.2% ( Figure 4 h).
[0454] ADAR2 overexpression
[0455] To test whether overexpression of ADAR2 from the READR vector could enhance CellREADR functionality, the mCherry module in the READR vector was replaced with ADAR2 cDNA. Ctip2 / 3 / Reporter mRuby3 or binary READ Fezf2 / Reporter mRuby3 sesRNA expression of Fezf2 and Ctip2 in the cortex of co-infected mice ( Fig.10 a- Fig.10 c). It was found that ADAR2 overexpression did not significantly enhance specificity or efficiency compared with binary vectors that rely on endogenous ADARs ( Fig.10 c- Fig.10 i).
[0456] Example 16 - RNA expression levels and CellREADR
[0457] In addition to Ctip2 and Fezf2 mRNAs that mark CFPNs (cortical projection neurons that send their axons to extracortical areas including the thalamus and spinal cord), sesRNAs targeting several other mRNAs expressed at a range of levels were constructed in the binary vector. 40 ( Fig.11 ), including PlxnD1 (intracerebro-telencephalic projection neurons (IT PNs) in L2 / 3 and L5a), Satb2 (IT PNs across upper and lower layers), Rorb (L4 pyramidal neurons), and vGAT (pan-γ-aminobutyric acid neurons). Several sesRNAs with specificity of 75% or higher were identified ( Fig.12 ). These results demonstrate that CellREADR is a robust approach and that targeting of specific cell types can be achieved by testing multiple sesRNAs per target.
[0458] Example 17 - Long-term effects of CellREADR
[0459] To evaluate the long-term effects of CellREADR sesRNA in vivo, we incubated READR in the mouse cortex. Ctip2 / 3 Quantitative RT-PCR assays for the expression of nine genes involved in glial activation and immunogenicity showed that READR Ctip2 / 3 There were no significant changes in the infected tissue ( Fig.13 ).
[0460] Example 18. Recording and controlling neuronal types using CellREADR
[0461] CellREADR efficacy was used to record and control neuronal function in mice. As a benchmark, CellREADR was compared to a cell type targeting approach based on transcriptional enhancers. The mscRE4 enhancer was identified to be effective in L5 pyramidal tract (PT) neurons, a subset of CFPN18. Therefore, the efficacy of the mscRE4 enhancer (i.e., PT enhancer) was compared to that of Ctip2 sesRNA3 ( Figure 4 i- Figure 4 p).
[0462] Co-infection of the PT enhancer-tTa2 / Reporter in the mouse forelimb sensory cortex GCaMP6sor READR Cti p 2 / 3 / Reporter GCaMP6s Mechanical stimulation of the forepaw in AAV-expressing mice activates the PT enhancer and READR Ctip2 / 3 Infected mice induced a reliable and time-locked increase in GCaMP6s signaling in the forelimb sensory cortex, as measured by fiber photometry ( Figure 4 i- Figure 4 l). This result indicates that the effector gene expression levels obtained by CellREADR are sufficient to monitor cellular physiology in living animals.
[0463] Co-infection of the PT enhancer-tTA2 / Reporter in the caudal forelimb motor area (CFA) ChRger2-eYFP or READR Cti p 2 / 3 / Reporter ChR g er2-eYFP In mice expressing AAV, photostimulation of the CFA induced reliable and time-locked forelimb movements, compared with mice expressing the PT enhancer, READR Ctip2 / 3 The movement seems stronger in Figure 4 m- Figure 4 p, Extended Data Video. 1). This result suggests that the levels of effector gene expression achieved through CellREADR are sufficient to control cellular function in behaving animals. Anatomical analysis of eYFP expression confirmed that READR Ctip2 / 3 Labeling of L5 PT neurons was revealed by axonal projections to subcortical targets including the striatum, thalamus, pons, and medulla ( Fig.14 ).
[0464] Example 19. CellREADR Targeting of Neuronal Types Across Mammalian Species
[0465] A series of experiments were performed in rat and human brains to demonstrate the universality of CellREADR across mammalian species. By targeting GABAergic neurons in rats using a binary AAV vector targeting vGAT mRNA, a pan-GABAergic transcript, CellREADR Fig.15 b) READR vGAT (hSyn-mCherry-sesRNA vGAT -smFlag-tTA2) and Reporter mNeon (TRE3g-mNeon) AAV to rat S1 barrel cortex ( Fig.15 a) and hippocampus ( Fig.15 d- Fig.15 The co-injection in c) specifically labeled the cortex ( Fig.15 c) and hippocampus ( Fig.15 d- Fig.15 c) GABAergic interneurons in the mitochondria. The expression of vGAT mRNA (magenta dye) and READR vGAT The specificity of co-labeling assays with GFP was 91.7% for the cortex and 93.8% for the hippocampus ( Fig.15 f- Fig.15 g). Tle4 is a conserved transcription factor that marks L6 corticothalamic (CT) pyramidal cells in rodents. Tle4 AAV-delivered sesRNA targeting exon 15 of Tle4 mRNA ( Fig.15 h) Labeled deep layer neurons, 62.5% of which were co-labeled with TLE4 antibody ( Fig.15 i- Fig.15 k).
[0466] Example 20. Neocortical organotypic culture platform
[0467] An organotypic culture platform was established to study CellREADR in human neocortical samples collected from epilepsy surgery 41 ( Fig.16 a). Infection of these samples with a GFP construct driven by the hSyn promoter (AAVrg-hSyn-eGFP) revealed dense viral labeling across multiple layers, with multiple observed morphologies and a predominance of pyramidal neurons characterized by prominent apical dendrites ( Fig.16 b, Fig.16 c). Two small RNA molecules targeting FOXP2 mRNA (forkhead box protein P2) were developed ( Figure 5 a, Figure 5 b), FOXP2 is an evolutionarily conserved gene expressed in cortical and striatal projection neurons and associated with the development of human language skills 42 In situ hybridization and immunostaining showed that FoxP2 expression was restricted to L6 CT neurons in mice 39 Differently, human FOXP2 is expressed across cortical layers ( Fig.16 d) In the binary READR FOXP2 / Reporter mNeon AAVs (hSyn-ClipF–sesRNA FOXP2 Five days after application of smV5-tTA2 and TRE3g-mNeon) to human neocortical slices, mNeon-labeled cell bodies were observed in the upper and deeper layers ( Figure 5 c, extended data, Fig.16 e) FOXP2 immunostaining reveals binary READR FOXP2 The specificity is nearly 80% ( Figure 5 d, Figure 5 e). The labeled neurons also exhibited electrophysiology consistent with glutamatergic pyramidal neurons ( Figure 5 f) and morphology ( Figure 5 g) Characteristics 43 Using two single READR FOXP2 vectors, each with a different sesRNA, and observed a specificity of over 97% for targeting FOXP2 neurons ( Fig.16 f- Fig.16 i).
[0468] Example 21. Targeting of human neocortical GABAergic cells
[0469] Targeting human neocortical GABAergic cells using sesRNA against VGAT ( Figure 5 h) Using binary READR VGAT / Reporter mNeon , cell labeling was observed across neocortical layers ( Figure 5 i), where labeled cells exhibit distinct morphological features of interneurons, including multipolar and smooth dendrites ( Figure 5 j) and the surprisingly dense vertically oriented axons ( Figure 5 i, Figure 5 k). In situ hybridization of VGAT mRNA showed a specificity of 76.5% ( Figure 5 l, Figure 5 m), which may be an underestimate because in situ hybridization may have reduced sensitivity in cultured tissues. In support of this possibility, very few labeled cells were observed to have pyramidal morphology ( Figure 5 i- Figure 5 l). Seven days after virus application, READR VGAT / Reporter mNeon Targeted patch clamp recordings of labeled interneurons revealed various intrinsic properties, including adaptive, rapid, and delayed onset firing ( Figure 5 n). Physiological characteristics of patch cells ( Figure 5 n) and partially reconstructed morphology ( Figure 5 o) Consistent with mammalian neocortical interneurons 44 Together, these results demonstrate the cross-species universality and utility of CellREADR.
[0470] Example 22. Targeted Neuron Types and Pathological Neuron Populations for Treatment of Epilepsy
[0471] Disease and clinical background
[0472] Epilepsy affects approximately 1% of the population and in developed countries, despite optimal use of anti-epileptic drugs 1 , up to 30% of patients continue to experience seizures. The most effective treatment for focal epilepsy is surgery, but this approach is only available to a very small number of patients because the removal of brain tissue has unacceptable consequences. The identification of novel therapeutic targets and the development of new treatment strategies are urgently needed. Gene therapy can modulate neuronal excitability in refractory epileptic foci while preserving function 1 However, the lack of sufficient cell type and disease state specificity is currently a major obstacle to effective gene therapy. 2 .
[0473] Focal epilepsy is produced by an imbalance of excitation and inhibition characterized by hypersynchronous neural activity in pathological brain networks1 1 Brain circuits include multiple excitatory and inhibitory cell types, each of which makes unique contributions to information processing and excitation-inhibition balance. 3,4 Neural activity in some cell types promotes epileptic seizures, while others suppress them 2 Therefore, it is crucial to achieve cell type-targeted modulation of neural activity at appropriate stages of the epileptic seizure process, such as seizure initiation, maintenance, etc. 1,2 Approaches that inhibit pathophysiological ensembles—those actually involved in seizure activity—may be particularly effective. CellREADR technology can use RNA sensors to achieve cell-type and disease-state specific modulation of brain circuit activity through the expression of druggable modulatory receptors (e.g., GPCRs) and ion channels, and therefore represents a promising approach to control and treat focal epilepsy.
[0474] Targeting GABAergic inhibitory neuron types
[0475] GABAergic interneurons mediate inhibitory control of brain circuits involving distinct neuronal types 4 . Although the vesicular GABA transporter (vGAT) is expressed in all GABA neurons, parvalbumin (PV), somatostatin (SST), calretinin (CR), and VIP mark several major subpopulations / types. The role of these interneuron types in epilepsy etiology remains incompletely understood. PV neurons have subtle effects and promote or inhibit seizures at different stages of epilepsy. CellREADR technology helps target mouse, rat, human neocortex 9 (see Table A) and more recently the macaque neocortex ( Fig.17) GABA interneurons in the PV and SST neurons of humans. Fig.18 ) was used for all human ex vivo cortical tissue removed from the temporal or frontal lobes of epileptic patients.
[0476] Table A_
[0477]
[0478]
[0479] Effectors and expected outcomes of GABA inhibitory neurons
[0480] A chemogenetic approach to suppress epileptic seizure activity by activating SST neuron-mediated inhibition using two types of ligand-gated mechanisms 1 Chemical genetics relies on the modification of endogenous receptors or the generation of modified chimeric receptors that respond to exogenous ligands.
[0481] First, excitatory DREADD (designer receptor specifically activated by a designer drug; hM3Dq excitatory receptor) 10 FDA-approved drugs clozapine-n-oxide or olanzapine can specifically activate DREADDs 11 The dosage of the medication may be adjusted to suppress seizures without causing side effects.
[0482] Second, excitatory PSAM (pharmacologically selective actuator module / pharmacologically selective effector molecule) 12 New PSAMs have been developed that are sensitive to varenicline, a drug approved for smoking cessation 13 .
[0483] An advantage of the chemogenetic approach is that the gene therapy is inert until administered, so it is possible to "turn the gene therapy off and on." In addition, the magnitude of the effect depends on the dose of the ligand. Therefore, the drug dose can be adjusted to avoid any potential side effects but still optimize efficacy. The cell-specific chemogenetic strategy based on CellREADR can be extended to other GABAergic and glutamatergic neuron types for the treatment of epileptic seizures and other neurological diseases.
[0484] Targeting Pathophysiological Neuronal Populations (PNE)
[0485] A particularly effective strategy for managing or treating epilepsy is to inhibit or control neurons and neuronal clusters that produce excessive activity, known as pathophysiological neuronal clusters (PNEs). CellREADR is useful for this purpose. Excessive and synchronized neuronal activity leads to a rapid upregulation of the immediate early gene (IEG) c-fos14,15 , which primarily marks the glutamatergic excitatory neurons that make up the PNE. c-fos RNA sensors have been constructed to target and modulate the PNE. A panel of 4 sensors has been tested, many of which have shown promising results in neuronal cultures. In addition to c-fos, there is one other IEG that can also be used to target the PNE 15 An extended list of .
[0486] Effector gene
[0487] Three types of effector genes are coupled to the c-fos sensor.
[0488] The first is the voltage-gated potassium channel Kv1.1 (KCNA1) 16 , which can reduce spikes in PNE neurons. This will inhibit the firing of neurons within the PNE.
[0489] The second is an inhibitory DREADD (hM4D(Gi) inhibitory receptor) 10 , which can be activated by the oral drug olanzapine.
[0490] The third is the invertebrate glutamate receptor (eGluCL), which is permeable to chloride.17,18 The eGluCL binds glutamate released during seizure activity and can also be activated by the FDA-approved drug ivermectin; the resulting chloride current inhibits neuronal activity. Ivermectin can also be used to reduce neuronal activity long-term or as a rescue drug.
[0491] A unique advantage of this approach to targeting PNE is that it is a "closed loop" control. Under normal physiological conditions, c-fos is not significantly expressed, so there is no effector expression. During epilepsy, upregulation of c-fos RNA will trigger effector translation to inhibit PNE activity. This strategy can be extended to other IEGs for the treatment of epileptic seizures and other neurological diseases.
[0492] deliver
[0493] All of the above CellREADR vectors were delivered to the epileptic focus using AAV vectors (serotype 2 / 9 and php.eb). In conventional epilepsy surgery, rather than removing brain tissue in the epileptic focus, therapeutic CellREADR AAV is injected into the lesion, thereby preserving the brain tissue.
[0494] Expected outcomes and improvements to current treatments
[0495] With respect to the SST sensor and CellREADR vector, oral administration of olanzapine (for excitatory DREADDs) or varenicline (for excitatory PSEMs) can activate SST interneurons to suppress focal epilepsy. With the c-fos sensor and CellREADR vector, oral administration of olanzapine (for inhibitory DREADDs) or varenicline (for inhibitory PSEMs) can reduce the firing of glutamatergic neurons in PNE to suppress epilepsy. In summary, these RNA therapeutics specific for designated cell types and designated disease states will transform the management and treatment of epilepsy.
[0496] References:
[0497] 1.Walker MC,Kullmann DM.(2020) Optogenetic and chemogenetic therapies for epilepsy. Neuropharmacology.2020 May 15;168:107751.doi:10.1016 / j.neuropharm.2019.107751.Epub 2019 Sep 5.PMID:31494141Review.
[0498] 2.Magloire V, Mercier MS, Kullmann DM, Pavlov I. (2019) GABAergic Interneurons in Seizures: Investigating Causality With Optogenetics. Neuroscientist.2019Aug;25(4):344-358.doi:10.1177 / 1073858418805002.Epub 2018Oct15.PMID:30317911Free PMC article.Review.
[0499] 3. Huang ZJ. (2014) Toward a genetic dissection of cortical circuits in the mouse. Neuron.2014Sep 17;83(6):1284-302.doi:10.1016 / j.neuron.2014.08.041.PMID:25233312Free PMC article.Review.
[0500] 4. Huang ZJ, Paul A. (2019) The diversity of GABAergic neurons and neural communication elements.Nat Rev Neurosci.2019Sep;20(9):563-572.doi:10.1038 / s41583-019-0195-4.Epub 2019 Jun 20.PMID:31222186 Free PMC article.Review.
[0501] 5.Taniguchi H,He M,Wu P,Kim S,Paik R,Sugino K,Kvitsiani D,Fu Y,Lu J,Lin Y,Miyoshi G,Shima Y,Fishell G,Nelson SB,Huang ZJ.(2011). A resource of Cre Driver lines for genetics targeting of GABAergic neurons in cerebral cortex. Neuron.2011Sep 22;71(6):995-1013.doi:10.1016 / j.neuron.2011.07.026.Epub2011Sep 21.PMID:21943598
[0502] 6.He M,Tucciarone J,Lee S,Nigro MJ,Kim Y,Levine JM,Kelly SM,KrugikovI,Wu P,Chen Y,Gong L,Hou Y,Osten P,Rudy B,Huang ZJ.(2016). Strategies and Tools for Combinatorial Targeting of GABAergic Neurons in Mouse Cerebral Cortex. Neuron.2016 Sep 21:91(6):1228-1243.doi:10.1016 / j.neuron.2016.08.021.Epub 2016 Sep 8.PMID:27618674
[0503] 7.Vormstein-Schneider D,Lin JD,Pelkey KA,Chittajallu R,Guo B,Arias-Garcia MA,Allaway K,Sakopoulos S,Schneider G,Stevenson O,Vergara J,Sharma J,Zhang Q,Franken TP,Smith J,Ibrahim LA,Estro, KF,Huzzi E,Burbridge T,Xu Q,Guo L,Vogel I,Sanchez V,Saldi GA,Gorissen BL,Yuan X,ZaghloulKA,Devinsky O,Sabatini BL,Batista-Brito R,Reynolds J,Feng G,Fu Z,McBain CJ,Fishell G J,Dimidschstein(2020). Viral manipulation of functionally distinct interneurons in mice, non-human primates and humans. Nat Neurosci.2020 Dec;23(12):1629-1636.doi:10.1038 / s41593-020-0692-9.Epub 2020 Aug 17.PMID:32807948
[0504] 8.Mich JK,Graybuck LT,Hess EE,Mahoney JT,Kojima Y,Ding Y,SomasundaramS,Miller JA,Kalmbach BE,Radaelli C,Gore BB,Weed N,Omstead V,Bishaw Y,Shapovalova NV,Martinez RA,Fong,Ong,Mhong S,Mr. P,Loftus L,Bertagnolli D,Goldy J,Casper T,Dee N,Opitz-Araya X,Cetin A,Smith KA,Gwinn RP,Cobbs C,Ko AL,Ojemann JG,Keene CD,Silbergeld DL,Sunkin SM,Gradinaru V,HorwitzGD,Tasic,Ht,Lesc,B. JT,Levi BP.(2021) Functional enhancer elements drive subclass-selective expression from mouse to primate neocortex. CellRep.2021 Mar30;34(13):108754.doi:10.1016 / j.celrep.2021.108754.PMID:33789096
[0505] 9.Qian Y,Li J,Zhao S,Matthews EA,Adoff M,Zhong W,An X,Yeo M,Park C,Yang X,Wang BS,Southwell DG,Huang ZJ.(2022) Programmable RNA sensing for cells monitoring and manipulation. Nature.2022 Oct 5.doi:10.1038 / s41586-022-05280-1.Online ahead of print.PMID:36198803
[0506] 10.Armbruster,B.N.,Li,X.,Pausch,M.H.,Herlitze,S.,Roth,B.L.,2007.Evolving the lock to fit the key to create a family of G protein-coupledreceptors potently activated by an inert ligand.Proc.Natl.Acad.Sci.104,5163-5168. https: / / doi.org / 10.1073 / pnas.0700293104 .
[0507] 11.Weston,M.,Kaserer,T.,Wu,A.,Mouravlev,A.,Carpenter,J.C.,Snowball,A.,Knauss,S.,von Schimmelmann,M.,During,M.J.,Lignani,G.,Schorge,S.,Young,D.,Kullmann,D.M.,Lieb,A.,2019.Olanzapine:a potent agonist at the hM4D(Gi)DREADDamenable to clinical translation of chemogenetics.Sci Adv 5 eaaw1567. https: / / doi.org / 10.1126 / sciadv.aaw1567 .
[0508] 12.Magnus,C.J.,Lee,P.H.,Atasoy,D.,Su,H.H.,Looger,L.L.,Sternson,S.M.,2011.Chemical and genetic engineering of selective ion channel-ligandinteractions.Science 333,1292-1296. https: / / doi.org / 10.1126 / science.1206606 .
[0509] 13.Magnus,C.J.,Lee,P.H.,Bonaventura,J.,Zemla,R.,Gomez,J.L.,Ramirez,M.H.,Hu,X.,Galvan,A.,Basu,J.,Michaelides,M.,Sternson,S.M.,2019.Ultrapotentchemoge-netics for research and potential clinical applications.Science364. https: / / doi.org / 10.1126 / science.aav5282 .
[0510] 14.Labiner DM,Butler LS,Cao Z,Hosford DA,Shin C,McNamara JO.(1993) Induction of c-fos mRNA by kindled seizures: complex relationship with neuronal burst firing. J Neurosci.1993Feb;13(2):744-51.doi:10.1523 / JNEUROSCI.13-02-00744.1993.
[0511] 15.Tyssowski KM,Gray JM. The neuronal stimulation-transcription coupling map. (2019)Curr Opin Neurobiol.2019Dec;59:87-94.doi:10.1016 / j.conb.2019.05.001.Epub 2019Jun 1.PMID:31163285Free PMC article.Review.
[0512] 16. Snowball A, Chabrol E, Wykes RC, Shekh-Ahmad T, Cornford JH, Lieb A, Hughes MP, Massaro G, Rahim AA, Hashemi KS, Kullmann DM, Walker MC, Schorge S. (2019) Epilepsy Gene Therapy Using an Engineered PotassiumChannel. JNeurosci.2019 Apr 17;39(16):3159-3169.doi:10.1523 / JNEUROSCI.1143-18.2019.Epub2019Feb 12.PMID:30755487
[0513] 17. Frazier, SJ, Cohen, BN, Lester, HA, 2013. An engineered glutamate-gated chloride (GluCl) channel for sensitive, consistent neuronal silencing by ivermectin. J. Biol. Chem. 288, 21029-21042. https: / / doi.org / 10.1074 / jbc.M112.423921 .
[0514] 18. Lieb, A., Qiu, Y., Dixon, CL, Heller, JP, Walker, MC, Schorge, S., Kullmann, DM, 2018. Biochemical autoregulatory gene therapy for focal epilepsy. Nat. Med. 24, 1324-1329. https: / / doi.org / 10.1038 / s41591-018-0103-x
[0515] Embodiment 23
[0516] CellREADR targeting of neuronal types in nonhuman primates.
[0517] We developed RNA sensors for macaque Foxp2 and vGAT, which label glutamatergic pyramidal neurons (a subpopulation) and GABAergic interneurons, respectively. We then generated binary AAV6 vectors that expressed EGFP dependent on RNA sensing. Using these AAV CellREADR vectors targeting macaque FOXP2 and vGAT mRNAs ( Fig.17 ), we will use the binary READR FOXP2 / Reporter mNeon and READRFOXP2 / Reporter mNeon AAV was injected into the V1 region of the macaque cortex. FOXP2 Fluorescence microscopy of infected cortex shows mNeons in subgranular pyramidal neurons, their apical dendrites, and efferent axons in the white matter, indicating glutamatergic pyramidal neurons. From READR vGAT Infected cortical mNeons were localized to morphologically diverse putative inhibitory neurons throughout the cortical laminae. Thus, CellREADR is effective in vivo in non-human primates.
[0518] Example 24. Cell-specific treatment of chronic pain
[0519] Disease and clinical background
[0520] The global prevalence of chronic pain is estimated to be 20-25%. Few chronic pain patients achieve complete relief from currently available medications, and more than half report inadequate relief. 1 Although conscious perception of pain requires an intact central nervous system (CNS), and CNS changes are evident in chronic pain states, ongoing peripheral nociceptive input plays an important role in the maintenance of chronic pain. 1 Nociceptors in the skin, muscles, joints, and internal organs respond selectively to noxious or potentially tissue-damaging stimuli and mediate peripheral pain input to the CNS. Despite detailed characterization of the mechanisms underlying nociceptor excitability and identification of several ion channels, receptors, and second messenger signaling molecules as convergent points, effective pain therapeutic interventions without deleterious side effects remain elusive. 1 The anatomical, physiological, and functional heterogeneity of nociceptive afferents, arising from their differential gene expression, has led to difficulties in the identification of new therapeutic agents and several notable failures in the translation of preclinical data into effective clinical interventions. 1 .
[0521] In the signal transduction mechanism within nociceptors following sensory stimulation, the firing of action potentials is the final output leading to afferent signals to the CNS. Nociceptive action potentials are primarily driven by voltage-gated sodium channels NaV1.7 and NaV1.8. Human genetic studies have highlighted the key role of NaV1.7 in the nociceptive process: gain-of-function mutations are associated with pain syndromes such as erythromelalgia and paroxysmal extreme pain disorder, whereas loss-of-function mutations are associated with congenital pain insensitivity. 2Therefore, nociceptors represent a key therapeutic target for chronic pain. A previous CRISPR-dCas9-based approach to downregulating Nav1.7 achieved long-term pain relief without altering motor function in mice. 3 The CellREADR technology enables modulation of sodium channels and other signaling mechanisms within specific types of nociceptors to achieve therapeutic effects while reducing side effects.
[0522] Targeting nociceptor and effector expression in dorsal root ganglia
[0523] NaV1.8 and TRPV1 are specifically expressed in nociceptors. RNA sensors for TRPV1 and NaV1.8 were used to establish specific contact with nociceptors. CellREADR-based cell type-specific small hairpin RNA (shRNA) was used in a knockdown approach to downregulate NaV1.7 and NaV1.8 mRNA in nociceptors. Binary expression vectors ( Fig. 20 ); tTA then activates shRNA transcription of NaV1.7 or NaV1.8 RNA. This binary CellREADR vector is packaged into AAV9.
[0524] Delivered via intrathecal injection into the cerebrospinal fluid via lumbar puncture
[0525] These AAV vectors were delivered intrathecally into the spinal fluid to infect neurons in the dorsal root ganglia. CellREADR was specifically expressed in nociceptors defined by the RNA sensor.
[0526] Expected outcomes and improvements to current treatments
[0527] CellREADR-mediated modulation of NaV1.7 and NaV1.8 and other signaling mechanisms within specific types of nociceptors may be more effective in achieving therapeutic effects with fewer side effects.
[0528] Targeting astrocytes and satellite glial cells
[0529] Astrocytes are essential for maintaining CNS homeostasis. Astrocyte "gliopathy" can lead to a variety of neurological disorders, including chronic pain. 4 Astrocytes can modulate nociceptive synaptic transmission through neuron-glial and glial-glial interactions, and spinal and supraspinal astrocytes are involved in the regulation of pain signaling and the maintenance of neuropathic pain. 4 In addition, astrocyte-mediated neuroinflammation is a key mechanism behind the persistence of chronic pain. 4Targeting specific pathways that lead to astrocyte pathology represents a new approach to developing chronic pain therapies.
[0530] Multiple cell types interact with nociceptive neurons and contribute to the pathogenesis of pain through different signaling mechanisms, including satellite glia, T cells, oligodendrocytes, and microglia 5 CellREADR is used to modulate neuron-glia interactions by targeting specific glial cell types for chronic pain treatment.
[0531] Satellite glial cells are located in the dorsal root ganglia of the peripheral nervous system and express markers such as Kir4.1 and FABP7 6 . RNA sensors for FABP7 target satellite glial cells. Potassium channel Kir4.1 is downregulated under pathological pain conditions 6 The function of Kir4.1 was restored by expressing potassium channels into FABP7+ satellite glial cells.
[0532] Under pathological conditions, vGluT1 is downregulated in the spinal cord, leading to glutamate receptor overactivation and chronic pain 4 RNA sensors for Aldh1L1 (an astrocyte-specific marker) targeting astrocytes and Fabp7 targeting satellite glial cells. The vesicular glutamate transporter vGluT1 is expressed in Aldhl1+ astrocytes. Notably, the intrathecal route can target not only sensory neurons in the DRG but also satellite glial cells in the DRG and astrocytes of the spinal cord.
[0533] CellREADR is a useful method to specifically label satellite glial cells in DRG and astrocytes in the spinal cord after intrathecal delivery. In addition, the CellREADR-based approach can restore the function of satellite glial cells and astrocytes in pathological states, thereby providing long-term relief and reversal of chronic pain.
[0534] References
[0535] 1. Gold MS, Gebhart GF. (2010) Nociceptor sensitization in pain pathogenesis. Nat Med.2010Nov;16(11):1248-57.doi:10.1038 / nm.2235.Epub 2010Oct14.PMID:20948530
[0536] 2.Waxman,S.G.Channel,neuronal and clinical function in sodiumchannelopathies:from genotype to phenotype.Nat.Neurosci.10,405-409(2007).
[0537] 3.Moreno AM,Alemán F,Catroli GF,Hunt M,Hu M,Dailamy A,Pla A,WollerSA,Palmer N,Parekh U,McDonald D,Roberts AJ,Goodwill V,Dryden I,Hevner RF,Delay L, Dos Santos G,Yaksh TL,Mali P.(2021) Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice. Sci Transl Med.2021 Mar 10;13(584):eaay9056.doi:10.1126 / scitranslmed.aay9056.PMID:33692134
[0538] 4.Ji RR,Donnelly CR,Nedergaard M.(2019) Astrocytes in chronic pain and itch. Nat Rev Neurosci.2019 Nov;20(11):667-685.doi:10.1038 / s41583-019-0218-1.Epub 2019 Sep 19.PMID:31537912
[0539] 5.Ji RR,Chamessian A,Zhang YQ.(2016) Pain regulation by non-neuronal cells and inflammation. Science.2016 Nov 4;354(6312):572-577.doi:10.1126 / science.aaf8924.PMID:27811267
[0540] 6.Hanani M,Spray DC.(2020) Emerging importance of satellite glia in nervous system function and dysfunction.Nat Rev Neurosci.2020 Sep;21(9):485-498.doi:10.1038 / s41583-020-0333-z.Epub 2020 Jul 22.PMID:32699292.
[0541] Example 24. Cell-specific intervention in Alzheimer's disease
[0542] Disease and clinical background
[0543] As observed in Alzheimer’s disease (AD), the most prevalent form of neurodegenerative disease, neuroinflammation is a central mechanism involved in neurodegeneration1,2. Apolipoprotein E4 (ApoE4) is the strongest genetic risk factor for AD and directly influences disease onset and progression by interacting with the main pathological features of AD, including amyloid β plaques, neurofibrillary tau tangles, and neuroinflammation1,2. In the CNS under basal conditions, astrocytes produce the most apoE; in the setting of brain injury or neurodegeneration, APOE expression is strongly upregulated in microglia.
[0544] Microglia and astrocytes are two major immune cells in the brain that are in a state of immunological vigilance, providing immune defense as well as housekeeping functions that promote neuronal health. In disease conditions, these immune cells become increasingly dysfunctional in regulating metabolic and immunoregulatory pathways, thereby promoting chronic inflammation-induced neurodegeneration; an important component of this pathological process is the increase in microglial-mediated synaptic phagocytosis1,2.
[0545] Compared with microglial-secreted apoE, astrocyte-derived apoE particles are significantly larger and therefore contain more lipid. Astrocyte-secreted apoE4, alone or in combination with other molecules such as C1q, can act as an opsonin for specific microglial receptors to activate microglial responses. In the P301S Tau mouse model of AD, ablation of astrocytic APOE4 significantly reduced Tau-mediated neurodegeneration, as well as phosphorylated Tau (pTau) pathology in neurons, oligodendrocytes, astrocytes, and microglia, and disease-associated gene signatures.3 Ablation of astrocytic APOE4 further reduced tau-induced synaptic loss and microglial phagocytosis of synaptic elements, suggesting that astrocytic apoE plays a key role in synaptic degeneration.3
[0546] Target cell type
[0547] Astrocytes and microglia in the brain, especially in the cerebral cortex. Marker genes / RNAs include
[0548] -Astrocytes: aldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 1 (EAAT1)
[0549] -Microglia: C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119), ionized calcium binding adaptor molecule 1 (IBA-1)
[0550] Target Gene
[0551] shRNA directed against ApoE4 RNA to achieve downregulation in astrocytes and / or microglia in the brain.
[0552] Figure 21 Constructs are described in which the first module of the readrRNA is driven by the hSyn promoter, which is followed by a spacer, a SES RNA specific for one of the above-mentioned target RNAs, and a tTA2 transcriptional activator that is translated after ADAR editing and binds to a TRE, which is located upstream of the first module of the readrRNA and drives the expression of a small hairpin RNA complementary to the ApoE4 RNA.
[0553] deliver
[0554] The AAV vector was used for the first test in the P300 tau mouse model and recapitulated the results of Wang and Holtzman Neuron 2021, demonstrating a reduction in tau-mediated neurodegeneration and synaptic phagocytosis.
[0555] In AD patients, as the disease progresses from preclinical to early and late stages, amyloid deposition begins in the temporal basal and frontal medial regions and successively affects the rest of the associated neocortex, primary sensorimotor areas, and medial temporal lobe, and finally the striatum.4,5 AAV vectors are injected into the temporal basal and frontal medial regions of early-stage patients to reduce the production of ApoE4 by astrocytes and microglia in these regions.
[0556] Expected Results
[0557] Reduction of ApoE4 production by astrocytes and microglia in the temporal basal and medial frontal regions attenuated neuroinflammatory responses and prevented tau-mediated neurodegeneration and synaptic phagocytosis by microglia. Together, these treatments attenuated or prevented the progression of AD.
[0558] References
[0559] 1.Parhizkar S,Holtzman DM.2022,APOE mediated neuroinflammation andneurodegeneration in Alzheimer's disease.Semin Immunol.2022Feb 26:101594.doi:10.1016 / j.smim.2022.101594.Online ahead of print.PMID:35232622
[0560] 2.Chen Y,Strickland MR,Soranno A,Holtzman DM.Apolipoprotein E:Structural Insights and Links to Alzheimer DiseasePathogenesis.Neuron.2021Jan 20;109(2):205-221.doi:10.1016 / j.neuron.2020.10.008.Epub 2020Nov 10.PMID:33176118
[0561] 3.Wang C,Xiong M,Gratuze M,Bao X,Shi Y,Andhey PS,Manis M,Schroeder C,Yin Z,Madore C,Butovsky O,Artyomov M,Ulrich JD,Holtzman DM.Selective removalof astrocytic APOE4strongly protects against tau-mediated neurodegenerationand decreases synaptic phagocytosis by microglia.Neuron.2021May19;109(10):1657-1674.e7.doi:10.1016 / j.neuron.2021.03.024.Epub2021Apr 7.PMID:33831349
[0562] 4.Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ; In vivostaging of regional amyloid deposition. Alzheimer's Disease NeuroimagingInitiative.Neurology.2017Nov14;89(20):2031-2038.doi:10.1212 / WNL.0000000000004643.Epub2017Oct 18.PMID:29046362
[0563] 5. Levin F, Jelistratova I, Betthauser TJ, Okonkwo O, Johnson SC, TeipelSJ, Grothe MJ. In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer's disease. Alzheimers ResTher. 2021Oct 21;13(1):178.doi:10.1186 / s13195-021-00918-0.PMID:34674764
[0564] Table 6. Plasmids encoding (i) a targeted exogenous transcript for proof-of-principle experiments, (ii) a readrRNA, or (iii) a gene responsive to (but not physically linked to) an encoded effector gene (e.g., a transactivator) are described herein.
[0565]
[0566]
[0567]
[0568]
[0569]
[0570] The UGT1A1 gene as an effector
[0571]
[0572] VEGFA coding sequence as effector
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579]
[0580]
[0581]
[0582]
[0583]
[0584]
[0585]
[0586]
[0587]
[0588]
[0589]
[0590]
[0591]
[0592]
[0593]
[0594]
[0595]
[0596]
[0597]
[0598]
[0599]
[0600]
[0601]
[0602]
[0603]
Claims
1. A modular RNA molecule comprising: (i) a 5' region containing a sensor domain, the sensor domain comprising a contiguous nucleotide stretch complementary to a corresponding contiguous nucleotide stretch of a cellular RNA of a mammalian central nervous system cell, wherein the sensor domain comprises a stop codon capable of being edited by an ADAR; and (ii) a 3' region containing a protein encoding domain, wherein the protein encoding domain is located downstream of and in frame with the sensor domain, in, After the modular RNA is introduced into the cell containing the Adar enzyme, the continuous nucleotide segment of the sensor domain forms an RNA duplex containing the stop codon with the corresponding nucleotide segment of the cellular RNA, wherein the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing the protein to be translated.
2. A modular RNA molecule comprising: i. a 5' region comprising a sensor domain, the sensor domain comprising a contiguous nucleotide stretch complementary to a corresponding contiguous nucleotide stretch of a cellular RNA of a peripheral nervous system cell of a mammal, wherein the sensor domain comprises a stop codon capable of being edited by an ADAR; and ii. a 3' region comprising a protein encoding domain, wherein the protein encoding domain is located downstream of and in frame with the sensor domain, in, After the modular RNA is introduced into the cell containing the Adar enzyme, the continuous nucleotide segment of the sensor domain forms an RNA duplex containing the stop codon with the corresponding nucleotide segment of the cellular RNA, wherein the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing the protein translation.
3. A modular RNA molecule according to claim 1 or claim 2, wherein the contiguous nucleotide segment of the sensor domain is capable of forming an RNA duplex with at least a portion of an mRNA, the portion comprising the corresponding contiguous nucleotide segment.
4. A modular RNA molecule according to claim 1 or claim 2, wherein the protein coding region encodes an effector protein.
5. A modular RNA molecule according to claim 1 or claim 2, wherein the molecule further encodes a self-cleaving 2A peptide located between the sensor domain and the 3' protein encoding domain.
6. The modular RNA molecule according to claim 5, wherein the self-cleaving 2A peptide is selected from one or more of the group consisting of a T2A peptide, a P2A peptide, an E2A peptide and a F2A peptide.
7. A modular RNA molecule according to claim 1 or claim 2, wherein the 3' protein coding domain comprises a protein selected from the group of a marker, a transcriptional activator and a transcriptional repressor.
8. A composition comprising: i) a first nucleic acid containing a modular RNA molecule, the modular RNA molecule comprising: (i) a sensor domain comprising a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a cellular RNA of a mammalian cell of the central nervous system, wherein the sensor domain comprises a stop codon editable by an ADAR; and (ii) a first protein coding region encoding an effector protein, wherein the first protein coding region is located downstream of and in frame with the sensor domain, and ii) a second nucleic acid comprising a second protein coding domain.
9. A composition comprising: i) a first nucleic acid comprising a modular RNA molecule comprising: (i) a sensor domain comprising a contiguous nucleotide stretch that is complementary to a corresponding contiguous nucleotide stretch of a cellular RNA of a mammalian cell of the peripheral nervous system, wherein the sensor domain comprises a stop codon editable by an ADAR; and (ii) a first protein coding region encoding an effector protein, wherein the first protein coding region is located downstream of and in frame with the sensor domain, and ii) a second nucleic acid comprising a second protein coding domain.
10. A composition according to claim 8 or claim 9, wherein the first and second nucleic acids comprise a single nucleic acid molecule.
11. A composition according to claim 8 or claim 9, wherein the first and second nucleic acids comprise two nucleic acid molecules.
12. A composition according to claim 8 or claim 9, wherein the first and second nucleic acids are covalently linked.
13. A composition according to claim 8 or claim 9, wherein the second protein coding domain is contained within a gene comprising transcriptional control elements, optionally comprising a promoter.
14. The composition according to claim 8 or 9, wherein the effector protein is bound to the gene.
15. A composition according to claim 8 or claim 9, wherein expression of the second protein-coding domain is regulated by the effector protein.
16. A composition according to claim 8 or claim 9, wherein the first protein coding domain encodes a transcriptional activator or a transcriptional repressor.
17. A composition according to claim 8 or claim 9, wherein the first protein coding domain encodes a DNA recombinase.
18. The composition of claim 8, wherein the cells comprise mammalian cortical cells.
19. The composition according to claim 9, wherein said cells comprise mammalian Schwann cells or mammalian satellite cells of said peripheral nervous system.
20. The composition of claim 8, wherein the first protein-coding domain encodes an effector protein comprising a transcriptional activator.
21. The composition according to claim 8 or 20, wherein the contiguous nucleotide stretch of the sensor domain is complementary to a contiguous nucleotide stretch of a selected cellular RNA of cortical cells encoded by the Fezf2 gene.
22. The composition of claim 8, 20 or 21, wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of an inducible promoter.
23. The composition of claim 9, wherein the first protein-coding domain encodes an effector protein comprising a transcriptional activator.
24. The composition according to claim 9 or 23, wherein the contiguous nucleotide stretch of the sensor domain is complementary to a contiguous nucleotide stretch of a selected cellular RNA of a surrounding CNS cell.
25. The composition of claim 9, 23 or 24, wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of an inducible promoter. The composition of claim 8 or claim 9, wherein the first protein coding region encodes an effector protein selected from the group consisting of: o a cell-killing protein selected from the group consisting of thymidine kinase (TK) and cytosine deaminase (CD), o a programmed cell death protein selected from the group consisting of CASP3, CASP9, BCL, GSDME, GSDMD, GZMA and GZMB, ○ A neural activating protein selected from the group consisting of: ChR2 and DREADD-M3Dq, ■ an immune enhancing protein selected from the group consisting of: IFNB, IFNG, TNFA, IL2, IL12, IL15 and CD40L, ■ physiological editing proteins selected from the group consisting of: NaChBac and Kir2.1, f) protein synthesis inhibitory proteins including ricin, ■ a neuroinhibitory protein selected from the group consisting of: DREADD-hM4D, NpHR and GtACR1, ■ Proteins involved in neural cell fate, such as NEUROD, and ■ Proteins involved in cell regeneration, including epidermal growth factor.
26. A nucleic acid delivery vehicle comprising the modular RNA molecule of claim 1 or 2 or the composition of claim 8 or claim 9, and / or a DNA encoding the modular RNA of claim 1 or 2 or the composition of claim 8 or claim 9.
27. The nucleic acid delivery vehicle according to claim 27, which is selected from the group consisting of nanoparticles, liposomes, vectors, exosomes, microbubbles, gene guns, and the Selective Endogenous Cell Delivery Encapsulation (SEND) system.
28. The nucleic acid delivery vehicle according to claim 28, comprising a viral vector.
29. The nucleic acid delivery vehicle according to claim 29, wherein the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus, vesicular stomatitis virus.
30. A modular RNA molecule according to claim 1 or claim 2, wherein the modular RNA molecule is encoded by a DNA vector.
31. The composition according to claim 8 or 9, wherein the modular RNA molecule is encoded by a DNA vector.
32. The delivery vehicle according to claim 27, wherein the modular RNA molecule is encoded by a DNA vector.
33. A pharmaceutical composition comprising the modular RNA molecule of claim 1 or claim 2, the composition of claim 8 or claim 9, or the delivery vehicle of claim 27, and a pharmaceutically acceptable carrier, excipient and / or diluent.
34. A cell comprising the modular RNA molecule of claim 1 or claim 2, the composition of claim 8 or claim 9, or the delivery vehicle of claim 27.
35. A cell according to claim 31, wherein the cell is a mammalian cell.
36. A kit comprising the modular RNA molecule of claim 1 or claim 2, the composition of claim 8 or claim 9, or the delivery vehicle of claim 27, and packaging thereof.
37. A method of introducing a modular RNA according to claim 1 or 2, a nucleic acid composition according to claim 8 or 9 encoding the modular RNA, or a delivery vehicle according to claim 27 comprising the modular RNA or the nucleic acid composition encoding the modular RNA into selected cells of a mammal, the method comprising: contacting the cells of the mammal with the modular RNA molecules, the nucleic acid composition encoding the modular RNA, or the delivery vehicle containing the modular RNA or the nucleic acid composition encoding the modular RNA under conditions that allow the cells of the mammal to contain the modular RNA or the delivery vehicle containing the modular RNA or the nucleic acid composition encoding the modular RNA, Wherein the modular RNA is according to claim 1 or claim 2, the nucleic acid composition is according to claim 8 or claim 9, and the delivery vehicle is according to claim 27.
38. A method of initiating ADAR editing of a stop codon to allow expression of an in-frame downstream encoded protein in a mammalian cell comprising a selected target cellular RNA, the method comprising: introducing into the cell of the mammal a modular RNA molecule comprising (i) a 5' region comprising a sensor domain, the sensor domain comprising a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of the selected cellular RNA, wherein the sensor domain comprises a stop codon editable by an ADAR; and (ii) a 3' region comprising a domain encoding an effector protein, wherein the protein coding region is located downstream of and in frame with the sensor domain, under conditions wherein the modular RNA is contained in the cell, wherein upon introduction of the modular RNA molecule into the mammal, an RNA duplex is formed in the cell between the contiguous nucleotide segment of the sensor domain and the corresponding contiguous nucleotide segment of the cellular RNA, wherein the RNA duplex comprises the ADAR-editable stop codon, and wherein ADAR edits the stop codon contained in the RNA duplex, thereby allowing translation of the protein, and wherein said protein is produced in said mammal.
39. A method of treating a disease or condition in a mammal, the method comprising: Providing a medicament comprising a modular RNA molecule according to claim 1 or claim 2, or a nucleic acid composition according to claim 8, 9, 11 or 12, or a delivery vehicle according to claim 27; and The agent is administered to the mammal in a therapeutically effective amount to allow translation of the 3'-encoded protein or the effector protein in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells can be used to treat the disease or disorder in the mammal.
40. The method according to claim 36, wherein the medicament comprising the composition of claim 8 or claim 9 or the delivery vehicle of claim 23 is administered, and the first protein coding region encoding the effector protein contained in the medicament encodes a transactivator protein that activates expression of the second protein coding region, and wherein expression of the second protein coding region in the selected cells is therapeutically effective in treating the disease or disorder.
41. A method of stimulating L5b / L6 cortical projection neuron signaling in a mouse forelimb sensory cortex in response to mechanical stimulation of the forepaw, the signal being as measured photometrically, the method comprising: administering the composition of claim 8 to the mouse, wherein the sensor domain comprises a contiguous nucleotide segment complementary to a corresponding contiguous nucleotide segment of a cellular RNA encoding Ctip2 or Fezf, wherein the first protein-coding domain encodes an effector protein comprising a transcriptional activator, and wherein the second nucleic acid comprises a gene encoding a reporter protein under the transcriptional control of an inducible promoter, wherein said administering provides for the production of said effector protein and said reporter protein, This allows stimulation of the L5b / L6CFPN signaling in the forelimb sensory cortex of the mouse.
42. A method of stimulating forelimb movement in response to light stimulation of the caudal forelimb area (CFA) of a mouse, the method comprising: administering the composition of claim 8 to the mouse, wherein the sensor domain comprises a contiguous nucleotide segment that is complementary to a corresponding contiguous nucleotide segment of a cellular RNA encoding Ctip2, wherein the first protein-coding domain encodes an effector protein that includes a transcriptional activator, and wherein the second nucleic acid comprises a gene encoding a light-activated reporter protein under the transcriptional control of an inducible promoter, wherein said administration provides for production of said effector protein and said light-activated reporter protein, thereby allowing for light stimulation of said forelimb movement of said mouse.
43. The method of claim 39, wherein a second gene is operably linked to the TRE-3G eukaryotic inducible promoter, the second gene encoding an enhanced yellow fluorescent protein (eYFP), and wherein the administering provides for the production of enhanced yellow fluorescent protein.
44. A pharmaceutical composition comprising the modular RNA molecule of claim 1 or claim 2 and / or the composition of claim 8 or claim 9 and / or the delivery system of claim 27, and a pharmaceutically acceptable carrier, excipient and / or diluent.
45. A cell comprising the modular RNA molecule of claim 1 or claim 2 and / or the composition of claim 8 or claim 9 and / or the delivery system of claim 27.
46. A kit comprising the modular RNA molecule of claim 1 or claim 2 and / or the composition of claim 8 or claim 9 and / or the delivery system of claim 27.
47. A method for identifying GABAergic neurons in a mammalian cortex in vivo, the method comprising: administering the composition of claim 8 to said mammal under conditions that allow the composition of claim 8 to transfect into cells of said S1 barrel cortex and hippocampus and express said protein coding region, wherein said contiguous nucleotide stretch of said sensor domain is complementary to a contiguous nucleotide stretch of a selected cellular vGAT RNA of a cortical cell, and wherein the first protein coding domain encodes an effector protein comprising a transcriptional activator and a second effector protein comprising a first reporter protein, and the second nucleic acid comprises a coding region for the second reporter protein under the transcriptional control of an inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the control of a promoter, and wherein the modular RNA molecule comprises a gene encoding a third reporter protein located upstream of the sensor domain and under the control of the promoter, wherein said protein is produced by said coding region, wherein detection of one or more of said first, second and third reporter proteins allows identification of GABAergic neurons comprising vGAT mRNA in the cortex of said mammal.
48. The method according to claim 44, wherein the sesRNA targeting vGAT mRNA is complementary to all or part of exon 1 of vGAT mRNA.
49. A method of identifying GABAergic neurons in the cortex of a mammal in vivo, said method comprising administering to said mammal a composition of claim 8 under conditions that permit transfection of mammalian cortical cells with said composition and production of said protein encoded by said composition, wherein said contiguous nucleotide stretch of said sensor domain is complementary to a contiguous nucleotide stretch of a selected cellular Tle4 RNA of a cortical cell, and wherein the first protein coding domain encodes an effector protein comprising a transcriptional activator and a second effector protein comprising a first reporter protein, and wherein the second nucleic acid comprises a second reporter protein coding region under the transcriptional control of an inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the control of a promoter, and wherein the modular RNA molecule comprises a gene encoding a third reporter protein upstream of the sensor domain and under the control of a promoter, Wherein detecting one or more of the first, second and third reporter proteins in cells of the mammalian cortex allows identification of the TLE4-positive projection neurons, thereby identifying GABAergic neurons in the mammalian cortex.
50. The method according to claim 46, wherein the sensor domain is complementary to all or part of exon 15 of Tle4 mRNA.
51. A method for determining the presence of cells comprising forkhead box protein P2 (FOXP2) RNA in the cortical layer of a cultured mammalian cortex, the method comprising: contacting a cultured cortical layer of a mammalian cortex with the composition of claim 9, wherein the contiguous nucleotide stretch of the sensor domain is complementary to a contiguous nucleotide stretch of a selected FOXP2 cellular RNA of a cortical cell, and wherein the first protein coding domain encodes an effector protein comprising a transcriptional activator and a second effector protein comprising a gene encoding a first reporter protein, and wherein the second nucleic acid comprises a second reporter protein coding region under the control of an inducible promoter, wherein the modular RNA molecule further comprises a gene encoding a third reporter protein upstream of the sensor domain, and One or more of the first, second and third reporter proteins are detected, wherein the detection on a cell body of the cortical layer indicates the presence of the cell.
52. A method of inhibiting neural activity that contributes to focal epileptic seizures in a mammal, the method comprising: administering to the mammal a therapeutically effective amount of an agent comprising a modular RNA molecule according to claim 1 or a nucleic acid composition according to claim 8 or a delivery vehicle according to claim 27, wherein the contiguous nucleotide segment of the sensor domain is complementary to a contiguous nucleotide segment of a cortical cell-selected cellular RNA encoded by an SST gene, and wherein the first protein coding domain encodes a) a transcriptional activator and b) a first effector protein, and wherein the second nucleic acid comprises a second effector protein coding region under the control of an inducible promoter induced by the transcriptional activator, wherein the modular RNA molecule further comprises a gene encoding a third effector protein upstream of the sensor domain, and The composition further comprises a gene encoding a DREADD receptor or a gene encoding a PSAM, and Wherein in the presence of a drug effective to activate the receptor encoded by the DREAD or PSAM gene, the DREAD receptor or the PSAM receptor is activated, thereby allowing the production of one or more of the effector proteins and treating epilepsy in the mammal.
53. A method of inhibiting neural activity that contributes to focal epileptic seizures in a mammal, the method comprising: administering to said mammal an agent in a therapeutically effective amount, said agent comprising a modular RNA molecule according to claim 1 or a nucleic acid composition according to claim 11 or a delivery vehicle according to claim 34; wherein said contiguous nucleotide segment of said sensor domain of said modular RNA is complementary to a contiguous nucleotide segment of a selected cfos cell RNA of a cortical cell, wherein a first protein-coding domain encodes a first effector protein comprising a transcriptional activator and a second effector protein comprising a gene encoding osmFlag, and wherein the second nucleic acid comprises a first reporter protein coding region under the control of an inducible promoter, wherein the first nucleic acid comprising the modular RNA molecule is under the control of a promoter, and wherein the modular RNA molecule comprises a gene encoding a second reporter protein upstream of the sensor domain and under the control of the promoter, The agent further comprises a gene encoding a DREADD receptor or a gene encoding a PSAM, and wherein said administering allows translation of said effector protein in selected cells of said mammal in the presence of an agent that activates said DREADD or said PSAM receptor, thereby producing said protein in said cells, wherein production of said protein in said cells is effective to inhibit neural activity that promotes focal epileptic seizures in said mammal.
54. A method of treating chronic pain in a mammal, the method comprising: administering to the mammal a therapeutically effective amount of an agent comprising a modular RNA molecule according to claim 1 or 2, or a nucleic acid composition according to claim 12, or a delivery vehicle according to claim 34; wherein the sensor domain of the modular RNA comprises a contiguous nucleotide segment complementary to a contiguous nucleotide segment of a selected TRPV1 or NaV1.8 cellular RNA, and the first protein-coding domain encodes an effector protein comprising a transcriptional activator, The modular RNA further comprises a domain encoding a shRNA that binds to NaV1.7 or NaV1.8 RNA, wherein the domain encoding the shRNA is under the control of an inducible promoter, wherein the transcriptional activator and the shRNA are produced in the cells of the mammal to treat chronic pain in the mammal.
55. A method for treating Alzheimer's disease in a mammal, the method comprising: administering to the mammal a therapeutically effective amount of an agent comprising a modular RNA molecule according to claim 1 or a nucleic acid composition according to claim 12 or a delivery vehicle according to claim 34; wherein the sensor domain of the modular RNA comprises a contiguous nucleotide segment complementary to a contiguous nucleotide segment of a selected cellular RNA, the selected cellular RNA being encoded by a gene selected from the group consisting of: a) a human astrocyte marker gene of aldehyde dehydrogenase family 1 member L1 (Aldh1L1), b) a glial fibrillary acidic protein (GFAP) gene, c) an excitatory amino acid transporter 1 (EAAT1) gene, and d) a microglial gene: C-X3-C motif chemokine receptor 1 (CX3CR1), e) a transmembrane protein 119 (TMEM119), and f) an ionized calcium binding adaptor molecule 1 (IBA-1), and wherein the first protein-coding domain of the modular RNA encodes a transcriptional activator, wherein the modular RNA further comprises a second coding domain encoding a repressor of ApoE4, the second coding domain being under the control of an inducible promoter, and wherein said transcriptional activator and said repressor are produced in said cell thereby treating and / or preventing the progression of Alzheimer's disease in said mammal.
56. The method according to claim 44 or 46, comprising administering the composition to the S1 barrel cortex and hippocampus of the mammal.
57. The method of claim 44, wherein the first reporter protein comprises an antigenic protein tag.
58. The method of claim 54, wherein the antigenic protein tag comprises smV5.
59. The composition according to claims 20, 23, 38, 39, 44-49, wherein the transcriptional activator comprises the tetracycline-dependent transcriptional activator tTA2.
60. The composition of claims 22, 25, 38, 39, 44-49, wherein the second protein coding region is under the transcriptional control of a TRE-3G eukaryotic inducible promoter.
